10-K/A

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C.  20549

FORM 10-K/A

(Amendment No. 1)

(Mark One)

þ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15 (d) OF THE SECURITIES EXCHANGE ACT OF 1934

For the fiscal year ended December 31, 2011

or

¨ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15 (d) OF THE SECURITIES EXCHANGE ACT OF 1934

For the transition period from            to

Commission File Number 1-8036

WEST PHARMACEUTICAL SERVICES, INC.

(Exact name of registrant as specified in its charter)

Pennsylvania	23-1210010
(State or other jurisdiction of incorporation or organization)	(I.R.S. Employer Identification Number)
101 Gordon Drive, PO Box 645, Lionville, PA	19341-0645
(Address of principal executive offices)	(Zip Code)

Registrant’s telephone number, including area code: 610-594-2900

Securities registered pursuant to Section 12(b) of the Act:

Title of each class	Name of each exchange on which registered
Common Stock, par value $.25 per share	New York Stock Exchange

Securities registered pursuant to Section 12 (g) of the Act:   None

Indicate by check mark if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act.

Yes  þ No  o

Indicate by check mark if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Act.

Yes  o No  þ

Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15 (d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days.  Yes  þ No  o

Indicate by check mark whether the registrant has submitted electronically and posted on its corporate Web site, if any, every Interactive Data File required to be submitted and posted pursuant to Rule 405 of Regulation S-T (§ 232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit and post such files).  Yes  þ No  o

Indicate by check mark if disclosure of delinquent filers pursuant to Item 405 of Regulation S-K is not contained herein, and will not be contained, to the best of registrant’s knowledge, in definitive proxy or information statements incorporated by reference in Part III of this Form 10-K or any amendment to this Form 10-K.  o

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, or a smaller reporting company.  See the definitions of “large accelerated filer,” “accelerated filer” and “smaller reporting company” in Rule 12b-2 of the Exchange Act.

Large accelerated filer	þ		Accelerated filer	o
Non-accelerated filer	o	(Do not check if a smaller reporting company)	Smaller reporting company	o

Indicate by check mark whether the registrant is a shell company (as defined in rule 12b-2 of the Exchange Act).  Yes o No  þ

The aggregate market value of the voting stock held by non-affiliates of the registrant as of June 30, 2011 was approximately $1,472,514,635 based on the closing price as reported on the New York Stock Exchange.

As of January 31, 2012, there were 33,779,282 shares of the registrant’s common stock outstanding.

DOCUMENTS INCORPORATED BY REFERENCE

Document	Parts Into Which Incorporated
Proxy Statement for the Annual Meeting of Shareholders to be held May 1, 2012	Part III

EXPLANATORY NOTE

The sole purpose of this Amendment No. 1 to our Annual Report on Form 10-K for the fiscal year ended December 31, 2011 (“Form 10-K”), as filed with the Securities and Exchange Commission (“SEC”) on February 29, 2012, is to furnish Exhibit 101 – Interactive Data File (“XBRL Exhibit”).

No other changes have been made to the Form 10-K other than the furnishing of the exhibit described above. This Amendment No. 1 to the Form 10-K speaks as of the original filing date of the Form 10-K, and does not reflect subsequent events occurring after the original filing date of the Form 10-K or modify or update in any way disclosures made in the Form 10-K.

Pursuant to Rule 406T of Regulation S-T, the XBRL Exhibit attached hereto are deemed not filed or part of a registration statement or prospectus for purposes of Sections 11 or 12 of the Securities Act of 1933, as amended, are deemed not filed for purposes of Section 18 of the Securities Exchange Act of 1934, as amended, and otherwise are not subject to liability under those sections.

ITEM 6.  EXHIBITS

See Index to Exhibits on pages F-1 through F-5 of this Report.

2

SIGNATURE

Pursuant to the requirements of Section 13 or 15(d) of the Securities Exchange Act of 1934, West Pharmaceutical Services, Inc. has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

   WEST PHARMACEUTICAL SERVICES, INC.

   (Registrant)

By: /s/ William J. Federici

   William J. Federici

   Vice President and Chief Financial Officer

March 1, 2012

3

EXHIBIT INDEX

Exhibit Number	Description
3.1	Our Amended and Restated Articles of Incorporation effective December 17, 2007 are incorporated by reference from our Form 8-K dated December 17, 2007.
3.2	Certificate of Amendment of our Amended and Restated Articles of Incorporation, is incorporated by reference from our Form 8-K filed on May 6, 2011.
3.3	Our Bylaws, as amended effective October 14, 2008 are incorporated by reference from our Form 8-K dated October 20, 2008.
4.1	Form of stock certificate for common stock is incorporated by reference from our 1998 10-K report.
4.2	Article 5, 6, 8(c) and 9 of our Amended and Restated Articles of Incorporation are incorporated by reference from our Form 8-K dated December 17, 2007.
4.3	Article I and V of our Bylaws, as amended through October 14, 2008, are incorporated by reference from our Form 8-K dated October 20, 2008.
4.4 (1)	Instruments defining the rights of holders of long-term debt securities of West and its subsidiaries have been omitted.
10.1	Lease Agreement dated December 17, 2010, by and between us and 530 Regency Drive Associates, L.P., a Pennsylvania limited partnership, is incorporated by reference from our 8-K dated December 22, 2010.
10.2	Letter to 530 Regency Drive Associates, L.P. exercising purchase option.
10.3	Lease dated as of December 31, 1992 between Lion Associates, L.P. and us relating to the lease of our headquarters in Lionville, Pa. is incorporated by reference from our 1992 10-K report.
10.4	First Addendum to Lease dated as of May 22, 1995 between Lion Associates, L.P. and us is incorporated by reference from our 1995 10-K report.
10.5	Lease dated as of December 14, 1999 between White Deer Warehousing & Distribution Center, Inc. and us relating to the lease of our site in Montgomery, Pa. is incorporated by reference from our 2002 10-K report.
10.6(2)	1999 Non-Qualified Stock Option Plan for Non-Employee Directors, effective as of April 27, 1999 (now terminated), is incorporated by reference from our 10-Q report for the quarter ended June 30, 1999.
10.7(2)	Amendment No. 1 to 1999 Non-Qualified Stock Option Plan for Non-Employee Directors, effective October 30, 2001, is incorporated by reference from our 2001 10-K report.
10.8(2)	Form of Second Amended and Restated Change-in-Control Agreement between us and certain of our executive officers dated as of March 25, 2000 is incorporated by reference from our 10-Q report for the quarter ended March 31, 2000.
10.9(2)	Form of Amendment No. 1 to Second Amended and Restated Change-in-Control Agreement dated as of May 1, 2001 between us and certain of our executive officers is incorporated by reference from our 2001 10-K report.

F-1

Exhibit Number	Description
10.10(2)	Form of Amendment No. 2 to Second Amended and Restated Change-in-Control Agreement between us and certain of our executive officers, dated as of various dates in December 2008, is incorporated by reference from our 2008 10-K report.
10.11(2)	Schedule of agreements with executive officers is incorporated by reference from our 2008 10-K report.
10.12(2)	Change-in-Control Agreement, dated as of January 21, 2011, between us and Jeffrey C. Hunt.
10.13(2)	Non-Competition Agreement, dated as of October 5, 1994, between us and Steven A. Ellers, is incorporated by reference from our 2007 10-K report.
10.14(2)	Employment Agreement, dated as of April 30, 2002, between us and Donald E. Morel, Jr. is incorporated by reference from our 10-Q report for the quarter ended September 30, 2002.
10.15(2)	Amendment #1 to the Employment Agreement between us and Donald E. Morel, Jr., dated as of December 19, 2008, is incorporated by reference from our 2008 10-K report.
10.16(2)	Non-Qualified Stock Option Agreement, dated as of April 30, 2002 between us and Donald E. Morel, Jr. is incorporated by reference from our 10-Q report for the quarter ended September 30, 2002.
10.17(2)	Indemnification Agreement, dated as of January 5, 2009 between us and Donald E. Morel, Jr. is incorporated by reference from our Form 8-K dated January 6, 2009.
10.18(2)	Supplemental Employees' Retirement Plan, as amended and restated effective January 1, 2008, is incorporated by reference from our 2008 10-K report.
10.19(2)	Non-Qualified Deferred Compensation Plan for Designated Employees, as amended and restated effective January 1, 2008, is incorporated by reference from our 2008 10-K report.
10.20(2)	Deferred Compensation Plan for Outside Directors, as amended and restated effective January 1, 2008, is incorporated by reference from our 2008 10-K report.
10.21(2)	1998 Key Employee Incentive Compensation Plan, dated March 10, 1998 (now terminated) is incorporated by reference from our 1997 10-K report.
10.22(2)	Amendment No. 1 to 1998 Key Employees Incentive Compensation Plan, effective October 30, 2001 is incorporated by reference from our 2001 10-K report.
10.23(2)	West Pharmaceutical Services, Inc. 2011 Omnibus Incentive Compensation Plan is incorporated by reference from our Form 8-K filed on May 6, 2011.
10.24(2)	2007 Omnibus Incentive Compensation Plan effective as of May 1, 2007, is incorporated by reference to Exhibit 99.1 of the Company’s Form 8-K dated May 4, 2007.
10.25(2)	2004 Stock-Based Compensation Plan (now terminated) is incorporated by reference from our Proxy Statement for the 2004 Annual Meeting of Shareholders.

F-2

Exhibit Number	Description
10.26(2)	Form of Director 2004 Non-Qualified Stock Option Award Agreement, issued pursuant to the 2004 Stock-Based Compensation Plan is incorporated by reference from our 10-Q report for the quarter ended September 30, 2004.
10.27(2)	Form of Director 2004 Stock Unit Award Agreement, issued pursuant to the 2004 Stock-Based Compensation Plan is incorporated by reference from our 10-Q report for the quarter ended September 30, 2004.
10.28(2)	Form of Director 2004 Non-Qualified Stock Option Agreement, issued pursuant to the 2004 Stock-Based Compensation Plan is incorporated by reference from our 10-Q report for the quarter ended September 30, 2004.
10.29(2)	Form of Executive 2005 Non-Qualified Stock Option Award Notice is incorporated by reference from our 10-Q report for the quarter ended September 30, 2005.
10.30(2)	Form of Director 2005 Non-Qualified Stock Option Award Notice is incorporated by reference from our 10-Q report for the quarter ended September 30, 2005.
10.31(2)	Form of Director 2005 Stock Unit Share Award Notice is incorporated by reference from our 10-Q report for the quarter ended September 30, 2005.
10.32(2)	Form of Executive 2006 Bonus and Incentive Share Award is incorporated by reference from our 10-Q report for the quarter ended March 31, 2006.
10.33(2)	Form of Executive 2006 Non-Qualified Stock Option Award is incorporated by reference from our 10-Q report for the quarter ended March 31, 2006.
10.34(2)	Form of 2006 Performance-Vesting Restricted (“PVR”) Share Award is incorporated by reference from our 10-Q report for the quarter ended March 31, 2006.
10.35(2)	Form of Director 2006 Non-Qualified Stock Option Award Notice is incorporated by reference from our 10-Q report for the quarter ended June 30, 2006.
10.36(2)	Form of Director 2006 Stock Unit Award Notice is incorporated by reference from our 10-Q report for the quarter ended June 30, 2006.
10.37(2)	Form of 2007 Bonus and Incentive Share Award, issued pursuant to the 2004 Stock-Based Compensation Plan, is incorporated by reference from our 10-Q report for the quarter ended March 31, 2007.
10.38(2)	Form of 2007 Non-Qualified Stock Option and Performance-Vesting Share Unit Award, issued pursuant to the 2004 Stock-Based Compensation Plan, is incorporated by reference from our 10-Q report for the quarter ended March 31, 2007.
10.39(2)	Form of Director 2007 Deferred Stock Award, issued pursuant to the 2007 Omnibus Incentive Compensation Plan, is incorporated by reference from our 10-Q report for the quarter ended June 30, 2007.
10.40(2)	Form of 2008 Bonus and Incentive Share Award, issued pursuant to the 2007 Omnibus Incentive Compensation Plan, is incorporated by reference from our 10-Q report for the quarter ended March 31, 2008.
10.41(2)	Form of 2008 Non-Qualified Stock Option and Performance-Vesting Share Unit Award, issued pursuant to the 2007 Omnibus Incentive Compensation Plan, is incorporated by reference from our 10-Q report for the quarter ended March 31, 2008.

F-3

Exhibit Number	Description
10.42(2)	Form of Director 2008 Deferred Stock Award, issued pursuant to the 2007 Omnibus Incentive Compensation Plan, is incorporated by reference from our 2008 10-K report.
10.43(2)	Form of 2009 Supplemental Long-Term Incentive Award, is incorporated by reference from our 10-Q report for the quarter ended September 30, 2009.
10.44	Credit Agreement, dated June 3, 2011, by and among us, certain of our subsidiaries, several banks and other financial institutions from time to time parties thereto (the “Lenders”) and PNC Bank, National Association, as administrative agent for the Lenders.
10.45	Security Agreement, dated June 3, 2011, by and among us, the subsidiaries of the Company listed on the signature pages thereto and PNC Bank, National Association, as administrative agent, for the holders of the Obligations.
10.46	Credit Agreement, dated as of June 4, 2010, among us, certain of our subsidiaries, the lenders party thereto from time to time, PNC Bank, National Association, as Administrative Agent, Bank of America, N.A. and Wells Fargo Bank, National Association, as Syndication Agents, Citizens Bank of Pennsylvania, as Documentation Agent, and PNC Capital Markets, LLC, as Lead Arranger is incorporated by reference from our 8-K report dated June 10, 2010.
10.47	Multi-Currency Note Purchase and Private Shelf Agreement, dated as of February 27, 2006, among us and The Prudential Insurance Company of America, Prudential Retirement Insurance and Annuity Company, Pruco Life Insurance Company, Pruco Life Insurance Company of New Jersey, American Skandia Life Assurance Corporation and Prudential Investment Management, Inc., is incorporated by reference to Exhibit 10.2 of the Company’s Current Report on Form 8-K, dated March 3, 2006.
10.48(3)	Agreement, effective as of January 1, 2005, between us and The Goodyear Tire & Rubber Company is incorporated by reference from our 10-Q report for the quarter ended June 30, 2005.
10.49(3)	First Agreement to Amend to Agreement, effective as of July 1, 2008, between us and The Goodyear Tire & Rubber Company is incorporated by reference from our 10-Q report for the quarter ended March 31, 2009.
10.50(3)	Supply Agreement, dated as of October 1, 2007, between us and Becton, Dickinson and Company is incorporated by reference from our 2007 10-K report.
10.51	Distributorship Agreement, dated January 25, 2007, between Daikyo Seiko, Ltd. and us is incorporated by reference from our 2006 10-K report.
10.52(3)	Amended and Restated Technology Exchange and Cross License Agreement, dated January 25, 2007, between us and Daikyo Seiko, Ltd. is incorporated by reference from our 2006 10-K report.
10.53(3)	Global Supply Agreement by and between ExxonMobil Chemical Company and us, entered into on July 28, 2011, and effective from January 1, 2011 through December 31, 2013 is incorporated by reference from our Form 8-K report filed on July 1, 2011.

F-4

Exhibit Number	Description
10.54(2)	Amendment to Letter Agreement, dated as of May 1, 2003, between us and Robert S. Hargesheimer is incorporated by reference from our 2003 10-K report.
10.55(2)	Amendment #2 to Letter Agreement, dated as of December 19, 2008, between us and Robert S. Hargesheimer, is incorporated by reference from our 2008 10-K report.
10.56(2)	Letter Agreement dated as of March 30, 2006 between us and Donald E. Morel, Jr. is incorporated by reference from our 10-Q report for the quarter ended June 30, 2006.
10.57	Note Purchase Agreement, dated as of July 28, 2005, among us and each of the purchasers listed on Schedule A thereto, is incorporated by reference from our 8-K report dated August 3, 2005.
10.58	Indemnification agreements between us and each of our directors in the form of Exhibit 10.1 to our Form 8-K report dated January 6, 2009, which is incorporated by reference.
12.1	Computation of Ratio of Earnings to Fixed Charges.
21.	Subsidiaries of the Company.
23.	Consent of Independent Registered Public Accounting Firm.
24.	Powers of Attorney.
31.1*	Certification by the Chief Executive Officer Pursuant to Section 302 of the Sarbanes-Oxley Act of 2002.
31.2*	Certification by the Chief Financial Officer Pursuant to Section 302 of the Sarbanes-Oxley Act of 2002.
32.1**	Certification by the Chief Executive Officer Pursuant to 18 U.S.C. Section 1350, as Adopted Pursuant to Section 906 of the Sarbanes-Oxley Act of 2002.
32.2**	Certification by Chief Financial Officer Pursuant to 18 U.S.C. Section 1350, as Adopted Pursuant to Section 906 of the Sarbanes-Oxley Act of 2002.
101.INS**	XBRL Instance Document
101.SCH**	XBRL Taxonomy Extension Schema Document
101.CAL**	XBRL Taxonomy Extension Calculation Linkbase Document
101.LAB**	XBRL Taxonomy Extension Label Linkbase Document
101.PRE**	XBRL Taxonomy Extension Presentation Linkbase Document
101.DEF**	XBRL Taxonomy Extension Definition Linkbase Document

(1) We agree to furnish to the SEC, upon request, a copy of each instrument with respect to issuances of long-term debt of the Company and its subsidiaries.

(2) Management compensatory plan.

(3) Certain portions of this exhibit have been omitted pursuant to a confidential treatment request submitted to the SEC.

* Filed herewith.

** Furnished herewith.

F-5

EX-31.1

EXHIBIT 31.1

CERTIFICATION

I, Donald E. Morel, Jr., Ph.D., certify that:

1. I have reviewed this annual report on Form 10-K of West Pharmaceutical Services, Inc.;

2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;

3. Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;

4. The registrant’s other certifying officer(s) and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:

(a) Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;

(b) Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;

(c) Evaluated the effectiveness of the registrant’s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and

(d) Disclosed in this report any change in the registrant’s internal control over financial reporting that occurred during the registrant’s most recent fiscal quarter (the registrant’s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant’s internal control over financial reporting; and

5. The registrant’s other certifying officer(s) and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant’s auditors and the audit committee of the registrant’s board of directors (or persons performing the equivalent functions):

(a) All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant’s ability to record, process, summarize and report financial information; and

(b) Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant’s internal control over financial reporting.

/s/ Donald E. Morel, Jr., Ph.D.

Donald E. Morel, Jr., Ph.D.

Chairman of the Board and Chief Executive Officer

Date: March 1, 2012

EX-31.2

EXHIBIT 31.2

CERTIFICATION

I, William J. Federici, certify that:

1. I have reviewed this annual report on Form 10-K of West Pharmaceutical Services, Inc.;

2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;

3. Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;

4. The registrant’s other certifying officer(s) and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:

(a) Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;

(b) Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;

(c) Evaluated the effectiveness of the registrant’s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and

(d) Disclosed in this report any change in the registrant’s internal control over financial reporting that occurred during the registrant’s most recent fiscal quarter (the registrant’s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant’s internal control over financial reporting; and

5. The registrant’s other certifying officer(s) and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant’s auditors and the audit committee of the registrant’s board of directors (or persons performing the equivalent functions):

(a) All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant’s ability to record, process, summarize and report financial information; and

(b) Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant’s internal control over financial reporting.

/s/ William J. Federici

William J. Federici

Vice President and Chief Financial Officer

Date:  March 1, 2012

EX-32.1

EXHIBIT 32.1

CERTIFICATION PURSUANT TO 18 U.S.C. SECTION 1350

AS ADOPTED PURSUANT TO SECTION 906 OF

THE SARBANES-OXLEY ACT OF 2002

In connection with the Annual Report of West Pharmaceutical Services, Inc. (the “Company”) on Form 10-K for the period ending December 31, 2011, as filed with the Securities and Exchange Commission on the date hereof (the “Report”), I, Donald E. Morel, Jr., Chairman and Chief Executive Officer of the Company, certify, pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, that:

(1) The Report fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934, as amended; and

(2) The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.

/s/ Donald E. Morel, Jr., Ph.D.

Donald E. Morel, Jr., Ph.D.

Chairman of the Board and Chief Executive Officer

March 1, 2012

EX-32.2

EXHIBIT 32.2

CERTIFICATION PURSUANT TO 18 U.S.C. SECTION 1350

AS ADOPTED PURSUANT TO SECTION 906 OF

THE SARBANES-OXLEY ACT OF 2002

In connection with the Annual Report of West Pharmaceutical Services, Inc. (the “Company”) on Form 10-K for the period ending December 31, 2011, as filed with the Securities and Exchange Commission on the date hereof (the “Report”), I, William, J. Federici, Vice President and Chief Financial Officer of the Company, certify, pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, that:

(1) The Report fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934, as amended; and

(2) The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.

/s/ William J. Federici

William J. Federici

Vice President and Chief Financial Officer

March 1, 2012

XML

Benefit Plans (Tables)

12 Months Ended

Dec. 31, 2011

Benefit Plans [Abstract]

Components of Net Periodic Benefit Cost

The components of net periodic benefit cost and other amounts recognized in other comprehensive income were as follows:

	Pension benefits									Other retirement benefits
($ in millions)	2011			2010			2009			2011		2010			2009
Net periodic benefit cost:
Service cost	$	8.9		$	8.6		$	7.8		$	1.2	$	1.1		$	0.8
Interest cost		16.0			15.7			14.9			1.0		0.8			0.9
Expected return on assets		(16.0	)		(14.7	)		(11.9	)		-		-			-
Amortization of prior service (credit) cost		(1.5	)		(1.1	)		(1.1	)		0.1		0.1			0.1
Amortization of transition obligation		0.1			0.1			0.1			-		-			-
Recognized actuarial losses (gains)		6.0			5.6			7.0			-		(0.1	)		-
Curtailment		(0.2	)		-			-			-		-			-
Settlement effects		0.8			-			-			-		-			-
Net periodic benefit cost	$	14.1		$	14.2		$	16.8		$	2.3	$	1.9		$	1.8

Other changes in plan assets and benefit obligations recognized in other comprehensive income, pre-tax:
Net loss (gain) arising during period	$	46.7		$	9.1		$	(2.9	)	$	1.3		$	(1.5	)	$	1.8
Prior service credit arising during period		-			(5.2	)		-			-			-			-
Amortization of prior service credit (cost)		1.5			1.1			1.1			(0.1	)		(0.1	)		(0.1	)
Amortization of transition obligation		(0.1	)		(0.1	)		(0.1	)		-			-			-
Amortization of actuarial (loss) gain		(6.0	)		(5.6	)		(7.0	)		-			0.1			-
Curtailment		0.2			-			-			0.4			-			-
Settlement effects		(0.8	)		-			-			-			-			-
Total recognized in other comprehensive income	$	41.5		$	(0.7	)	$	(8.9	)	$	1.6		$	(1.5	)	$	1.7
Total recognized in net periodic benefit cost and other comprehensive income	$	55.6		$	13.5		$	7.9		$	3.9		$	0.4		$	3.5

Net periodic benefit cost by geographic location is as follows:

	Pension benefits						Other retirement benefits
($ in millions)	2011		2010		2009		2011		2010		2009
U.S. plans	$	11.4	$	11.7	$	14.9	$	2.3	$	1.9	$	1.8
International plans		2.7		2.5		1.9		-		-		-
Net periodic benefit cost	$	14.1	$	14.2	$	16.8	$	2.3	$	1.9	$	1.8

Changes in projected benefit obligation

The following tables present the changes in the projected benefit obligation and the fair value of plan assets, as well as the funded status of the plans:

	Pension benefits						Other retirement benefits
($ in millions)	2011			2010			2011			2010
Change in benefit obligation:
Benefit obligation, January 1	$	(283.5	)	$	(262.8	)	$	(18.1	)	$	(18.1	)
Service cost		(8.9	)		(8.6	)		(1.2	)		(1.1	)
Interest cost		(16.0	)		(15.7	)		(1.0	)		(0.9	)
Participants’ contributions		-			-			(0.3	)		(0.4	)
Actuarial (loss) gain		(27.3	)		(15.9	)		(1.4	)		1.5
Amendments/transfers in		(0.4	)		5.2			-			-
Benefits/expenses paid		16.4			12.4			0.7			0.9
Curtailment		(0.8	)		-			(0.4	)
Foreign currency translation		0.6			1.9			-			-
Benefit obligation, December 31	$	(319.9	)	$	(283.5	)	$	(21.7	)	$	(18.1	)

Change in plan assets:
Fair value of assets, January 1	$	212.3		$	193.5		$	-		$	-
Actual return on assets		(2.8	)		21.6			-			-
Employer contribution		20.4			10.3			0.4			0.5
Participants’ contribution		-			-			0.3			0.4
Benefits/expenses paid		(16.4	)		(12.5	)		(0.7	)		(0.9	)
Foreign currency translation		(0.2	)		(0.6	)		-			-
Fair value of assets, December 31	$	213.3		$	212.3		$	-		$	-
Funded status at end of year	$	(106.6	)	$	(71.2	)	$	(21.7	)	$	(18.1	)

Amount recognized in the balance sheet

Amounts recognized in the balance sheet were as follows:

	Pension benefits						Other retirement benefits
($ in millions)	2011			2010			2011			2010
Current liabilities	$	(1.2	)	$	(1.1	)	$	(1.1	)	$	(1.0	)
Noncurrent liabilities		(105.4	)		(70.1	)		(20.6	)		(17.1	)
	$	(106.6	)	$	(71.2	)	$	(21.7	)	$	(18.1	)

The amounts in accumulated other comprehensive loss, pre-tax, consisted of:

	Pension benefits						Other retirement benefits
($ in millions)	2011			2010			2011		2010
Net actuarial loss (gain)	$	131.3		$	92.1		$	0.2	$	(1.5	)
Transition obligation		0.4			0.5			-		-
Prior service (credit) cost		(10.2	)		(12.7	)		0.1		0.2
Total	$	121.5		$	79.9		$	0.3	$	(1.3	)

Estimated future benefit payments

Benefit payments expected to be paid under our defined benefit pension plans in the next ten years are as follows:

($ in millions)	Domestic Plans		International Plans		Total
2012	$	15.5	$	1.2	$	16.7
2013		16.7		1.4		18.1
2014		19.4		1.6		21.0
2015		20.9		1.6		22.5
2016		22.3		2.1		24.4
2017 to 2021		130.2		14.1		144.3
	$	225.0	$	22.0	$	247.0

Weighted-average assumption used to determine benefit obligation and net periodic benefit cost

Weighted average assumptions used to determine net periodic benefit cost were as follows:

	Pension benefits									Other retirement benefits
	2011			2010			2009			2011			2010			2009
Discount rate		5.55	%		5.92	%		6.38	%		5.25	%		5.25	%		6.25	%
Rate of compensation increase		4.33	%		4.36	%		4.37	%		-			-			-
Long-term rate of return on assets		7.59	%		7.60	%		7.66	%		-			-			-

Weighted average assumptions used to determine the benefit obligations were as follows:

	Pension benefits						Other retirement benefits
	2011			2010			2011			2010
Discount rate		4.87	%		5.61	%		4.50	%		5.25	%
Rate of compensation increase		4.33	%		4.36	%		-			-

Weighted-average asset allocation

The weighted average asset allocations by asset category for our pension plans, at December 31, were as follows:

	2011			2010
Equity securities		68	%		69	%
Debt securities		31	%		31	%
Other		1	%		-
		100	%		100	%

The following are our target asset allocations and acceptable allocation ranges:

	Target allocation			Allocation range
Equity securities		65	%		60%-70	%
Debt securities		35	%		30%-40	%
Other		0	%		0%-5	%

Fair value of plan assets

The following tables present the fair value of our pension plan assets, utilizing the fair value hierarchy discussed in Note 13, Fair Value Measurements:

	Balance at
	December 31,		Basis of Fair Value Measurements
($ in millions)	2011		Level 1		Level 2		Level 3
Cash	$	0.2	$	0.2	$	-	$	-
Equity securities:
Indexed mutual funds		102.2		102.2		-		-
International mutual funds		40.0		40.0		-		-
Fixed income securities:
Mutual funds		65.6		65.6		-		-
Insurance contract		1.3		-		1.3		-
Balanced mutual fund		4.0		4.0		-		-
	$	213.3	$	212.0	$	1.3	$	-

	Balance at
	December 31,			Basis of Fair Value Measurements
($ in millions)	2010			Level 1			Level 2		Level 3
Cash overdrafts	$	(0.6	)	$	(0.6	)	$	-	$	-
Equity securities:
Indexed mutual funds		108.1			108.1			-		-
International mutual funds		37.7			37.7			-		-
Fixed income securities:
Mutual funds		65.6			65.6			-		-
Insurance contract		1.5			-			1.5		-
	$	212.3		$	210.8		$	1.5	$	-

XML

Fair Value of Financial Instruments (Details) (USD $) In Millions, unless otherwise specified	12 Months Ended
	Dec. 31, 2011	Dec. 31, 2010
Assets: [Abstract]
Short-term investments	$ 26.5	$ 0.6
Deferred compensation assets	3.3	3.6
Total assets at fair value	29.8	4.2
Liabilities: [abstract]
Contingent consideration	2.1	2.3
Deferred compensation liabilities	4.6	5.4
Interest rate swap contracts	8.8	6.1
Total Liabilities at Fair Value	15.5	13.8
Other Financial Instruments [Abstract]
Fair value of long-term debt	279.2	344.2
Long-term debt	299.3	358.1
Contingent Consideration [Member]
Level 3 Fair Value Measurements [Roll Forward]
Beginning Balance	2.3	2.8
Additional contingent consideration acquired		1.8
Increase in fair value recorded in earnings	0.5	0.2
Reduction in fair value recorded in earnings	(0.8)	(2.1)
Changes in foreign currency exchange rates	0.1	(0.4)
Ending Balance	2.1	2.3
Fair Value, Inputs, Level 1 [Member]
Assets: [Abstract]
Short-term investments	26.5	0.6
Deferred compensation assets	3.3	3.6
Total assets at fair value	29.8	4.2
Liabilities: [abstract]
Deferred compensation liabilities	4.6	5.4
Total Liabilities at Fair Value	4.6	5.4
Fair Value, Inputs, Level 2 [Member]
Liabilities: [abstract]
Interest rate swap contracts	8.8	6.1
Total Liabilities at Fair Value	8.8	6.1
Fair Value, Inputs, Level 3 [Member]
Liabilities: [abstract]
Contingent consideration	2.1	2.3
Total Liabilities at Fair Value	$ 2.1	$ 2.3

XML

Comprehensive Income (Details) (USD $) In Millions, unless otherwise specified	Dec. 31, 2011	Dec. 31, 2010	Dec. 31, 2009
Accumulated other comprehensive loss, net of tax [Abstract]
Foreign currency translation	$ 10.2	$ 22.0
Unrealized gains (losses) on securities of affiliates	0.4	0.1	(0.5)
Unrealized losses on derivatives	(5.4)	(3.7)
Defined benefit pension and other postretirement plans	(76.7)	(49.7)
Accumulated other comprehensive loss	$ (71.5)	$ (31.3)

XML

Benefit Plans (Details) (USD $) In Millions, unless otherwise specified	12 Months Ended
	Dec. 31, 2011	Dec. 31, 2010	Dec. 31, 2009
Defined Benefit Plans and Other Postretirement Benefit Plans Table Text Block [Line Items]
Defined contribution plan employer contribution	$ 3.5	$ 3.4	$ 3.4
Net periodic benefit cost: [Abstract]
Curtailment gain, net	(0.2)
Settlement loss	0.8
Other changes in plan assets and benefit obligations recognized in other comprehensive income, pre-tax: [Abstract]
Curtailment gain, net	0.2
Settlement loss	0.8
Amounts recognized in balance sheet [Abstract]
Current liabilities	(2.3)	(2.1)
Noncurrent liabilities	(126.0)	(87.2)
Estimated future benefit payment [Abstract]
2012	16.7
2013	18.1
2014	21.0
2015	22.5
2016	24.4
2017 to 2021	144.3
Total	247.0
Minimum ERISA funding requirement, U.S. qualified plan	17.2
Allocation range [Abstract]
Assumed healthcare cost trend rate used to determine benefit obligations (in hundredths)	8.50%
Ultimate health care cost trend rate (in hundredths)	5.00%
Year that rate reaches ultimate trend rate	2,019
One percentage point increase - effect on post-retirement benefit obligation	1.1
One percentage point decrease - effect on post-retirement benefit obligation	1.0
Assumed healthcare cost trend rate used to determine net periodic benefit cost (in hundredths)	9.00%
Ultimate health care cost trend rate for net periodic benefit cost (in hundredths)	5.00%
Year that rate reaches ultimate trend rate, net periodic benefit cost	2,019
One percentage point change in the rate - effect on service and interest cost components	0.2
Cash [Member]
Change in benefit obligation: [Roll Forward]
Fair value of assets, period end	0.2
Fair value of assets	0.2
Allocation range [Abstract]
Fair value of assets	0.2
Cash Overdrafts [Member]
Change in benefit obligation: [Roll Forward]
Fair value of assets, period end		(0.6)
Fair value of assets		(0.6)
Allocation range [Abstract]
Fair value of assets		(0.6)
Balanced Mutual Fund [Member]
Change in benefit obligation: [Roll Forward]
Fair value of assets, period end	4.0
Fair value of assets	4.0
Allocation range [Abstract]
Fair value of assets	4.0
Indexed Mutual Funds, Equity [Members]
Change in benefit obligation: [Roll Forward]
Fair value of assets, period end	102.2	108.1
Fair value of assets	102.2	108.1
Allocation range [Abstract]
Fair value of assets	102.2	108.1
International Mutual Funds, Equity [Member]
Change in benefit obligation: [Roll Forward]
Fair value of assets, period end	40.0	37.7
Fair value of assets	40.0	37.7
Allocation range [Abstract]
Fair value of assets	40.0	37.7
Fixed Income Mutual Funds [Member]
Change in benefit obligation: [Roll Forward]
Fair value of assets, period end	65.6	65.6
Fair value of assets	65.6	65.6
Allocation range [Abstract]
Fair value of assets	65.6	65.6
Insurance Contract [Member]
Change in benefit obligation: [Roll Forward]
Fair value of assets, period end	1.3	1.5
Fair value of assets	1.3	1.5
Allocation range [Abstract]
Fair value of assets	1.3	1.5
Level 1 [Member]
Change in benefit obligation: [Roll Forward]
Fair value of assets, period end	212.0	210.8
Fair value of assets	212.0	210.8
Allocation range [Abstract]
Fair value of assets	212.0	210.8
Level 1 [Member] | Cash [Member]
Change in benefit obligation: [Roll Forward]
Fair value of assets, period end	0.2
Fair value of assets	0.2
Allocation range [Abstract]
Fair value of assets	0.2
Level 1 [Member] | Cash Overdrafts [Member]
Change in benefit obligation: [Roll Forward]
Fair value of assets, period end		(0.6)
Fair value of assets		(0.6)
Allocation range [Abstract]
Fair value of assets		(0.6)
Level 1 [Member] | Balanced Mutual Fund [Member]
Change in benefit obligation: [Roll Forward]
Fair value of assets, period end	4.0
Fair value of assets	4.0
Allocation range [Abstract]
Fair value of assets	4.0
Level 1 [Member] | Indexed Mutual Funds, Equity [Members]
Change in benefit obligation: [Roll Forward]
Fair value of assets, period end	102.2	108.1
Fair value of assets	102.2	108.1
Allocation range [Abstract]
Fair value of assets	102.2	108.1
Level 1 [Member] | International Mutual Funds, Equity [Member]
Change in benefit obligation: [Roll Forward]
Fair value of assets, period end	40.0	37.7
Fair value of assets	40.0	37.7
Allocation range [Abstract]
Fair value of assets	40.0	37.7
Level 1 [Member] | Fixed Income Mutual Funds [Member]
Change in benefit obligation: [Roll Forward]
Fair value of assets, period end	65.6	65.6
Fair value of assets	65.6	65.6
Allocation range [Abstract]
Fair value of assets	65.6	65.6
Level 2 [Member]
Change in benefit obligation: [Roll Forward]
Fair value of assets, period end	1.3	1.5
Fair value of assets	1.3	1.5
Allocation range [Abstract]
Fair value of assets	1.3	1.5
Level 2 [Member] | Insurance Contract [Member]
Change in benefit obligation: [Roll Forward]
Fair value of assets, period end	1.3	1.5
Fair value of assets	1.3	1.5
Allocation range [Abstract]
Fair value of assets	1.3	1.5
Pension Benefits [Member]
Net periodic benefit cost: [Abstract]
Service cost	8.9	8.6	7.8
Interest cost	16.0	15.7	14.9
Expected return on assets	(16.0)	(14.7)	(11.9)
Amortization of prior service (credit) cost	(1.5)	(1.1)	(1.1)
Amortization of transition obligation	0.1	0.1	0.1
Recognized actuarial losses (gains)	6.0	5.6	7.0
Curtailment gain, net	(0.2)
Settlement loss	0.8
Net periodic benefit cost	14.1	14.2	16.8
Other changes in plan assets and benefit obligations recognized in other comprehensive income, pre-tax: [Abstract]
Net loss (gain) arising during period	46.7	9.1	(2.9)
Prior service credit arising during period		(5.2)
Curtailment	0.2
Settlement effects	(0.8)
Amortization of prior service credit (cost)	1.5	1.1	1.1
Amortization of transition obligation	(0.1)	(0.1)	(0.1)
Amortization of actuarial (loss) gain	(6.0)	(5.6)	(7.0)
Total recognized in other comprehensive income	41.5	(0.7)	(8.9)
Total recognized in net periodic benefit cost and other comprehensive income	55.6	13.5	7.9
Curtailment gain, net	0.2
Settlement loss	0.8
Change in benefit obligation: [Roll Forward]
Benefit obligation, beginning period	(283.5)	(262.8)
Service cost	(8.9)	(8.6)	(7.8)
Interest cost	(16.0)	(15.7)
Actuarial (loss) gain	(27.3)	(15.9)
Amendments/transfers in	(0.4)	5.2
Benefits/expenses paid	16.4	12.4
Curtailment	(0.8)
Foreign currency translation	0.6	1.9
Benefit obligation, period end	(319.9)	(283.5)	(262.8)
Fair value of assets, beginning period	212.3	193.5
Actual return on assets	(2.8)	21.6
Employer contribution	20.4	10.3
Foreign currency translation	(0.2)	(0.6)
Benefits/expenses paid	(16.4)	(12.4)
Fair value of assets, period end	213.3	212.3	193.5
Funded status at end of year	(106.6)	(71.2)
Fair value of assets	213.3	212.3	193.5
Amounts recognized in balance sheet [Abstract]
Current liabilities	(1.2)	(1.1)
Noncurrent liabilities	(105.4)	(70.1)
Total	(106.6)	(71.2)
Amounts in accumulated other comprehensive loss, pre tax [Abstract]
Net actuarial loss (gain)	131.3	92.1
Transition obligation	0.4	0.5
Prior service (credit) cost	(10.2)	(12.7)
Total	121.5	79.9
Net actuarial loss that will be amortized into net pension expense over the next fiscal year	8.3
Transition obligation that will be amortized into net pension expense over the next fiscal year	0.1
Prior service credit that will be amortized into net pension expense over the next fiscal year	(1.4)
Accumulated benefit obligation	316.7	280.4
Estimated future benefit payment [Abstract]
Estimated future employer contributions in next fiscal year	19.8
Weighted-average assumption used to determine net periodic benefit cost [Abstract]
Discount rate (in hundredths)	5.55%	5.92%	6.38%
Rate of compensation increase (in hundredths)	4.33%	4.36%	4.37%
Long-term rate of return on assets (in hundredths)	7.59%	7.60%	7.66%
Weighted-average assumption used to determine benefit obligation [Abstract]
Discount rate (in hundredths)	4.87%	5.61%
Rate of compensation increase (in hundredths)	4.33%	4.36%
Weighted average asset allocations [Abstract]
Equity securities (in hundredths)	68.00%	69.00%
Debt securities (in hundredths)	31.00%	31.00%
Other (in hundredths)	1.00%
Total (in hundredths)	100.00%	100.00%
Allocation range [Abstract]
Fair value of assets	213.3	212.3	193.5
Other Retirement Benefits [Member]
Net periodic benefit cost: [Abstract]
Service cost	1.2	1.1	0.8
Interest cost	1.0	0.8	0.9
Amortization of prior service (credit) cost	0.1	0.1	0.1
Recognized actuarial losses (gains)		(0.1)
Net periodic benefit cost	2.3	1.9	1.8
Other changes in plan assets and benefit obligations recognized in other comprehensive income, pre-tax: [Abstract]
Net loss (gain) arising during period	1.3	(1.5)	1.8
Curtailment	0.4
Amortization of prior service credit (cost)	(0.1)	(0.1)	(0.1)
Amortization of actuarial (loss) gain		0.1
Total recognized in other comprehensive income	1.6	(1.5)	1.7
Total recognized in net periodic benefit cost and other comprehensive income	3.9	0.4	3.5
Change in benefit obligation: [Roll Forward]
Benefit obligation, beginning period	(18.1)	(18.1)
Service cost	(1.2)	(1.1)	(0.8)
Interest cost	(1.0)	(0.9)
Participants' contributions	(0.3)	(0.4)
Actuarial (loss) gain	(1.4)	1.5
Benefits/expenses paid	0.7	0.9
Curtailment	(0.4)
Benefit obligation, period end	(21.7)	(18.1)	(18.1)
Employer contribution	0.4	0.5
Participants' contribution	0.3	0.4
Benefits/expenses paid	(0.7)	(0.9)
Funded status at end of year	(21.7)	(18.1)
Amounts recognized in balance sheet [Abstract]
Current liabilities	(1.1)	(1.0)
Noncurrent liabilities	(20.6)	(17.1)
Total	(21.7)	(18.1)
Amounts in accumulated other comprehensive loss, pre tax [Abstract]
Net actuarial loss (gain)	0.2	(1.5)
Prior service (credit) cost	0.1	0.2
Total	0.3	(1.3)
Prior service credit that will be amortized into net pension expense over the next fiscal year	0.1
Estimated future benefit payment [Abstract]
Estimated future employer contributions in next fiscal year	1.1
Weighted-average assumption used to determine net periodic benefit cost [Abstract]
Discount rate (in hundredths)	5.25%	5.25%	6.25%
Weighted-average assumption used to determine benefit obligation [Abstract]
Discount rate (in hundredths)	4.50%	5.25%
U.S. Other Retirement Benefit Plans [Member]
Net periodic benefit cost: [Abstract]
Net periodic benefit cost	2.3	1.9	1.8
International Pension Benefit Plans [Member]
Net periodic benefit cost: [Abstract]
Net periodic benefit cost	2.7	2.5	1.9
Change in benefit obligation: [Roll Forward]
Fair value of assets, beginning period	18.6
Fair value of assets, period end	19.6	18.6
Fair value of assets	19.6	18.6
Amounts in accumulated other comprehensive loss, pre tax [Abstract]
Accumulated benefit obligation	42.6	40.5
Estimated future benefit payment [Abstract]
Estimated future employer contributions in next fiscal year	1.8
Weighted-average assumption used to determine benefit obligation [Abstract]
Discount rate (in hundredths)	4.72%	5.09%
Rate of compensation increase (in hundredths)	2.70%	2.71%
Allocation range [Abstract]
Fair value of assets	19.6	18.6
U.S. Pension Benefit Plans [Member]
Net periodic benefit cost: [Abstract]
Net periodic benefit cost	11.4	11.7	14.9
Weighted-average assumption used to determine net periodic benefit cost [Abstract]
Long-term rate of return on assets (in hundredths)	7.75%	7.75%	7.75%
Weighted-average assumption used to determine benefit obligation [Abstract]
Discount rate (in hundredths)	4.90%	5.70%
Rate of compensation increase (in hundredths)	4.50%	4.50%
Percentage of global plan assets (in hundredths)	91.00%
Target allocation [Abstract]
Equity securities (in hundredths)	65.00%
Debt securities	35.00%
Allocation range [Abstract]
Equity securities, minimum (in hundredths)	60.00%
Equity securities, maximum (in hundredths)	70.00%
Debt securities, minimum (in hundredths)	30.00%
Debt securities, maximum (in hundredths)	40.00%
Other, maximum (in hundredths)	5.00%
U. S. Plans [Member]
Estimated future benefit payment [Abstract]
2012	15.5
2013	16.7
2014	19.4
2015	20.9
2016	22.3
2017 to 2021	130.2
Total	225.0
International Plans [Member]
Estimated future benefit payment [Abstract]
2012	1.2
2013	1.4
2014	1.6
2015	1.6
2016	2.1
2017 to 2021	14.1
Total	$ 22.0

XML

Derivative Financial Instruments (Details) In Millions, unless otherwise specified	12 Months Ended																		1 Months Ended	12 Months Ended
	Dec. 31, 2011 USD ($)	Dec. 31, 2010 USD ($)	Dec. 31, 2011 Cash Flow Hedges [Member] USD ($)	Dec. 31, 2010 Cash Flow Hedges [Member] USD ($)	Dec. 31, 2010 Cash Flow Hedges [Member] Foreign Currency Hedge Contracts [Member] Cost of Goods and Services Sold [Member] USD ($)	Dec. 31, 2011 Cash Flow Hedges [Member] Foreign Currency Hedge Contracts [Member] Net Sales [Member] USD ($)	Dec. 31, 2011 Cash Flow Hedges [Member] Interest Rate Swap Contracts [Member] Interest Expense [Member] USD ($)	Dec. 31, 2010 Cash Flow Hedges [Member] Interest Rate Swap Contracts [Member] Interest Expense [Member] USD ($)	Dec. 31, 2011 Net Investment Hedges [Member] USD ($)	Dec. 31, 2010 Net Investment Hedges [Member] USD ($)	Dec. 31, 2011 Net Investment Hedges [Member] Foreign Currency - Denominated Debt [Member] Foreign Exchange (Gains) Losses and Other [Member] USD ($)	Dec. 31, 2010 Net Investment Hedges [Member] Foreign Currency - Denominated Debt [Member] Foreign Exchange (Gains) Losses and Other [Member] USD ($)	Dec. 31, 2011 Interest Rate Swap, Series A Note [Member]	Dec. 31, 2011 Interest Rate Swap, Series B Note [Member]	Dec. 31, 2011 Euro-Denominated Note [Member] USD ($)	Dec. 31, 2011 Euro-Denominated Note [Member] EUR (€)	Dec. 31, 2011 Yen-Denominated Note [Member] USD ($)	Dec. 31, 2011 Yen-Denominated Note [Member] JPY (¥)	Jan. 31, 2011 Commodity Call Options [Member] USD ($) bbl	Dec. 31, 2011 Commodity Call Options [Member] USD ($)	Dec. 31, 2010 Commodity Call Options [Member] USD ($)	Dec. 31, 2011 Forward-Start Interest Rate Swap [Member] USD ($)
Derivative [Line Items]
Amount of Hedged Item																						$ 43.0
Fixed Interest Rate (in hundredths)													5.32%	5.51%								5.41%
Variable Rate Basis													three-month LIBOR	three-month LIBOR								one-month LIBOR
Maximum term (in years)																						five
Notional amount, nonderivative instruments																81.5		500.0
Cumulative foreign currency translation loss, pre-tax															5.2		1.0
Cumulative foreign currency translation loss, net of tax															3.2		0.6
Commodity Price Risk [Abstract]
Purchased call options, barrels of crude oil (in barrels)																			77,900
Premium paid to purchase call options																			0.5
Gain (loss) recorded in cost of goods and services sold, call options																				0.6	0.3
Derivative Instruments, Gain (Loss) [Line Items]
Amount of Gain (Loss) Recognized in OCI			(5.2)	(3.0)	0.5	(0.3)	(4.9)	(3.5)	1.3	3.9	1.3	3.9
Amount of Gain (Loss) Reclassified from Accumulated OCI into Income			3.5	2.7	(0.5)	0.3	3.2	3.2
Ineffectiveness, cash flow hedges	0	0
Ineffectiveness, net investment hedges	$ 0	$ 0

XML

Goodwill and Intangibles (Tables)

12 Months Ended

Dec. 31, 2011

Goodwill and Intangibles [Abstract]

Goodwill

The changes in the carrying amount of goodwill by reportable segment were as follows:

($ in millions)	Packaging Systems			Delivery Systems			Total
Balance, December 31, 2009	$	39.3		$	74.9		$	114.2
Additions		-			1.8			1.8
Foreign currency translation		(2.7	)		(0.8	)		(3.5	)
Balance, December 31, 2010		36.6			75.9			112.5
Foreign currency translation		(0.7	)		(0.3	)		(1.0	)
Balance, December 31, 2011	$	35.9		$	75.6		$	111.5

Intangible Assets and Accumulated Amortization

Intangible assets and accumulated amortization as of December 31 were as follows:

	2011							2010
($ in millions)	Cost		Accumulated Amortization			Net		Cost		Accumulated Amortization			Net
Patents and licensing	$	17.0	$	(6.7	)	$	10.3	$	15.7	$	(5.5	)	$	10.2
In-process R&D/technology		3.5		-			3.5		3.4		-			3.4
Trademarks		12.0		(0.8	)		11.2		12.1		(0.6	)		11.5
Customer relationships		29.7		(11.2	)		18.5		29.7		(9.5	)		20.2
Customer contracts		11.4		(3.1	)		8.3		11.5		(2.5	)		9.0
Non-compete agreements		3.9		(3.7	)		0.2		3.9		(3.1	)		0.8
	$	77.5	$	(25.5	)	$	52.0	$	76.3	$	(21.2	)	$	55.1

XML

Commitments and Contingent Liabilities (Details) (USD $) In Millions, unless otherwise specified	12 Months Ended
	Dec. 31, 2011	Dec. 31, 2010	Dec. 31, 2009
Commitments and Contingent Liabilities [Abstract]
Operating lease terms	ranging from one month to 20 years
Expected costs to construct new facility	$ 36.3
Expected direct capital expenditures	24.6
Expected costs for new facility, time period (in years)	1
Net rental expense	11.4	10.2	12.9
Sublease income	0.8	0.7	0.7
Operating Leases, Future Minimum Payments Due [Abstract]
2012	12.2
2013	6.3
2014	5.6
2015	4.1
2016	3.5
Thereafter	17.6
Total	49.3
Less sublease income	0.4
Total net	48.9
Unconditional contractual commitments for the purchase of raw materials, utilities and equipment	21.7
Unconditional contractual commitments due within one year	13.8
Accrual for insurance obligations	9.2
Receivable due from insurance company	5.2
Brazilian government penalties and interest on tax obligations, accrual	$ 7.8

XML

New Accounting Standards

12 Months Ended

Dec. 31, 2011

New Accounting Standards [Abstract]

New Accounting Standards

Note 17: New Accounting Standards

Recently Adopted Standards

In June 2011, the Financial Accounting Standards Board (“FASB”) issued guidance which requires an entity to present the total of comprehensive income, the components of net income, and the components of other comprehensive income either in a single continuous statement of comprehensive income, or in two separate but consecutive statements. This guidance eliminates the option to report components of other comprehensive income as part of the statement of equity. This guidance is effective for reporting periods beginning on or after December 15, 2011. In December 2011, the FASB issued updated guidance allowing entities to continue to report reclassifications of items out of accumulated other comprehensive income consistent with previous presentation requirements, but no other requirements included within the June 2011 guidance were affected. We were in compliance with this guidance as of December 31, 2011.

In December 2010, the FASB issued amended guidance for business combinations. The update addresses diversity in the interpretation of the pro forma revenue and earnings disclosure requirements for business combinations, and defines the periods for which pro forma information should be presented. This guidance was effective for us as of January 1, 2011 and will be applied prospectively to business combinations entered into on or after that date.

In September 2009, the FASB issued revised guidance for multiple-deliverable revenue arrangements. The guidance requires companies to allocate revenue in these types of arrangements based on an element’s estimated selling price if vendor-specific or other third-party evidence is not available. This guidance also expands required disclosures. We adopted this guidance as of January 1, 2011, on a prospective basis. The adoption did not have a material impact on our financial statements.

Standards Issued Not Yet Adopted

In September 2011, the FASB issued guidance for the impairment testing of goodwill. The guidance permits an entity to first assess qualitative factors to determine whether it is more-likely-than-not that the fair value of a reporting unit is less than its carrying amount as a basis for determining whether it is necessary to perform the two-step goodwill impairment test. This guidance is effective for annual and interim goodwill impairment tests performed for fiscal years beginning after December 15, 2011. Management believes that the adoption will not have a material impact on our financial statements.

In May 2011, the FASB issued guidance to provide a consistent definition of fair value and ensure that the fair value measurement and disclosure requirements are similar between U.S. GAAP and International Financial Reporting Standards. It also changes certain fair value measurement principles and expands the disclosures for fair value measurements that are estimated using significant unobservable inputs. This guidance is effective prospectively for fiscal years, and interim periods within those years, beginning after December 15, 2011. Management believes that the adoption will not have a material impact on our financial statements.

XML

Property plant and equipment (Details) (USD $) In Millions, unless otherwise specified	12 Months Ended
	Dec. 31, 2011	Dec. 31, 2010	Dec. 31, 2009
Property, Plant and Equipment [Line Items]
Property, plant and equipment	$ 1,136.8	$ 1,077.2
Depreciation expense	71.1	68.8	63.9
Capitalized leased assets, gross, buildings and improvements	2.3	2.4
Capitalized leased assets, gross, machinery and equipment	1.9	3.6
Accumulated depreciation, property, plant and equipment accounted for as capitalized leases	1.1	1.1
Capital Leases, Future Minimum Payments Due [Abstract]
2012	0.4
2013	0.3
2014	0.2
2015	0.2
Accrued liability, construction of new corporate office	22.4
Capitalized interest	1.1	0.9	2.4
Buildings and Improvements [Member]
Property, Plant and Equipment [Line Items]
Expected useful lives, minimum (in years)	5
Expected useful lives, maximum (in years)	50
Property, plant and equipment	284.1	276.4
Machinery and Equipment [Member]
Property, Plant and Equipment [Line Items]
Expected useful lives, minimum (in years)	10
Expected useful lives, maximum (in years)	15
Property, plant and equipment	565.7	568.7
Tools, Dies and Molds [Member]
Property, Plant and Equipment [Line Items]
Expected useful lives, minimum (in years)	4
Expected useful lives, maximum (in years)	7
Property, plant and equipment	85.8	84.8
Computer Equipment & Software [Member]
Property, Plant and Equipment [Line Items]
Expected useful lives, minimum (in years)	3
Expected useful lives, maximum (in years)	10
Property, plant and equipment	76.2	68.2
Land [Member]
Property, Plant and Equipment [Line Items]
Property, plant and equipment	8.9	9.0
Construction in Progress [Member]
Property, Plant and Equipment [Line Items]
Property, plant and equipment	$ 116.1	$ 70.1

XML

Summary of Significant Accounting Policies (Details) (USD $) In Millions, unless otherwise specified	Dec. 31, 2011	Dec. 31, 2010
Summary of Significant Accounting Policies [Abstract]
Finished goods	$ 67.1	$ 65.1
Work in process	19.6	21.4
Raw materials	65.1	60.5
Inventories	151.8	147.0
Allowance for doubtful accounts	$ 0.3	$ 0.5

XML

Segment Information (Tables)

12 Months Ended

Dec. 31, 2011

Segment Information [Abstract]

Sales by Significant Product

The following table provides information on sales by significant product group:

($ in millions)	2011			2010			2009
Pharmaceutical packaging	$	731.1		$	661.2		$	637.3
Disposable medical components		106.9			100.0			104.6
Laboratory and other services		19.4			23.8			34.1
Packaging Systems		857.4			785.0			776.0
Healthcare devices		177.4			178.8			165.9
Consumer products		69.4			64.7			57.4
Injection and administration systems		59.0			55.3			42.9
Tooling and other services		30.9			25.3			18.8
Delivery Systems		336.7			324.1			285.0
Intersegment sales elimination		(1.8	)		(4.4	)		(5.3	)
Net sales	$	1,192.3		$	1,104.7		$	1,055.7

Financial Information by Geographical Area

The following table presents sales and net property, plant and equipment, by the country in which the legal subsidiary is domiciled and assets are located:

	Sales						Property, Plant and Equipment, Net
($ in millions)	2011		2010		2009		2011		2010		2009
United States	$	543.6	$	528.2	$	502.8	$	272.6	$	232.8	$	242.5
Germany		184.1		151.5		148.3		118.1		117.8		129.9
France		94.2		89.0		105.3		41.3		42.4		45.9
Other European countries		242.7		225.6		209.3		69.9		77.2		83.2
Other		127.7		110.4		90.0		91.7		84.6		75.6
	$	1,192.3	$	1,104.7	$	1,055.7	$	593.6	$	554.8	$	577.1

Segment Information

The following tables provide summarized financial information for our segments:

($ in millions)	Packaging Systems		Delivery Systems		Corporate and Eliminations			Consolidated
2011
Net sales	$	857.4	$	336.7	$	(1.8	)	$	1,192.3
Operating profit	$	152.6	$	9.8	$	(52.8	)	$	109.6
Interest expense, net		-		-		(16.9	)		(16.9	)
Income before income taxes	$	152.6	$	9.8	$	(69.7	)	$	92.7
Segment assets	$	843.5	$	365.6	$	190.0		$	1,399.1
Capital expenditures		66.2		26.1		3.1			95.4
Depreciation and amortization expense		53.6		18.5		3.6			75.7
2010
Net sales	$	785.0	$	324.1	$	(4.4	)	$	1,104.7
Operating profit	$	139.3	$	9.7	$	(58.3	)	$	90.7
Interest expense, net		-		-		(16.2	)		(16.2	)
Income before income taxes	$	139.3	$	9.7	$	(74.5	)	$	74.5
Segment assets	$	814.4	$	350.6	$	129.3		$	1,294.3
Capital expenditures		48.9		16.3		5.9			71.1
Depreciation and amortization expense		50.7		19.0		3.5			73.2
2009
Net sales	$	776.0	$	285.0	$	(5.3	)	$	1,055.7
Operating profit	$	138.3	$	9.9	$	(50.7	)	$	97.5
Interest expense, net		-		-		(14.4	)		(14.4	)
Income before income taxes	$	138.3	$	9.9	$	(65.1	)	$	83.1
Segment assets	$	824.7	$	335.1	$	111.2		$	1,271.0
Capital expenditures		84.8		18.6		1.5			104.9
Depreciation and amortization expense		46.7		18.5		2.9			68.1

XML

Debt (Details) In Millions, except Per Share data, unless otherwise specified	12 Months Ended					12 Months Ended		12 Months Ended		12 Months Ended			12 Months Ended			2 Months Ended	12 Months Ended					12 Months Ended		1 Months Ended	12 Months Ended
	Dec. 31, 2011 USD ($)	Dec. 31, 2010 USD ($)	Dec. 31, 2009 USD ($)	Dec. 31, 2011 Capital Leases [Member] USD ($)	Dec. 31, 2010 Capital Leases [Member] USD ($)	Dec. 31, 2011 Series A Floating Rate Notes Due 2012 [Member] USD ($)	Dec. 31, 2010 Series A Floating Rate Notes Due 2012 [Member] USD ($)	Dec. 31, 2011 Series B Floating Rate Notes Due 2015 [Member] USD ($)	Dec. 31, 2010 Series B Floating Rate Notes Due 2015 [Member] USD ($)	Dec. 31, 2011 EURO Note A Due 2013 [Member] USD ($)	Dec. 31, 2011 EURO Note A Due 2013 [Member] EUR (€)	Dec. 31, 2010 EURO Note A Due 2013 [Member] USD ($)	Dec. 31, 2011 EURO Note B Due 2016 [Member] USD ($)	Dec. 31, 2011 EURO Note B Due 2016 [Member] EUR (€)	Dec. 31, 2010 EURO Note B Due 2016 [Member] USD ($)	Apr. 30, 2007 Convertible Debt Due 2047 [Member] USD ($)	Dec. 31, 2011 Convertible Debt Due 2047 [Member] USD ($)	Dec. 31, 2010 Convertible Debt Due 2047 [Member] USD ($)	Dec. 31, 2011 Floating Rate Notes [Member] USD ($)	Dec. 31, 2011 EURO Note [Member] EUR (€)	Dec. 31, 2011 Term Loan Due 2014 [Member] USD ($)	Dec. 31, 2011 Revolving Credit Facility Due 2014 [Member] USD ($)	Jun. 30, 2010 Revolving Credit Facility Due 2014 [Member] USD ($)	Jun. 30, 2010 Prior Credit Facility [Member] USD ($)	Dec. 31, 2011 $50 Million Credit Facility [Member] USD ($)
Debt Disclosure [Abstract]
Notes payable and other current debt	$ 50.1	$ 0.3
Total debt	349.4	358.4
Line of Credit Facility [Line Items]
Line of credit facility, current borrowing capacity																						225.0
Basis spread on variable interest rate, maximum (in hundredths)																						2.75%			1.50%
Line of credit facility capacity, maximum																						275.0			50.0
Credit facility agreement, interest coverage ratio description																									interest coverage ratio greater than or equal to 2.50 to 1.00
Credit facility agreement, leverage ratio description																									total leverage ratio no greater than 3.50 to 1.00
Line of credit facility swing-line loans, maximum																						20.0
Line of credit facility, Maximum amount available for the issuance of standby letters of credit																						20.0
Variable rate basis						LIBOR		LIBOR														LIBOR			one-month LIBOR
Basis spread on variable interest rate, minimum (in hundredths)																						1.75%
Debt covenant, total indebtedness to earnings before income tax, maximum																						Under the leverage ratio, our total indebtedness cannot exceed three-and one-half (3.5) times our earnings before income tax, depreciation and amortization for any period of four consecutive quarters
Extinguishment of debt																								26.6
Debt issuance costs																5.2							1.7		0.3
Quarterly commitment fee, minimum (in hundredths)																						0.325%
Quarterly commitment fee, maximum (in hundredths)																						0.55%
Letters of credit outstanding																						3.3
Unused commitment level																						215.3
Interest rate (in hundredths)						1.20%		1.30%		4.20%	4.20%		4.40%	4.40%			4.00%				8.40%	2.10%
Line of credit facility, expiration date																						2014
Debt Instrument [Line Items]
Debt instrument, Face amount						50.0		25.0		26.3	20.4		79.0	61.1					75.0	81.5
Tranches of private placement of notes	2
Long-term debt	299.3	358.1				50.0	50.0	25.0	25.0	26.3		27.0	79.0		81.0		161.5	161.5			0.2
Interest rate, minimum (in hundredths)				5.30%
Interest rate, maximum (in hundredths)				6.00%
Term of debt (in years)										7 years	7 years		10 years	10 years
Stated interest rate (in hundredths)						1.20%		1.30%		4.20%	4.20%		4.40%	4.40%			4.00%				8.40%	2.10%
Convertible debt, conversion price (in dollars per share)																	$ 55.44
Conversion ratio of debt per $1,000 of debt																	18.0386
Debentures automatic conversion feature																	On or after March 20, 2012, if our common stock closing price exceeds 150% of the then prevailing conversion price for at least 20 trading days during any 30 consecutive trading day period, we have the option to cause the debentures to be automatically converted into West shares at the prevailing conversion rate.
Net proceeds from the offering of convertible debt																156.3
Interest expense	19.3	17.7	17.6
Capital leases				1.0	1.7
Line of credit facility, amount outstanding	6.4	12.2
Long-term debt	299.3	358.1				50.0	50.0	25.0	25.0	26.3		27.0	79.0		81.0		161.5	161.5			0.2
Debt instrument, maturity date						Jul. 28, 2012		Jul. 28, 2015		Feb. 27, 2013	Feb. 27, 2013		Feb. 27, 2016	Feb. 27, 2016			Mar. 15, 2047
Variable rate basis						LIBOR		LIBOR														LIBOR			one-month LIBOR
Basis spread on variable interest rate, maximum (in hundredths)						0.80%		0.90%
Debt issuance costs																5.2							1.7		0.3
Aggregate annual maturities of long-term debt [Abstract]
2013	26.7
2014	6.6
2015	25.0
2016	79.5
Thereafter	$ 161.5

XML

Net Income Per Share (Details) (USD $) In Millions, unless otherwise specified	12 Months Ended
	Dec. 31, 2011	Dec. 31, 2010	Dec. 31, 2009
Net income per share
Net income, as reported, for basic net income per share	$ 75.5	$ 65.3	$ 72.6
Plus: interest expense on convertible debt, net of tax	4.3	4.3	4.3
Net income for diluted net income per share	$ 79.8	$ 69.6	$ 76.9
Weighted average common shares outstanding (in shares)	33.7	33.3	32.8
Assumed stock options exercised and awards vested, based on the treasury stock method (in shares)	0.4	0.5	0.6
Assumed conversion of convertible debt, based on the if-converted method (in shares)	2.9	2.9	2.9
Weighted average shares assuming dilution (in shares)	37.0	36.7	36.3
Antidilutive options excluded from computation of diluted net income (in shares)	1.6	1.1	1.1

XML

Summary of Significant Accounting Policies

12 Months Ended

Dec. 31, 2011

Summary of Significant Accounting Policies [Abstract]

Summary of Significant Accounting Policies

Note 1: Summary of Significant Accounting Policies

Principles of Consolidation:The consolidated financial statements include the accounts of West Pharmaceutical Services, Inc. and its majority-owned subsidiaries (which may be referred to as “West”, the “Company”, “we”, “us” or “our”) after the elimination of intercompany transactions. We have no participation or other rights in variable interest entities.

Reclassifications:  Certain reclassifications were made to prior period financial statements to conform to the current year presentation.

Use of Estimates: The financial statements are prepared in conformity with generally accepted accounting principles in the United States (“U.S. GAAP”). These principles require management to make estimates and assumptions that affect the reported amounts of assets, liabilities, revenues and expenses and the disclosure of contingencies in the financial statements. Actual amounts realized may differ from these estimates.

Cash and Cash Equivalents:  Cash equivalents include time deposits, certificates of deposit and all highly liquid debt instruments with maturities of three months or less at the time of purchase.

Accounts Receivable: Our accounts receivable balance was net of an allowance for doubtful accounts of $0.3 million and $0.5 million at December 31, 2011 and 2010, respectively. We record the allowance based on a specific identification methodology.

Inventories: Inventories are valued at the lower of standard cost (which approximates actual cost on a first-in-first-out basis) or market. The following is a summary of inventories at December 31:

($ in millions)	2011		2010
Finished goods	$	67.1	$	65.1
Work in process		19.6		21.4
Raw materials		65.1		60.5
	$	151.8	$	147.0

Property, Plant and Equipment: Property, plant and equipment assets are carried at cost. Maintenance and minor repairs and renewals are charged to expense as incurred. Costs incurred for computer software developed or obtained for internal use are capitalized for application development activities and immediately expensed for preliminary project activities or post-implementation activities. Upon sale or retirement of depreciable assets, costs and related accumulated depreciation are eliminated, and gains or losses are recognized in restructuring and other items. Depreciation and amortization are computed principally using the straight-line method over the estimated useful lives of the assets, or the remaining term of the lease, if shorter.

Impairment of Goodwill and Other Intangible Assets: Goodwill and indefinite-lived intangibles are tested for impairment at least annually, following the completion of our annual budget and long-range planning process, or whenever circumstances indicate that the carrying value of these assets may not be recoverable. Goodwill is tested for impairment as part of the reporting unit to which it belongs. Our reporting units are the same as, or one level below, our operating segments. The goodwill impairment test first requires a comparison of the fair value of each reporting unit to its carrying amount, including goodwill. If the carrying amount exceeds fair value, a second step must be performed. The second step requires the comparison of the carrying amount of the goodwill to its implied fair value, which is calculated as if the reporting unit had just been acquired as of the testing date. Any excess of the carrying amount of goodwill over the implied fair value would represent an impairment loss.

Certain trademarks and in-process R&D have been determined to have indefinite lives and, therefore, are not subject to amortization. Impairment testing for indefinite-lived intangible assets requires a comparison between the fair value and carrying value of the asset, and any excess carrying value would represent an impairment. Fair values are primarily determined using discounted cash flow analyses.

Intangible assets with finite lives are amortized using the straight-line method over their estimated useful lives of 5 to 25 years, and reviewed for recovery whenever circumstances indicate that the carrying value of these assets may not be recoverable.

Impairment of Long-Lived Assets: Long-lived assets, including property, plant and equipment, are tested for impairment whenever circumstances indicate that the carrying value of these assets may not be recoverable. An asset is considered impaired if the carrying value of the asset exceeds the sum of the future expected undiscounted cash flows to be derived from the asset. Once an asset is considered impaired, an impairment loss is recorded within restructuring and other items for the difference between the asset's carrying value and its fair value. For assets held and used in the business, management determines fair value using estimated future cash flows to be derived from the asset, discounted to a net present value using an appropriate discount rate. For assets held for sale or for investment purposes, management determines fair value by estimating the proceeds to be received upon sale of the asset, less disposition costs.

Employee Benefits: The measurement of the obligations under our defined benefit pension and postretirement medical plans are subject to a number of assumptions. These include the rate of return on plan assets (for funded plans) and the rate at which the future obligations are discounted to present value. U.S. GAAP requires the recognition of an asset or liability for the funded status of a defined benefit postretirement plan, as measured by the difference between the fair value of plan assets, if any, and the benefit obligation. For a pension plan, the benefit obligation is the projected benefit obligation; for any other postretirement plan, such as a retiree health plan, the benefit obligation is the accumulated postretirement benefit obligation. See Note 14, Benefit Plans, for a more detailed discussion of our pension and other retirement plans.

Financial Instruments: All derivatives are recognized as either assets or liabilities in the balance sheet and recorded at their fair value. For a derivative designated as hedging the exposure to variable cash flows of a forecasted transaction (referred to as a cash flow hedge), the effective portion of the derivative's gain or loss is initially reported as a component of other comprehensive income, net of tax, and subsequently reclassified into earnings when the forecasted transaction affects earnings. For a derivative designated as hedging the exposure to changes in the fair value of a recognized asset or liability or a firm commitment (referred to as a fair value hedge), the derivative’s gain or loss is recognized in earnings in the period of change together with the offsetting loss or gain on the hedged item. For a derivative designated as hedging the foreign currency exposure of a net investment in a foreign operation, the gain or loss is reported in other comprehensive income, net of tax, as part of the cumulative translation adjustment. The ineffective portion of any derivative used in a hedging transaction is recognized immediately into earnings. Derivative financial instruments that are not designated as hedges are also recorded at fair value, with the change in fair value recognized immediately into earnings. We do not purchase or hold any derivative financial instrument for investment or trading purposes.

Foreign Currency Translation: Foreign currency transaction gains and losses are recognized in the determination of net income. Foreign currency translation adjustments of subsidiaries and affiliates operating outside of the United States are accumulated in other comprehensive income, a separate component of equity.

Revenue Recognition: Revenue is recognized when persuasive evidence of a sales arrangement exists, title and risk of loss have transferred, the selling price is fixed or determinable, and collectability is reasonably assured. Generally, sales are recognized upon shipment or upon delivery to our customers’ site, based upon shipping terms or legal requirements. Some customers receive pricing rebates upon attaining established sales volumes. We record rebate costs when sales occur based on our assessment of the likelihood that these volumes will be attained. We also establish product return liabilities for customer quality claims when such amounts are deemed probable and can be reasonably estimated.

Shipping and Handling Costs: Shipping and handling costs are included in cost of goods and services sold. Shipping and handling costs billed to customers in connection with the sale are included in net sales.

Research and Development: Research and development expenditures are for the creation, engineering and application of new or improved products and processes. Expenditures include primarily salaries and outside services for those directly involved in research and development activities and are expensed as incurred.

Environmental Remediation and Compliance Costs: Environmental remediation costs are accrued when such costs are probable and reasonable estimates are determinable. Cost estimates include investigation, cleanup and monitoring activities; such estimates are adjusted, if necessary, based on additional findings. Environmental compliance costs are expensed as incurred as part of normal operations.

Litigation: From time to time, we are involved in product liability matters and other legal proceedings and claims generally incidental to our normal business activities. In accordance with U.S. GAAP, we accrue for loss contingencies when it is probable that a liability has been incurred and the amount of the loss can be reasonably estimated. These estimates are based on an analysis made by internal and external legal counsel considering information known at the time. Legal costs in connection with loss contingencies are expensed as incurred.

Income Taxes: Deferred income taxes are recognized by applying enacted statutory tax rates, applicable to future years, to temporary differences between the tax basis and financial statement carrying values of our assets and liabilities. Valuation allowances are established when it is more likely than not that all or a portion of a deferred tax asset will not be realized. No provision is made for the U.S. income taxes on the undistributed earnings of wholly-owned foreign subsidiaries as such earnings are intended to be permanently reinvested. We recognize interest costs related to income taxes in interest expense and penalties within restructuring and other items. The tax law ordering approach is used for purposes of determining whether an excess tax benefit has been realized during the year.

Stock-Based Compensation: Under the fair value provisions of U.S. GAAP, stock-based compensation cost is measured at the grant date based on the value of the award and is recognized as expense over the vesting period. In order to determine the fair value of stock options on the grant date, the company uses the Black-Scholes valuation model.

Net Income Per Share: Basic net income per share is computed by dividing net income attributable to common shareholders by the weighted average number of shares of common stock outstanding during each period. Net income per share assuming dilution considers the dilutive effect of outstanding stock options and other stock awards based on the treasury stock method, as well as convertible debt based on the if-converted method. The treasury stock method assumes the use of exercise proceeds to repurchase common stock at the average fair market value in the period. The if-converted method assumes conversion of the debt at the beginning of the reporting period (or at time of issuance, if later). In addition, interest charges applicable to the convertible debt, net of tax, are added back to net income for the purpose of this calculation.

XML

Acquisitions (Details) (USD $) In Millions, unless otherwise specified			12 Months Ended
	Dec. 31, 2011	Dec. 31, 2010	Dec. 31, 2011 La Model Ltd. [Member]	Jul. 01, 2010 La Model Ltd. [Member]	Jul. 06, 2009 Plastef Investissements SA [Member]
Business Acquisition [Line Items]
Outstanding shares acquired (in hundredths)				100.00%
Cash consideration				$ 2.5	$ 16.9
Contingent consideration, at fair value	2.1	2.3		1.5	2.6
Purchase Price Allocation [Abstract]
Intangible assets				3.3
Goodwill				1.2	7.8
Deferred tax liabilities				0.6
Property, plant and equipment					4.9
Other intangible assets					8.8
Real property and equipment lease obligations					2.4
Estimated probable range of contingent consideration payments (in years)			Five
Estimated probable range of contingent consideration, minimum			0
Estimated probable range of contingent consideration, maximum			$ 5.0

XML

Income Taxes (Tables)

12 Months Ended

Dec. 31, 2011

Income Taxes [Abstract]

Reconciliation of unrecognized tax benefits

A reconciliation of the beginning and ending amount of the liability for unrecognized tax benefits is as follows:

($ in millions)	2011			2010
Balance at January 1	$	5.0		$	5.6
Additions for tax positions taken in the current year		1.3			0.6
Additions for tax positions of prior years		0.7			1.1
Reduction for expiration of statute of limitations/audits		(0.7	)		(2.3	)
Balance at December 31	$	6.3		$	5.0

Components of income before taxes

The components of income before income taxes are:

($ in millions)	2011		2010		2009
U.S. operations	$	15.8	$	7.2	$	6.5
International operations		76.9		67.3		76.6
Total income before income taxes	$	92.7	$	74.5	$	83.1

Income tax provision components, by jurisdiction

The related provision for income taxes consists of:

($ in millions)	2011		2010			2009
Current:
Federal	$	-	$	0.6		$	0.3
State		-		0.2			0.1
International		20.6		14.6			17.9
Current income tax provision		20.6		15.4			18.3
Deferred:
Federal and state		2.7		(0.5	)		(5.1	)
International		0.2		(1.3	)		0.3
Deferred income tax provision		2.9		(1.8	)		(4.8	)
Income tax expense	$	23.5	$	13.6		$	13.5

Components of deferred tax assets and liabilities

The significant components of our deferred tax assets and liabilities at December 31 are:

($ in millions)	2011			2010
Deferred tax assets
Net operating loss carryforwards	$	21.7		$	28.1
Tax credit carryforwards		42.5			33.3
Restructuring and impairment charges		1.7			5.5
Capital loss carryforwards		-			1.4
Pension and deferred compensation		62.3			48.6
Other		9.3			8.7
Valuation allowance		(19.3	)		(24.9	)
Total deferred tax assets		118.2			100.7
Deferred tax liabilities:
Accelerated depreciation		41.2			39.5
Other		6.5			7.1
Total deferred tax liabilities		47.7			46.6
Net deferred tax asset	$	70.5		$	54.1

Federal tax rate reconciliation

A reconciliation of the U.S. federal corporate tax rate to our effective consolidated tax rate on income before income taxes follows:

	2011			2010			2009
U.S. federal corporate tax rate		35.0	%		35.0	%		35.0	%
Tax on international operations less than U.S. tax rate		(8.9	)		(11.0	)		(7.6	)
Non-benefited losses		-			1.4			2.0
Reversal of prior valuation allowance		(0.1	)		(0.2	)		(1.2	)
Reversal of reserves for unrecognized tax benefits		-			(3.0	)		(3.4	)
U.S. tax on international earnings, net of foreign tax credits		(1.5	)		(2.2	)		(3.2	)
State income taxes, net of federal tax effect		0.7			(1.6	)		(1.1	)
General business credits and Section 199 Deduction		(2.4	)		(1.5	)		(5.4	)
Other		2.5			1.4			1.1
Effective tax rate		25.3	%		18.3	%		16.2	%

XML

Restructuring and Other Items (Tables)

12 Months Ended

Dec. 31, 2011

Restructuring and Other Items [Abstract]

Schedule of restructuring and other items

Restructuring and other items consisted of:

($ in millions)	2011			2010			2009
Restructuring and related charges
Severance and post-employment benefits	$	2.3		$	10.5		$	3.0
Impairments and asset write-offs		-			5.2			5.3
Other restructuring charges		3.0			0.2			0.4
Total restructuring and related charges		5.3			15.9			8.7
Other items:
Special separation benefits		2.9			-			-
Acquisition-related contingencies		(0.2	)		(1.8	)		-
Brazil tax amnesty benefit		-			-			(2.0	)
Foreign exchange losses and other		1.5			1.7			1.8
Total other items		4.2			(0.1	)		(0.2	)
Total restructuring and other items	$	9.5		$	15.8		$	8.5

Rollforward of restructuring obligations

The following table presents activity related to our restructuring obligations recorded within other current liabilities:

($ in millions)	Severance and benefits			Other Costs			Total
Balance, December 31, 2009	$	1.9		$	0.1		$	2.0
Charges		10.4			0.2			10.6
Cash payments		(2.1	)		(0.3	)		(2.4	)
Balance, December 31, 2010		10.2			-			10.2
Charges		2.3			3.0			5.3
Cash payments		(6.3	)		(2.6	)		(8.9	)
Non-cash adjustment		-			0.2			0.2
Balance, December 31, 2011	$	6.2		$	0.6		$	6.8

XML

Affiliated Companies (Details) (USD $) In Millions, unless otherwise specified	12 Months Ended
	Dec. 31, 2011	Dec. 31, 2010	Dec. 31, 2009
Schedule of Equity Method Investments [Line Items]
Ownership interest (in hundredths)	49.00%
Unremitted income of affiliated companies	$ 37.5	$ 31.5	$ 27.4
Dividends received from affiliated companies	0.3	0.3	0.3
Unrealized (gains) losses on securities of affiliates	(0.4)	(0.1)	0.5
Purchases and royalty payments made to affiliates	66.4	49.3	45.4
Purchases and royalty due and payable	9.2	4.3
Sales to affiliates	4.5	2.4	1.9
Due from affiliates	1.3	0.5
Investments in equity method affiliates	$ 56.2	$ 48.2
Aluplast S.A. de C.V. [Member]
Schedule of Equity Method Investments [Line Items]
Ownership interest (in hundredths)	49.00%
Pharma Tap S.A. de C.V. [Member]
Schedule of Equity Method Investments [Line Items]
Ownership interest (in hundredths)	49.00%
Daikyo Seiko, Ltd. [Member]
Schedule of Equity Method Investments [Line Items]
Ownership interest (in hundredths)	25.00%

XML

Restructuring and Other Items (Details) (USD $) In Millions, unless otherwise specified	12 Months Ended
	Dec. 31, 2011	Dec. 31, 2010	Dec. 31, 2009
Restructuring and related charges [Abstract]
Severance and post-employment benefits	$ 2.3	$ 10.5	$ 3.0
Impairments and asset write-offs	0	5.2	5.3
Other restructuring charges	3.0	0.2	0.4
Total restructuring and related charges	5.3	15.9	8.7
Other items [Abstract]
Acquisition-related contingencies	(0.2)	(1.8)	0
Special separation benefits	2.9	0	0
Brazil tax amnesty benefit	0	0	(2.0)
Foreign exchange (gains) losses and other	1.5	1.7	1.8
Total other items	4.2	(0.1)	(0.2)
Total restructuring and other items	9.5	15.8	8.5
Restructuring Obligation [Roll forward]
Beginning Balance	10.2	2.0
Charges	5.3	10.6
Cash Payments	(8.9)	(2.4)
Non-cash adjustment	0.2
Ending Balance	6.8	10.2	2.0
Severance and post-employment benefits	2.3	10.5	3.0
Other restructuring charges	3.0	0.2	0.4
Purchase price contingent consideration at fair value	2.1	2.3
Acquisition-related contingencies	(0.2)	(1.8)	0
Cost-basis investment impairment charge			0.8
Reduction in contingent consideration liability - eris	0.8	1.8
Increase in contingent consideration liability - SmartDose	0.5
2010 Program [Member]
Restructuring and related charges [Abstract]
Severance and post-employment benefits		10.1
Restructuring Obligation [Roll forward]
Expected total restructuring and related charges	22.0
Expected cash expenditures	17.0
Expected non-cash charges	5.0
Total restructuring and related charges	5.3	14.5
Severance and post-employment benefits		10.1
Impairments and asset write-offs		4.4
2009 Program [Member]
Restructuring and related charges [Abstract]
Severance and post-employment benefits		0.4
Restructuring Obligation [Roll forward]
Total restructuring and related charges		1.4	7.6
Severance and post-employment benefits		0.4
Impairments and asset write-offs		0.8
Other exit costs		0.2
Restructuring and related charges incurred to date		9.0
2007 Program [Member]
Restructuring Obligation [Roll forward]
Total restructuring and related charges			1.1
Severance and benefits [Member]
Restructuring Obligation [Roll forward]
Beginning Balance	10.2	1.9
Charges	2.3	10.4
Cash Payments	(6.3)	(2.1)
Non-cash adjustment	0
Ending Balance	6.2	10.2
Other Costs [Member]
Restructuring Obligation [Roll forward]
Beginning Balance	0	0.1
Charges	3.0	0.2
Cash Payments	(2.6)	(0.3)
Non-cash adjustment	0.2
Ending Balance	$ 0.6	$ 0

XML

Derivative Financial Instruments (Tables)

12 Months Ended

Dec. 31, 2011

Derivative Financial Instruments [Abstract]

Effects of Derivative Instruments on Other Comprehensive Income ('OCI') and earnings

The following table summarizes the effects of derivative instruments designated as hedges on other comprehensive income (“OCI”) and earnings for the year ended December 31:

	Amount of Gain (Loss) Recognized in OCI						Amount of (Gain) Loss Reclassified from Accumulated OCI into Income					Location of Gain (Loss) Reclassified from Accumulated OCI into Income
($ in millions)	2011			2010			2011		2010
Cash Flow Hedges:
Foreign currency hedge contracts	$	(0.3	)	$	-		$	0.3	$	-		Net sales
Foreign currency hedge contracts		-			0.5			-		(0.5	)	Cost of goods and services sold
Interest rate swap contracts		(4.9	)		(3.5	)		3.2		3.2		Interest expense
Total	$	(5.2	)	$	(3.0	)	$	3.5	$	2.7
Net Investment Hedges:
Foreign currency-denominated debt	$	1.3		$	3.9		$	-	$	-		Foreign exchange losses and other
Total	$	1.3		$	3.9		$	-	$	-

XML

Net Income Per Share (Tables)

12 Months Ended

Dec. 31, 2011

Net income per share

Net income and shares used in basic and diluted net income per share

The following table reconciles net income and shares used in the calculation of basic net income per share to those used for diluted net income per share:

($ and shares in millions)	2011		2010		2009
Net income, as reported, for basic net income per share	$	75.5	$	65.3	$	72.6
Plus: interest expense on convertible debt, net of tax		4.3		4.3		4.3
Net income for diluted net income per share	$	79.8	$	69.6	$	76.9
Weighted average common shares outstanding		33.7		33.3		32.8
Assumed stock options exercised and awards vested, based on the treasury stock method		0.4		0.5		0.6
Assumed conversion of convertible debt, based on the if-converted method		2.9		2.9		2.9
Weighted average shares assuming dilution		37.0		36.7		36.3

XML

CONSOLIDATED STATEMENTS OF CASH FLOWS (USD $) In Millions, unless otherwise specified	12 Months Ended
	Dec. 31, 2011	Dec. 31, 2010	Dec. 31, 2009
Cash flows from operating activities:
Net income	$ 75.5	$ 65.3	$ 72.6
Adjustments to reconcile net income to net cash provided by operating activities of continuing operations:
Depreciation	71.1	68.8	63.9
Amortization	4.6	4.4	4.2
Stock-based compensation	8.4	7.8	7.5
(Gain) loss on sales of equipment	(0.2)	0.7	0.9
Asset impairments	0	4.4	5.8
Deferred income taxes	2.9	(1.8)	(4.8)
Pension and other retirement plans, net	(4.5)	5.4	5.9
Equity in undistributed earnings of affiliates, net of dividends	(6.0)	(4.2)	(2.7)
Changes in assets and liabilities, net of acquisitions:
(Increase) decrease in accounts receivable	(25.5)	9.4	(6.0)
Increase in inventories	(9.3)	(20.7)	(6.4)
Increase in other current assets	(3.1)	(3.9)	(0.1)
Increase (decrease) in accounts payable	24.6	(0.3)	(0.7)
Changes in other assets and liabilities	(7.8)	3.0	(2.4)
Net cash provided by operating activities	130.7	138.3	137.7
Cash flows from investing activities:
Capital expenditures	(95.4)	(71.1)	(104.9)
Acquisition of patents and other long-term assets	(1.4)	(2.7)	(2.9)
Acquisition of businesses, net of cash acquired	0	(3.7)	(16.9)
Sales of investments	15.6	8.9	5.3
Purchases of investments	(41.2)	(7.2)	(2.7)
Other, net	1.9	1.8	0.2
Net cash used in investing activities	(120.5)	(74.0)	(121.9)
Cash flows from financing activities:
Borrowings under revolving credit agreements	193.4	26.6	16.4
Repayments under revolving credit agreements	(199.9)	(39.8)	(22.3)
Debt issuance costs	(0.3)	(1.7)	0
Changes in other debt, including overdrafts	(0.5)	(1.1)	(4.3)
Dividend payments	(23.2)	(21.7)	(20.1)
Issuance of common stock from treasury	5.8	3.7	5.0
Excess tax benefit from employee stock plans	3.5	2.1	4.0
Shares repurchased for employee tax withholdings	(3.5)	(2.1)	(1.3)
Net cash used in financing activities	(24.7)	(34.0)	(22.6)
Effect of exchange rates on cash	(3.9)	(3.2)	2.7
Net (decrease) increase in cash and cash equivalents	(18.4)	27.1	(4.1)
Cash and cash equivalents at beginning of period	110.2	83.1	87.2
Cash and cash equivalents at end of period	91.8	110.2	83.1
Supplemental cash flow information:
Interest paid, net of amounts capitalized	18.2	16.8	15.5
Income taxes paid, net	20.4	16.5	19.0
Accrued capital expenditures	33.8	7.1	9.9
Dividends declared, not paid	$ 6.1	$ 5.7	$ 5.3

XML

Comprehensive Income (Tables)

12 Months Ended

Dec. 31, 2011

Comprehensive Income [Abstract]

Accumulated Other Comprehensive Income Loss Net Of Tax

The components of accumulated other comprehensive loss, net of tax, at December 31 were as follows:

($ in millions)	2011			2010
Foreign currency translation	$	10.2		$	22.0
Unrealized gains on securities of affiliates		0.4			0.1
Unrealized losses on derivatives		(5.4	)		(3.7	)
Defined benefit pension and other postretirement plans		(76.7	)		(49.7	)
	$	(71.5	)	$	(31.3	)

XML

Stock-Based Compensation (Tables)

12 Months Ended

Dec. 31, 2011

Stock-Based Compensation [Abstract]

Stock-based compensation expense

The following table summarizes our stock-based compensation expense for the years ended December 31:

($ in millions)	2011		2010		2009
Stock option and appreciation rights	$	4.4	$	3.7	$	3.7
Performance-vesting shares		3.0		2.2		1.8
Performance-vesting units		0.2		0.1		-
Performance-vesting shares/units dividend equivalents		0.1		0.2		0.2
Employee stock purchase plan		0.3		0.3		0.3
Deferred compensation plans		0.4		1.3		1.5
Total stock-based compensation expense	$	8.4	$	7.8	$	7.5

Changes in outstanding options

The following table summarizes changes in outstanding options:

(in millions, except per share data)	2011			2010			2009
Options outstanding, January 1		2.9			2.7			2.6
Granted		0.5			0.6			0.4
Exercised		(0.4	)		(0.3	)		(0.3	)
Forfeited		(0.1	)		(0.1	)		-
Options outstanding, December 31		2.9			2.9			2.7
Options exercisable, December 31		1.8			1.8			1.7
Weighted Average Exercise Price		2011			2010			2009
Options outstanding, January 1	$	32.32		$	29.09		$	26.91
Granted		40.85			42.47			32.12
Exercised		17.69			14.88			13.70
Forfeited		41.40			41.47			37.43
Options outstanding, December 31	$	35.79		$	32.32		$	29.09
Options exercisable, December 31	$	32.91		$	27.77		$	24.52

Changes in outstanding SARs

The following table summarizes changes in outstanding SARs:

	2011			2010			2009
SARs outstanding, January 1		111,048			78,512			56,012
Granted		63,024			36,255			22,500
Exercised		(7,685	)		(3,719	)		-
Forfeited		(4,281	)		-			-
SARs outstanding, December 31		162,106			111,048			78,512
SARs exercisable, December 31		58,900			41,439			24,861

Weighted Average Exercise Price	2011		2010		2009
SARs outstanding, January 1	$	39.74	$	38.04	$	40.43
Granted		41.13		42.68		32.09
Exercised		39.15		32.50		-
Forfeited		40.85		-		-
SARs outstanding, December 31		40.28		39.74		38.04
SARs exercisable, December 31	$	39.72	$	39.16	$	39.22

Outstanding PVS awards

The following table summarizes changes in our outstanding PVS awards:

	2011			2010			2009
Non-vested PVS awards, January 1		347,550			327,498			330,458
Granted at target level		101,099			123,068			125,600
Adjustments above/(below) target		(58,175	)		(48,364	)		(5,112	)
Vested and converted		(51,756	)		(50,337	)		(80,083	)
Forfeited		(10,199	)		(4,315	)		(43,365	)
Non-vested PVS awards, December 31		328,519			347,550			327,498
Weighted Average Grant Date Fair Value		2011			2010			2009
Non-vested PVS awards, January 1	$	39.21		$	39.63		$	40.62
Granted at target level		40.85			42.34			32.12
Adjustments above/(below) target		41.95			44.99			32.69
Vested and converted		40.85			38.22			32.69
Forfeited		38.46			37.61			39.10
Non-vested PVS awards, December 31	$	38.77		$	39.21		$	39.63

Outstanding PVU awards

The following table summarizes changes in our outstanding PVU awards:

	2011			2010			2009
Non-vested PVU awards, January 1		23,420			20,792			19,346
Granted at target level		13,442			7,697			7,200
Adjustments above/(below) target		(4,165	)		(2,484	)		(345	)
Vested and converted		(3,963	)		(2,585	)		(5,409	)
Forfeited		(1,718	)		-			-
Non-vested PVU awards, December 31		27,286			23,420			20,792
Weighted Average Grant Date Fair Value		2011			2010			2009
Non-vested PVU awards, January 1	$	38.94		$	39.17		$	39.85
Granted at target level		41.11			42.30			32.09
Adjustments above/(below) target		41.05			38.22			32.59
Vested and converted		40.85			38.22			32.59
Forfeited		37.55			-			-
Non-vested PVU awards, December 31	$	39.30		$	38.94		$	39.17

XML

Segment Information (Details) (USD $) In Millions, unless otherwise specified	12 Months Ended
	Dec. 31, 2011	Dec. 31, 2010	Dec. 31, 2009
Revenue from External Customer [Line Items]
General segment information	Our business operations are organized into two reportable segments
Net sales by significant product group [Abstract]
Net sales	$ 1,192.3	$ 1,104.7	$ 1,055.7
Single customer net sales threshold basis, minimum (in hundredths)	10.00%
Sales and net property, plant and equipment, by country [Abstract]
Net sales	1,192.3	1,104.7	1,055.7
Property, Plant and Equipment, Net	593.6	554.8	577.1
Segment Reporting, Reconciling Item for Operating Profit (Loss) from Segment to Consolidated [Line Items]
Net sales	1,192.3	1,104.7	1,055.7
Total operating profit	109.6	90.7	97.5
Interest expense, net	(16.9)	(16.2)	(14.4)
Income before income taxes	92.7	74.5	83.1
Segment assets	1,399.1	1,294.3	1,271.0
Capital expenditures	95.4	71.1	104.9
Depreciation and amortization expense	75.7	73.2	68.1
United States [Member]
Net sales by significant product group [Abstract]
Net sales	543.6	528.2	502.8
Sales and net property, plant and equipment, by country [Abstract]
Net sales	543.6	528.2	502.8
Property, Plant and Equipment, Net	272.6	232.8	242.5
Segment Reporting, Reconciling Item for Operating Profit (Loss) from Segment to Consolidated [Line Items]
Net sales	543.6	528.2	502.8
Germany [Member]
Net sales by significant product group [Abstract]
Net sales	184.1	151.5	148.3
Sales and net property, plant and equipment, by country [Abstract]
Net sales	184.1	151.5	148.3
Property, Plant and Equipment, Net	118.1	117.8	129.9
Segment Reporting, Reconciling Item for Operating Profit (Loss) from Segment to Consolidated [Line Items]
Net sales	184.1	151.5	148.3
France [Member]
Net sales by significant product group [Abstract]
Net sales	94.2	89.0	105.3
Sales and net property, plant and equipment, by country [Abstract]
Net sales	94.2	89.0	105.3
Property, Plant and Equipment, Net	41.3	42.4	45.9
Segment Reporting, Reconciling Item for Operating Profit (Loss) from Segment to Consolidated [Line Items]
Net sales	94.2	89.0	105.3
Other European Countries [Member]
Net sales by significant product group [Abstract]
Net sales	242.7	225.6	209.3
Sales and net property, plant and equipment, by country [Abstract]
Net sales	242.7	225.6	209.3
Property, Plant and Equipment, Net	69.9	77.2	83.2
Segment Reporting, Reconciling Item for Operating Profit (Loss) from Segment to Consolidated [Line Items]
Net sales	242.7	225.6	209.3
Other Countries [Member]
Net sales by significant product group [Abstract]
Net sales	127.7	110.4	90.0
Sales and net property, plant and equipment, by country [Abstract]
Net sales	127.7	110.4	90.0
Property, Plant and Equipment, Net	91.7	84.6	75.6
Segment Reporting, Reconciling Item for Operating Profit (Loss) from Segment to Consolidated [Line Items]
Net sales	127.7	110.4	90.0
Packaging Systems [Member]
Net sales by significant product group [Abstract]
Net sales	857.4	785.0	776.0
Sales and net property, plant and equipment, by country [Abstract]
Net sales	857.4	785.0	776.0
Segment Reporting, Reconciling Item for Operating Profit (Loss) from Segment to Consolidated [Line Items]
Net sales	857.4	785.0	776.0
Total operating profit	152.6	139.3	138.3
Income before income taxes	152.6	139.3	138.3
Segment assets	843.5	814.4	824.7
Capital expenditures	66.2	48.9	84.8
Depreciation and amortization expense	53.6	50.7	46.7
Delivery Systems [Member]
Net sales by significant product group [Abstract]
Net sales	336.7	324.1	285.0
Sales and net property, plant and equipment, by country [Abstract]
Net sales	336.7	324.1	285.0
Segment Reporting, Reconciling Item for Operating Profit (Loss) from Segment to Consolidated [Line Items]
Net sales	336.7	324.1	285.0
Total operating profit	9.8	9.7	9.9
Income before income taxes	9.8	9.7	9.9
Segment assets	365.6	350.6	335.1
Capital expenditures	26.1	16.3	18.6
Depreciation and amortization expense	18.5	19.0	18.5
Other Unallocated Items [Member]
Net sales by significant product group [Abstract]
Net sales	(1.8)	(4.4)	(5.3)
Sales and net property, plant and equipment, by country [Abstract]
Net sales	(1.8)	(4.4)	(5.3)
Segment Reporting, Reconciling Item for Operating Profit (Loss) from Segment to Consolidated [Line Items]
Net sales	(1.8)	(4.4)	(5.3)
Total operating profit	(52.8)	(58.3)	(50.7)
Interest expense, net	(16.9)	(16.2)	(14.4)
Income before income taxes	(69.7)	(74.5)	(65.1)
Segment assets	190.0	129.3	111.2
Capital expenditures	3.1	5.9	1.5
Depreciation and amortization expense	3.6	3.5	2.9
Pharmaceutical Packaging [Member] | Packaging Systems [Member]
Net sales by significant product group [Abstract]
Net sales	731.1	661.2	637.3
Sales and net property, plant and equipment, by country [Abstract]
Net sales	731.1	661.2	637.3
Segment Reporting, Reconciling Item for Operating Profit (Loss) from Segment to Consolidated [Line Items]
Net sales	731.1	661.2	637.3
Disposable Medical Components [Member] | Packaging Systems [Member]
Net sales by significant product group [Abstract]
Net sales	106.9	100.0	104.6
Sales and net property, plant and equipment, by country [Abstract]
Net sales	106.9	100.0	104.6
Segment Reporting, Reconciling Item for Operating Profit (Loss) from Segment to Consolidated [Line Items]
Net sales	106.9	100.0	104.6
Laboratory and Other Services [Member] | Packaging Systems [Member]
Net sales by significant product group [Abstract]
Net sales	19.4	23.8	34.1
Sales and net property, plant and equipment, by country [Abstract]
Net sales	19.4	23.8	34.1
Segment Reporting, Reconciling Item for Operating Profit (Loss) from Segment to Consolidated [Line Items]
Net sales	19.4	23.8	34.1
Healthcare Devices [Member] | Delivery Systems [Member]
Net sales by significant product group [Abstract]
Net sales	177.4	178.8	165.9
Sales and net property, plant and equipment, by country [Abstract]
Net sales	177.4	178.8	165.9
Segment Reporting, Reconciling Item for Operating Profit (Loss) from Segment to Consolidated [Line Items]
Net sales	177.4	178.8	165.9
Consumer Products [Member] | Delivery Systems [Member]
Net sales by significant product group [Abstract]
Net sales	69.4	64.7	57.4
Sales and net property, plant and equipment, by country [Abstract]
Net sales	69.4	64.7	57.4
Segment Reporting, Reconciling Item for Operating Profit (Loss) from Segment to Consolidated [Line Items]
Net sales	69.4	64.7	57.4
Injection and Administration Systems [Member] | Delivery Systems [Member]
Net sales by significant product group [Abstract]
Net sales	59.0	55.3	42.9
Sales and net property, plant and equipment, by country [Abstract]
Net sales	59.0	55.3	42.9
Segment Reporting, Reconciling Item for Operating Profit (Loss) from Segment to Consolidated [Line Items]
Net sales	59.0	55.3	42.9
Tooling and Other Services [Member] | Delivery Systems [Member]
Net sales by significant product group [Abstract]
Net sales	30.9	25.3	18.8
Sales and net property, plant and equipment, by country [Abstract]
Net sales	30.9	25.3	18.8
Segment Reporting, Reconciling Item for Operating Profit (Loss) from Segment to Consolidated [Line Items]
Net sales	$ 30.9	$ 25.3	$ 18.8

XML

CONSOLIDATED STATEMENTS OF INCOME (USD $) In Millions, except Per Share data, unless otherwise specified	12 Months Ended
	Dec. 31, 2011	Dec. 31, 2010	Dec. 31, 2009
Consolidated Statements of Income [Abstract]
Net sales	$ 1,192.3	$ 1,104.7	$ 1,055.7
Cost of goods and services sold	853.0	786.6	752.1
Gross profit	339.3	318.1	303.6
Research and development	29.1	23.9	19.9
Selling, general and administrative expenses	191.1	187.7	177.7
Restructuring and other items (Note 3)	9.5	15.8	8.5
Operating profit	109.6	90.7	97.5
Interest expense	18.2	16.8	15.2
Interest income	(1.3)	(0.6)	(0.8)
Income before income taxes	92.7	74.5	83.1
Income tax expense	23.5	13.6	13.5
Equity in net income of affiliated companies	6.3	4.4	3.0
Net income	$ 75.5	$ 65.3	$ 72.6
Basic	$ 2.24	$ 1.96	$ 2.21
Diluted	$ 2.16	$ 1.89	$ 2.12
Basic	33.7	33.3	32.8
Diluted	37.0	36.7	36.3
Dividends declared per share	$ 0.70	$ 0.66	$ 0.62

XML

Income Taxes (Details) (USD $) In Millions, unless otherwise specified	12 Months Ended
	Dec. 31, 2011	Dec. 31, 2010	Dec. 31, 2009
Changes in liability for unrecognized tax benefits [Roll forward]
Beginning Balance	$ 5.0	$ 5.6
Additions for tax positions taken in the current year	1.3	0.6
Additions for tax positions of prior years	0.7	1.1
Reduction for expiration of statute of limitations/audits	(0.7)	(2.3)
Ending Balance	6.3	5.0	5.6
Income tax uncertainties [Abstract]
Accrued liabilities for interest and penalties	0.4	0.4
Tax-related interest expense	0.1
Tax-related interest income		0.1
Unrecognized tax benefits that would favorably impact the effective income tax rate	5.9
Amount of unrecognized tax benefits which may change	0.3
U.S. operations	15.8	7.2	6.5
International operations	76.9	67.3	76.6
Income before income taxes	92.7	74.5	83.1
Current: [Abstract]
Federal	0	0.6	0.3
State	0	0.2	0.1
International	20.6	14.6	17.9
Current income tax provision	20.6	15.4	18.3
Deferred: [Abstract]
Federal and state	2.7	(0.5)	(5.1)
International	0.2	(1.3)	0.3
Deferred income tax provision	2.9	(1.8)	(4.8)
Income tax expense	23.5	13.6	13.5
Deferred tax assets [Abstract]
Net operating loss carryforwards	21.7	28.1
Tax credit carryforwards	42.5	33.3
Restructuring and impairment charges	1.7	5.5
Capital loss carryforwards	0	1.4
Pension and deferred compensation	62.3	48.6
Other	9.3	8.7
Valuation allowance	(19.3)	(24.9)
Total deferred tax assets	118.2	100.7
Deferred tax liabilities: [Abstract]
Accelerated depreciation	41.2	39.5
Other	6.5	7.1
Total deferred tax liabilities	47.7	46.6
Net deferred tax asset	70.5	54.1
U.S. federal corporate tax rate	35.00%	35.00%	35.00%
Tax on international operations less than U.S. tax rate	(8.90%)	(11.00%)	(7.60%)
Non-benefited losses	0.00%	1.40%	2.00%
Reversal of prior valuation allowance	(0.10%)	(0.20%)	(1.20%)
Reversal of reserves for unrecognized tax benefits	0.00%	(3.00%)	(3.40%)
U.S. tax on international earnings, net of foreign tax credits	(1.50%)	(2.20%)	(3.20%)
State income taxes, net of federal tax effect	0.70%	(1.60%)	(1.10%)
General business credits and Section 199 Deduction	(2.40%)	(1.50%)	(5.40%)
Other	2.50%	1.40%	1.10%
Effective tax rate	25.30%	18.30%	16.20%
Operating Loss Carryforwards [Line Items]
Deferred tax asset attributable to carryforwards	21.7	28.1
Tax credit carryforwards, expiration date [Abstract]
Undistributed earnings reinvested indefinitely in foreign subsidiaries	568.2
Federal Jurisdiction [Member] | Research and Development [Member]
Tax Credit Carryforward [Line Items]
Tax credit carryforwards	9.2
Tax credit carryforwards, expiration date [Abstract]
2021	0.1
2022	0.5
Expiring after 2022	8.6
Foreign Jurisdiction [Member]
Deferred tax assets [Abstract]
Net operating loss carryforwards	6.6
Operating Loss Carryforwards [Line Items]
Operating loss carryforwards	26.3
Deferred tax asset attributable to carryforwards	6.6
Foreign loss carryforwards with no expiration date	15.7
Foreign Jurisdiction [Member] | Foreign Credit [Member]
Tax Credit Carryforward [Line Items]
Tax credit carryforwards	27.5
Tax credit carryforwards, expiration date [Abstract]
2012	2.6
2014	0.4
2015	3.5
2016	1.8
2017	2.4
2018	1.9
2019	3.1
2020	3.2
2021	8.6
State Jurisdiction [Member]
Deferred tax assets [Abstract]
Net operating loss carryforwards	15.1
Operating Loss Carryforwards [Line Items]
Operating loss carryforwards	255.4
Deferred tax asset attributable to carryforwards	15.1
State loss carryforwards expiring in 2013	0.1
State loss carryforwards expiring after 2013	255.3
State Jurisdiction [Member] | Research and Development [Member]
Tax Credit Carryforward [Line Items]
Tax credit carryforwards	3.5
Tax credit carryforwards, expiration date [Abstract]
2021	0.8
2022	0.8
Expiring after 2022	$ 1.9

XML

CONSOLIDATED BALANCE SHEETS (Parenthetical) (USD $) In Millions, except Per Share data, unless otherwise specified	Dec. 31, 2011	Dec. 31, 2010
Equity:
Preferred stock, shares authorized (in shares)	3.0	3.0
Preferred stock, shares issued (in shares)	0	0
Preferred stock, shares outstanding (in shares)	0	0
Common stock, par value (in dollars per share)	$ 0.25	$ 0.25
Common stock, shares authorized (in shares)	50.0	50.0
Common stock, shares issued (in shares)	34.3	34.3
Common stock, shares outstanding (in shares)	33.7	33.3
Treasury stock, at cost (in shares)	0.6	1.0

XML

Affiliated Companies (Tables)

12 Months Ended

Dec. 31, 2011

Affiliated Companies [Abstract]

Equity Method Investments

At December 31, 2011, the following affiliated companies were accounted for under the equity method:

	Location	Ownership interest
West Pharmaceutical Services Mexico, S.A. de C.V.	Mexico		49	%
Aluplast S.A. de C.V.	Mexico		49	%
Pharma Tap S.A. de C.V.	Mexico		49	%
Daikyo Seiko, Ltd. (“Daikyo”)	Japan		25	%

XML

Benefit Plans

12 Months Ended

Dec. 31, 2011

Benefit Plans [Abstract]

Benefit Plans

Note 14: Benefit Plans

Certain of our U.S. and international subsidiaries sponsor defined benefit pension plans. In 2006, the U.S. qualified defined benefit pension plan was converted to a cash balance plan.  In addition, we provide minimal death benefits for certain U.S. retirees and pay a portion of healthcare costs for retired U.S. salaried employees and their dependents. Benefits for participants are coordinated with Medicare and the plan mandates Medicare risk (“HMO”) coverage wherever possible and caps the total contribution for non-HMO coverage. We also sponsor a defined contribution plan for certain salaried and hourly U.S. employees. Our 401(k) plan contributions were $3.5 million for 2011 and $3.4 million for both 2010 and 2009.

Pension and Other Retirement Benefits

The components of net periodic benefit cost and other amounts recognized in other comprehensive income were as follows:

	Pension benefits									Other retirement benefits
($ in millions)	2011			2010			2009			2011		2010			2009
Net periodic benefit cost:
Service cost	$	8.9		$	8.6		$	7.8		$	1.2	$	1.1		$	0.8
Interest cost		16.0			15.7			14.9			1.0		0.8			0.9
Expected return on assets		(16.0	)		(14.7	)		(11.9	)		-		-			-
Amortization of prior service (credit) cost		(1.5	)		(1.1	)		(1.1	)		0.1		0.1			0.1
Amortization of transition obligation		0.1			0.1			0.1			-		-			-
Recognized actuarial losses (gains)		6.0			5.6			7.0			-		(0.1	)		-
Curtailment		(0.2	)		-			-			-		-			-
Settlement effects		0.8			-			-			-		-			-
Net periodic benefit cost	$	14.1		$	14.2		$	16.8		$	2.3	$	1.9		$	1.8

Other changes in plan assets and benefit obligations recognized in other comprehensive income, pre-tax:
Net loss (gain) arising during period	$	46.7		$	9.1		$	(2.9	)	$	1.3		$	(1.5	)	$	1.8
Prior service credit arising during period		-			(5.2	)		-			-			-			-
Amortization of prior service credit (cost)		1.5			1.1			1.1			(0.1	)		(0.1	)		(0.1	)
Amortization of transition obligation		(0.1	)		(0.1	)		(0.1	)		-			-			-
Amortization of actuarial (loss) gain		(6.0	)		(5.6	)		(7.0	)		-			0.1			-
Curtailment		0.2			-			-			0.4			-			-
Settlement effects		(0.8	)		-			-			-			-			-
Total recognized in other comprehensive income	$	41.5		$	(0.7	)	$	(8.9	)	$	1.6		$	(1.5	)	$	1.7
Total recognized in net periodic benefit cost and other comprehensive income	$	55.6		$	13.5		$	7.9		$	3.9		$	0.4		$	3.5

Net periodic benefit cost by geographic location is as follows:

	Pension benefits						Other retirement benefits
($ in millions)	2011		2010		2009		2011		2010		2009
U.S. plans	$	11.4	$	11.7	$	14.9	$	2.3	$	1.9	$	1.8
International plans		2.7		2.5		1.9		-		-		-
Net periodic benefit cost	$	14.1	$	14.2	$	16.8	$	2.3	$	1.9	$	1.8

In 2011, as a result of the closure of a plant in the United States, we recorded a $0.2 million net curtailment gain in restructuring and other items, related to our U.S. qualified and postretirement medical plans. In addition, during the fourth quarter of 2011, due to the retirement of our former President and Chief Operating Officer, we recorded an $0.8 million settlement loss related to one of our non-qualified defined benefit pension plans.

The following tables present the changes in the projected benefit obligation and the fair value of plan assets, as well as the funded status of the plans:

	Pension benefits						Other retirement benefits
($ in millions)	2011			2010			2011			2010
Change in benefit obligation:
Benefit obligation, January 1	$	(283.5	)	$	(262.8	)	$	(18.1	)	$	(18.1	)
Service cost		(8.9	)		(8.6	)		(1.2	)		(1.1	)
Interest cost		(16.0	)		(15.7	)		(1.0	)		(0.9	)
Participants’ contributions		-			-			(0.3	)		(0.4	)
Actuarial (loss) gain		(27.3	)		(15.9	)		(1.4	)		1.5
Amendments/transfers in		(0.4	)		5.2			-			-
Benefits/expenses paid		16.4			12.4			0.7			0.9
Curtailment		(0.8	)		-			(0.4	)
Foreign currency translation		0.6			1.9			-			-
Benefit obligation, December 31	$	(319.9	)	$	(283.5	)	$	(21.7	)	$	(18.1	)

Change in plan assets:
Fair value of assets, January 1	$	212.3		$	193.5		$	-		$	-
Actual return on assets		(2.8	)		21.6			-			-
Employer contribution		20.4			10.3			0.4			0.5
Participants’ contribution		-			-			0.3			0.4
Benefits/expenses paid		(16.4	)		(12.5	)		(0.7	)		(0.9	)
Foreign currency translation		(0.2	)		(0.6	)		-			-
Fair value of assets, December 31	$	213.3		$	212.3		$	-		$	-
Funded status at end of year	$	(106.6	)	$	(71.2	)	$	(21.7	)	$	(18.1	)

International pension plan assets, at fair value, included in the preceding table were $19.6 million and $18.6 million at December 31, 2011 and 2010, respectively.

Amounts recognized in the balance sheet were as follows:

	Pension benefits						Other retirement benefits
($ in millions)	2011			2010			2011			2010
Current liabilities	$	(1.2	)	$	(1.1	)	$	(1.1	)	$	(1.0	)
Noncurrent liabilities		(105.4	)		(70.1	)		(20.6	)		(17.1	)
	$	(106.6	)	$	(71.2	)	$	(21.7	)	$	(18.1	)

The amounts in accumulated other comprehensive loss, pre-tax, consisted of:

	Pension benefits						Other retirement benefits
($ in millions)	2011			2010			2011		2010
Net actuarial loss (gain)	$	131.3		$	92.1		$	0.2	$	(1.5	)
Transition obligation		0.4			0.5			-		-
Prior service (credit) cost		(10.2	)		(12.7	)		0.1		0.2
Total	$	121.5		$	79.9		$	0.3	$	(1.3	)

The actuarial net loss, transition obligation and prior service credit for the defined benefit pension plans that will be amortized from accumulated other comprehensive loss into net pension expense over the next fiscal year are $8.3 million, $0.1 million and $(1.4) million, respectively. The prior service cost for the other retirement benefit plan that will be amortized from accumulated other comprehensive loss into expense over the next fiscal year is $0.1 million.

The accumulated benefit obligation for all defined benefit pension plans was $316.7 million and $280.4 million at December 31, 2011 and 2010, respectively, including $42.6 million and $40.5 million, respectively, for international pension plans.

All of the defined benefit pension plans have projected benefit obligations and accumulated benefit obligations in excess of plan assets as of December 31, 2011 and 2010.

Benefit payments expected to be paid under our defined benefit pension plans in the next ten years are as follows:

($ in millions)	Domestic Plans		International Plans		Total
2012	$	15.5	$	1.2	$	16.7
2013		16.7		1.4		18.1
2014		19.4		1.6		21.0
2015		20.9		1.6		22.5
2016		22.3		2.1		24.4
2017 to 2021		130.2		14.1		144.3
	$	225.0	$	22.0	$	247.0

In 2012, we expect to contribute $19.8 million to pension plans, of which $1.8 million is for international plans. Included in this amount is a minimum ERISA (Employee Retirement Income Security Act) funding requirement for the U.S. qualified pension plan of $17.2 million. In addition, we expect to contribute $1.1 million to other retirement plans in 2012. We periodically consider additional, voluntary contributions depending on the investment returns generated by pension plan assets, changes in benefit obligation projections and other factors.

Weighted average assumptions used to determine net periodic benefit cost were as follows:

	Pension benefits									Other retirement benefits
	2011			2010			2009			2011			2010			2009
Discount rate		5.55	%		5.92	%		6.38	%		5.25	%		5.25	%		6.25	%
Rate of compensation increase		4.33	%		4.36	%		4.37	%		-			-			-
Long-term rate of return on assets		7.59	%		7.60	%		7.66	%		-			-			-

Weighted average assumptions used to determine the benefit obligations were as follows:

	Pension benefits						Other retirement benefits
	2011			2010			2011			2010
Discount rate		4.87	%		5.61	%		4.50	%		5.25	%
Rate of compensation increase		4.33	%		4.36	%		-			-

The discount rate used to determine the benefit obligations for U.S. pension plans was 4.90% and 5.70% as of December 31, 2011 and 2010, respectively.  The weighted average discount rate used to determine the benefit obligations for all international plans was 4.72% and 5.09% as of December 31, 2011 and 2010, respectively. The rate of compensation increase for U.S. plans was 4.50% for 2011 and 2010, while the weighted average rate for all international plans was 2.70% for 2011 and 2.71% for 2010. Other retirement benefits were only available to U.S. employees. The long-term rate of return for U.S. plans, which accounts for 91% of global plan assets, was 7.75% for 2011, 2010 and 2009.

The assumed healthcare cost trend rate used to determine benefit obligations was 8.50% for all participants in 2011, decreasing to 5.00% by 2019. Increasing the assumed healthcare cost trend rate by one percentage point would result in a $1.1 million increase in the postretirement obligation, whereas a decrease of one percentage point would result in a $1.0 million decrease in the postretirement obligation. The assumed healthcare cost trend rate used to determine net periodic benefit cost was 9.00% for all participants in 2011, decreasing to 5.00% by 2019. The effect of a one percentage point change in the rate would be a $0.2 million increase or decrease in the aggregate service and interest cost components.

The weighted average asset allocations by asset category for our pension plans, at December 31, were as follows:

	2011			2010
Equity securities		68	%		69	%
Debt securities		31	%		31	%
Other		1	%		-
		100	%		100	%

Our U.S. pension plan is managed as a balanced portfolio comprised of two components: equity and fixed income debt securities. Equity investments are used to maximize the long-term real growth of fund assets, while fixed income investments are used to generate current income, provide for a more stable periodic return, and to provide some protection against a prolonged decline in the market value of equity investments. Temporary funds may be held as cash. We maintain a long-term strategic asset allocation policy which provides guidelines for ensuring that the fund's investments are managed with the short-term and long-term financial goals of the fund, while allowing the flexibility to react to unexpected changes in capital markets.

The following are our target asset allocations and acceptable allocation ranges:

	Target allocation			Allocation range
Equity securities		65	%		60%-70	%
Debt securities		35	%		30%-40	%
Other		0	%		0%-5	%

Diversification across and within asset classes is the primary means by which we mitigate risk. We maintain guidelines for all asset and sub-asset categories in order to avoid excessive investment concentrations. Fund assets are monitored on a regular basis. If at any time the fund asset allocation is not within the acceptable allocation range, funds will be reallocated. We also review the fund on a regular basis to ensure that the investment returns received are consistent with the short-term and long-term goals of the fund and with comparable market returns. We are prohibited from pledging fund securities and from investing pension fund assets in our own stock, securities on margin or derivative securities.

The following tables present the fair value of our pension plan assets, utilizing the fair value hierarchy discussed in Note 13, Fair Value Measurements:

	Balance at
	December 31,		Basis of Fair Value Measurements
($ in millions)	2011		Level 1		Level 2		Level 3
Cash	$	0.2	$	0.2	$	-	$	-
Equity securities:
Indexed mutual funds		102.2		102.2		-		-
International mutual funds		40.0		40.0		-		-
Fixed income securities:
Mutual funds		65.6		65.6		-		-
Insurance contract		1.3		-		1.3		-
Balanced mutual fund		4.0		4.0		-		-
	$	213.3	$	212.0	$	1.3	$	-

	Balance at
	December 31,			Basis of Fair Value Measurements
($ in millions)	2010			Level 1			Level 2		Level 3
Cash overdrafts	$	(0.6	)	$	(0.6	)	$	-	$	-
Equity securities:
Indexed mutual funds		108.1			108.1			-		-
International mutual funds		37.7			37.7			-		-
Fixed income securities:
Mutual funds		65.6			65.6			-		-
Insurance contract		1.5			-			1.5		-
	$	212.3		$	210.8		$	1.5	$	-

XML

Debt (Tables)

12 Months Ended

Dec. 31, 2011

Debt Disclosure [Abstract]

Long-term debt obligations , net of current maturities

The following table summarizes our long-term debt obligations, net of current maturities, at December 31. The interest rates shown in parentheses are as of December 31, 2011:

($ in millions)	2011			2010
Revolving credit facility, due 2014 (2.1%)	$	6.4		$	12.2
Series A floating rate notes, due 2012 (1.2%)		50.0			50.0
Series B floating rate notes, due 2015 (1.3%)		25.0			25.0
Euro note A, due 2013 (4.2%)		26.3			27.0
Euro note B, due 2016 (4.4%)		79.0			81.0
Convertible debt, due 2047 (4.0%)		161.5			161.5
Term loan, due 2014 (8.4%)		0.2			-
Capital leases, due through 2016 (5.3 - 6.0%)		1.0			1.7
		349.4			358.4
Less current maturities of long-term debt		(50.1	)		(0.3	)
	$	299.3		$	358.1

XML

Commitments and Contingent Liabilities

12 Months Ended

Dec. 31, 2011

Commitments and Contingent Liabilities [Abstract]

Commitments and Contingent Liabilities

Note 16: Commitments and Contingencies

At December 31, 2011, we were obligated under various operating lease agreements with terms ranging from one month to 20 years. Net rental expense in 2011, 2010 and 2009 was $11.4 million, $10.2 million and $12.9 million, respectively, and is net of sublease income of $0.8 million, $0.7 million and $0.7 million, respectively.

At December 31, 2011, future minimum rental payments under non-cancelable operating leases were:

Year	($ in millions)
2012	$	12.2
2013		6.3
2014		5.6
2015		4.1
2016		3.5
Thereafter		17.6
Total		49.3
Less sublease income		0.4
	$	48.9

At December 31, 2011, outstanding unconditional contractual commitments for the purchase of raw materials, utilities and equipment amounted to $21.7 million, of which, $13.8 million is due to be paid in 2012.

In 2011, we entered into an agreement for the construction and development of our new corporate office and research building. The estimated purchase price of the building, under this agreement, is $36.3 million. The actual purchase price will be based on construction and development costs incurred. Payment is due for the portion of the building covered by this contract upon final settlement, which is expected to occur by early 2013. In addition to this amount, we also expect to directly incur $24.6 million in capital expenditures related to the building over the next twelve months.

We have letters of credit totaling $3.3 million supporting the reimbursement of workers’ compensation and other claims paid on our behalf by insurance carriers. Our accrual for insurance obligations was $9.2 million at December 31, 2011, of which $5.2 million is in excess of our deductible and, therefore, is reimbursable by the insurance company.

During 2009, we enrolled in a tax amnesty program offered by the Brazilian government which provided for reduced penalties and interest on certain of our tax obligations. This matter is currently awaiting final disposition in the Brazilian court system. Our total accrual at December 31, 2011 related to these matters and adjusted for expected amnesty benefits, was $7.8 million.

XML

CONSOLIDATED STATEMENT OF EQUITY (USD $) In Millions	Total	Common Stock [Member]	Capital in Excess of Par Value [Member]	Treasury Stock [Member]	Retained earnings [Member]	Accumulated other comprehensive (loss) income [Member]
Balance, Beginning at Dec. 31, 2008	$ 487.1	$ 8.6	$ 69.3	$ (63.2)	$ 517.3	$ (44.9)
Balance, Beginning (in shares) at Dec. 31, 2008		34.3		(1.6)
Net income	72.6				72.6
Shares issued under stock plans	6.6		(5.9)	12.5
Shares issued under stock plans (in shares)				0.4
Stock-based compensation	5.5		5.5
Shares repurchased for employee tax withholdings	(1.4)			(1.4)
Shares repurchased for employee tax withholdings (in shares)				(0.1)
Excess tax benefit from employee stock plans	4.0		4.0
Cash dividends declared	(20.5)				(20.5)
Other comprehensive income (loss), net of tax	25.2					25.2
Balance, Ending at Dec. 31, 2009	579.1	8.6	72.9	(52.1)	569.4	(19.7)
Balance, Ending (in shares) at Dec. 31, 2009		34.3		(1.3)
Net income	65.3				65.3
Shares issued under stock plans	8.3		(4.4)	12.7
Shares issued under stock plans (in shares)				0.4
Stock-based compensation	6.7		6.7
Shares repurchased for employee tax withholdings	(2.1)			(2.1)
Shares repurchased for employee tax withholdings (in shares)				(0.1)
Excess tax benefit from employee stock plans	2.1		2.1
Cash dividends declared	(22.1)				(22.1)
Other comprehensive income (loss), net of tax	(11.6)					(11.6)
Balance, Ending at Dec. 31, 2010	625.7	8.6	77.3	(41.5)	612.6	(31.3)
Balance, Ending (in shares) at Dec. 31, 2010		34.3		(1.0)
Net income	75.5				75.5
Shares issued under stock plans	8.9		(13.1)	22.0
Shares issued under stock plans (in shares)				0.5
Stock-based compensation	8.6		8.6
Shares repurchased for employee tax withholdings	(3.5)			(3.5)
Shares repurchased for employee tax withholdings (in shares)				(0.1)
Excess tax benefit from employee stock plans	3.5		3.5
Cash dividends declared	(23.6)				(23.6)
Other comprehensive income (loss), net of tax	(40.2)					(40.2)
Balance, Ending at Dec. 31, 2011	$ 654.9	$ 8.6	$ 76.3	$ (23.0)	$ 664.5	$ (71.5)
Balance, Ending (in shares) at Dec. 31, 2011		34.3		(0.6)

XML

CONSOLIDATED STATEMENTS OF COMPREHENSIVE INCOME (USD $) In Millions, unless otherwise specified	12 Months Ended
	Dec. 31, 2011	Dec. 31, 2010	Dec. 31, 2009
CONSOLIDATED STATEMENTS OF COMPREHENSIVE INCOME (Parenthetical) [Abstract]
Net income	$ 75.5	$ 65.3	$ 72.6
Foreign currency translation adjustments	(11.8)	(13.0)	19.0
Defined benefit pension and other postretirement plans: [Abstract]
Prior service credit arising during period, net of tax of $2.0	0	3.2	0
Net actuarial loss arising during period, net of tax of $(17.9), $(2.6) and $(1.1)	(30.1)	(5.0)	0
Curtailment arising during period, net of tax of $(0.2)	(0.4)	0	0
Settlement effects arising during the period, net of tax of $0.3	0.5	0	0
Less: amortization of actuarial loss, net of tax of $2.2, $2.1 and $2.7	3.8	3.4	4.3
Less: amortization of prior service credit, net of tax of $(0.5), $(0.4) and $(0.4)	(0.9)	(0.6)	(0.6)
Less: amortization of transition obligation	0.1	0.1	0.1
Net gains on investment securities, net of tax of $0.2, $0.4 and $0.3	0.3	0.6	0.4
Net (losses) gains on derivatives, net of tax of $(1.1), $(0.2) and $1.2	(1.7)	(0.3)	2.0
Other comprehensive (loss) income, net of tax	(40.2)	(11.6)	25.2
Comprehensive income	$ 35.3	$ 53.7	$ 97.8

XML

Property plant and equipment

12 Months Ended

Dec. 31, 2011

Property plant and equipment [Abstract]

Property plant and equipment

Note 9: Property, Plant and Equipment

A summary of gross property, plant and equipment at December 31 is presented in the following table:

($ in millions)	Expected useful lives (years)		2011		2010
Land			$	8.9	$	9.0
Buildings and improvements		5-50		284.1		276.4
Machinery and equipment		10-15		565.7		568.7
Molds and dies		4-7		85.8		84.8
Computer hardware and software		3-10		76.2		68.2
Construction in progress				116.1		70.1
			$	1,136.8	$	1,077.2

Depreciation expense for the years ended December 31, 2011, 2010 and 2009 was $71.1 million, $68.8 million and $63.9 million, respectively.

Capitalized leases included in ‘buildings and improvements’ were $2.3 million and $2.4 million at December 31, 2011 and 2010, respectively. Capitalized leases included in ‘machinery and equipment’ were $1.9 million and $3.6 million at December 31, 2011 and 2010, respectively.  Accumulated depreciation on all property, plant and equipment accounted for as capitalized leases was $1.1 million and $1.1 million at December 31, 2011 and 2010, respectively. At December 31, 2011, future minimum payments under capital leases were $0.4 million in 2012, $0.3 million in 2013, $0.2 million in 2014 and $0.2 million in 2015.

Under the terms of our construction and development agreement, the majority of costs required to construct our new corporate office and research building will be incurred by our counterparty during the construction period and paid by us at settlement. All construction costs incurred during 2011 and 2012, which are not due until settlement, will be accrued to property, plant and equipment and other long-term liabilities until they are paid. As of December 31, 2011, we have accrued $22.4 million of construction and development costs. See Note 16, Commitments and Contingencies, for further discussion of this capital project.

We capitalize interest on borrowings during the active construction period of major capital projects. Capitalized interest is added to the cost of the underlying assets and is amortized over the useful lives of the assets. Capitalized interest for the years ended December 31, 2011, 2010 and 2009 was $1.1 million, $0.9 million and $2.4 million, respectively.

XML

Document And Entity Information (USD $)	12 Months Ended
	Dec. 31, 2011	Jan. 31, 2012	Jun. 30, 2011
Entity Registrant Name	WEST PHARMACEUTICAL SERVICES INC
Entity Central Index Key	0000105770
Current Fiscal Year End Date	--12-31
Entity Well-known Seasoned Issuer	Yes
Entity Voluntary Filers	No
Entity Current Reporting Status	Yes
Entity Filer Category	Large Accelerated Filer
Entity Public Float			$ 1,472,514,635
Entity Common Stock, Shares Outstanding		33,779,282
Document Fiscal Year Focus	2011
Document Fiscal Period Focus	FY
Document Type	10-K
Amendment Flag	false
Document Period End Date	Dec. 31, 2011

XML

Affiliated Companies

12 Months Ended

Dec. 31, 2011

Affiliated Companies [Abstract]

Affiliated Companies

Note 10: Affiliated Companies

At December 31, 2011, the following affiliated companies were accounted for under the equity method:

	Location	Ownership interest
West Pharmaceutical Services Mexico, S.A. de C.V.	Mexico		49	%
Aluplast S.A. de C.V.	Mexico		49	%
Pharma Tap S.A. de C.V.	Mexico		49	%
Daikyo Seiko, Ltd. (“Daikyo”)	Japan		25	%

Unremitted income of affiliated companies included in consolidated retained earnings amounted to $37.5 million, $31.5 million and $27.4 million at December 31, 2011, 2010 and 2009, respectively. Dividends received from affiliated companies were $0.3 million in 2011, 2010 and 2009.

Our equity in unrealized (gains) losses of Daikyo's investment in securities available-for-sale and derivative instruments, included in accumulated other comprehensive loss was $(0.4) million, $(0.1) million and $0.5 million at December 31, 2011, 2010 and 2009, respectively.

Our purchases and royalty payments made to affiliates totaled $66.4 million, $49.3 million and $45.4 million, respectively, in 2011, 2010 and 2009, of which $9.2 million and $4.3 million was due and payable as of December 31, 2011 and 2010, respectively. The majority of these transactions relate to a distributorship agreement allowing us to purchase and re-sell Daikyo products. Sales to affiliates were $4.5 million, $2.4 million and $1.9 million, respectively, in 2011, 2010 and 2009, of which $1.3 million and $0.5 million was receivable as of December 31, 2011 and 2010, respectively.

At December 31, 2011 and 2010, the aggregate carrying amount of investments in equity method affiliates was $56.2 million and $48.2 million, respectively.

XML

CONSOLIDATED STATEMENTS OF COMPREHENSIVE INCOME (Parenthetical) (USD $) In Millions, unless otherwise specified	12 Months Ended
	Dec. 31, 2011	Dec. 31, 2010	Dec. 31, 2009
Defined benefit pension and other postretirement plans: [Abstract]
Prior service credit arising during period, tax	$ 0	$ 2.0	$ 0
Net actuarial loss arising during period, tax	(17.9)	(2.6)	(1.1)
Amortization of actuarial loss, tax	2.2	2.1	2.7
Amortization of prior service credit, tax	(0.5)	(0.4)	(0.4)
Curtailment arising during period, tax	(0.2)	0	0
Settlement effects arising during the period, tax	0.3	0	0
Net gains on investment securities, tax	0.2	0.4	0.3
Net (losses) gains on derivatives, tax	$ (1.1)	$ (0.2)	$ 1.2

XML

Income Taxes

12 Months Ended

Dec. 31, 2011

Income Taxes [Abstract]

Income Taxes

Note 4: Income Taxes

Because we are a global organization, we and our subsidiaries file income tax returns in the U.S. Federal jurisdiction and various state and foreign jurisdictions. During 2011, the statute of limitations for the 2007 U.S. Federal tax year lapsed, leaving tax years 2008 through 2011 open to examination. For U.S. state and local jurisdictions, tax years 2007 through 2011 are open to examination. We are also subject to examination in various foreign jurisdictions for tax years 2005 through 2011.

A reconciliation of the beginning and ending amount of the liability for unrecognized tax benefits is as follows:

($ in millions)	2011			2010
Balance at January 1	$	5.0		$	5.6
Additions for tax positions taken in the current year		1.3			0.6
Additions for tax positions of prior years		0.7			1.1
Reduction for expiration of statute of limitations/audits		(0.7	)		(2.3	)
Balance at December 31	$	6.3		$	5.0

In addition, we had balances in accrued liabilities for interest and penalties of $0.4 million and $0.4 million at December 31, 2011 and 2010, respectively. During 2011, we recognized less than $0.1 million in tax-related interest expense and in 2010 we recognized $0.1 million in tax-related interest income. As of December 31, 2011, we had $6.3 million of total gross unrecognized tax benefits, of which $5.9 million, if recognized, would favorably impact the effective income tax rate. It is reasonably possible that, due to the expiration of statutes and the closing of tax audits, the liability for unrecognized tax benefits may be reduced by approximately $0.3 million during the next twelve months, which would favorably impact our effective tax rate.

The components of income before income taxes are:

($ in millions)	2011		2010		2009
U.S. operations	$	15.8	$	7.2	$	6.5
International operations		76.9		67.3		76.6
Total income before income taxes	$	92.7	$	74.5	$	83.1

The related provision for income taxes consists of:

($ in millions)	2011		2010			2009
Current:
Federal	$	-	$	0.6		$	0.3
State		-		0.2			0.1
International		20.6		14.6			17.9
Current income tax provision		20.6		15.4			18.3
Deferred:
Federal and state		2.7		(0.5	)		(5.1	)
International		0.2		(1.3	)		0.3
Deferred income tax provision		2.9		(1.8	)		(4.8	)
Income tax expense	$	23.5	$	13.6		$	13.5

Deferred income taxes result from temporary differences between the amount of assets and liabilities recognized for financial reporting and tax purposes.

The significant components of our deferred tax assets and liabilities at December 31 are:

($ in millions)	2011			2010
Deferred tax assets
Net operating loss carryforwards	$	21.7		$	28.1
Tax credit carryforwards		42.5			33.3
Restructuring and impairment charges		1.7			5.5
Capital loss carryforwards		-			1.4
Pension and deferred compensation		62.3			48.6
Other		9.3			8.7
Valuation allowance		(19.3	)		(24.9	)
Total deferred tax assets		118.2			100.7
Deferred tax liabilities:
Accelerated depreciation		41.2			39.5
Other		6.5			7.1
Total deferred tax liabilities		47.7			46.6
Net deferred tax asset	$	70.5		$	54.1

A reconciliation of the U.S. federal corporate tax rate to our effective consolidated tax rate on income before income taxes follows:

	2011			2010			2009
U.S. federal corporate tax rate		35.0	%		35.0	%		35.0	%
Tax on international operations less than U.S. tax rate		(8.9	)		(11.0	)		(7.6	)
Non-benefited losses		-			1.4			2.0
Reversal of prior valuation allowance		(0.1	)		(0.2	)		(1.2	)
Reversal of reserves for unrecognized tax benefits		-			(3.0	)		(3.4	)
U.S. tax on international earnings, net of foreign tax credits		(1.5	)		(2.2	)		(3.2	)
State income taxes, net of federal tax effect		0.7			(1.6	)		(1.1	)
General business credits and Section 199 Deduction		(2.4	)		(1.5	)		(5.4	)
Other		2.5			1.4			1.1
Effective tax rate		25.3	%		18.3	%		16.2	%

At December 31, 2011, we have fully utilized all of our U.S. federal net operating loss carryforwards. State operating loss carryforwards of $255.4 million, created a deferred tax asset of $15.1 million, while foreign operating loss carryforwards of $26.3 million, created a deferred tax asset of $6.6 million. Management estimates that certain state and foreign operating loss carryforwards are unlikely to be utilized and the associated deferred tax assets have been fully reserved. State loss carryforwards expire as follows: $0.1 million in 2013 and $255.3 million thereafter. Foreign loss carryforwards will begin to expire in 2013, while $15.7 million of the total $26.3 million will not expire.

As of December 31, 2011, we had available foreign tax credit carryforwards of $27.5 million expiring as follows: $2.6 million in 2012, $0.4 million in 2014, $3.5 million in 2015, $1.8 million in 2016, $2.4 million in 2017, $1.9 million in 2018, $3.1 million in 2019, $3.2 million in 2020 and $8.6 million in 2021. We have U.S. federal and state research and development credit carryforwards of $9.2 million and $3.5 million, respectively. The $9.2 million of U.S. federal research and development credits expire as follows: $0.1 million expire in 2021, $0.5 million expire in 2022 and $8.6 million expire after 2022. The $3.5 million of state research and development credits expire as follows: $0.8 million expire in 2021, $0.8 million expire in 2022 and $1.9 million expire after 2022.

Undistributed earnings of foreign subsidiaries amounted to $568.2 million at December 31, 2011, on which deferred income taxes have not been provided because such earnings are intended to be reinvested indefinitely outside of the United States.

XML

Restructuring and Other Items

12 Months Ended

Dec. 31, 2011

Restructuring and Other Items [Abstract]

Restructuring and Other Items

Note 3: Restructuring and Other Items

Restructuring and other items consisted of:

($ in millions)	2011			2010			2009
Restructuring and related charges
Severance and post-employment benefits	$	2.3		$	10.5		$	3.0
Impairments and asset write-offs		-			5.2			5.3
Other restructuring charges		3.0			0.2			0.4
Total restructuring and related charges		5.3			15.9			8.7
Other items:
Special separation benefits		2.9			-			-
Acquisition-related contingencies		(0.2	)		(1.8	)		-
Brazil tax amnesty benefit		-			-			(2.0	)
Foreign exchange losses and other		1.5			1.7			1.8
Total other items		4.2			(0.1	)		(0.2	)
Total restructuring and other items	$	9.5		$	15.8		$	8.5

Restructuring and Related Charges

In December 2010, our Board of Directors approved a restructuring plan designed to reduce our cost structure and improve operating efficiency. The plan involves the 2011 closure of a plant in the United States, a reduction in operations at a manufacturing facility in England, and the elimination of certain operational and administrative functions in other locations. Under this plan, we expect to incur total restructuring and related charges of approximately $22.0 million through the end of 2012, which consist of approximately $17.0 million in cash expenditures for severance and costs associated with the plant closure and fixed asset relocation, and approximately $5.0 million in non-cash asset impairment and disposal charges. During 2011, we incurred charges of $5.3 million related to this plan. During 2010, we incurred charges of $14.5 million, consisting of $10.1 million in severance and post-employment benefits and $4.4 million in asset impairment charges. The balance of the charges related to this plan will be recognized as incurred during 2012.

During 2010, we also incurred $1.4 million in restructuring and related charges in connection with the 2009 restructuring program, including $0.4 million in employee severance and post-employment benefits, $0.8 million in asset disposal charges and $0.2 million in other exit costs. We incurred a total of $9.0 million in restructuring and related charges, as part of this plan, through its completion in 2010.

During 2009, we incurred $7.6 million in restructuring and related charges related to the 2009 plan. Also in 2009, we incurred $1.1 million in restructuring costs, consisting mainly of employee severance benefits, asset impairments and accelerated depreciation associated with the completion of a 2007 restructuring plan for our former Tech Group segment.

The following table presents activity related to our restructuring obligations recorded within other current liabilities:

($ in millions)	Severance and benefits			Other Costs			Total
Balance, December 31, 2009	$	1.9		$	0.1		$	2.0
Charges		10.4			0.2			10.6
Cash payments		(2.1	)		(0.3	)		(2.4	)
Balance, December 31, 2010		10.2			-			10.2
Charges		2.3			3.0			5.3
Cash payments		(6.3	)		(2.6	)		(8.9	)
Non-cash adjustment		-			0.2			0.2
Balance, December 31, 2011	$	6.2		$	0.6		$	6.8

During the third quarter of 2011, as a result of the closure of a plant in Montgomery, Pennsylvania, we recorded a $0.2 million net curtailment gain related to our U.S. qualified and postretirement medical plans.

Other Items

During 2011, we incurred $2.9 million in special separation benefits related to the retirement of our former President and Chief Operating Officer. These costs consisted primarily of stock-based compensation expense and a settlement loss related to one of our non-qualified defined benefit pension plans. The respective equity compensation arrangements were amended to allow certain of his awards to continue to vest over the original vesting period instead of being forfeited upon separation, resulting in a revaluation of the awards and acceleration of expense.

As discussed in Note 2, Acquisitions, the purchase price in the 2009 acquisition of the éris safety syringe system included contingent consideration with an initial fair value of $2.6 million, which was recorded as a liability at the acquisition date. During 2011 and 2010, we reduced this liability for contingent consideration by $0.8 million and $1.8 million, respectively, bringing the liability balance to zero. This reduction reflects our assessment that none of the contractual operating targets will be achieved over the earnout period, which ends in 2014. During 2011, we also increased the liability for contingent consideration related to our 2010 acquisition of technology used in our SmartDose electronic patch injector system by $0.5 million.

In 2009, we enrolled in a tax amnesty program in Brazil which provided for reduced penalties and interest on certain tax-related obligations. We recognized a pre-tax benefit of $2.0 million in 2009 relating to our participation in this program. In addition, in 2009, we determined that a cost-basis investment was impaired and recorded an $0.8 million charge to write-off the investment, which was recorded within foreign exchange losses and other.

XML

Stock-Based Compensation

12 Months Ended

Dec. 31, 2011

Stock-Based Compensation [Abstract]

Stock-Based Compensation

Note 15: Stock-Based Compensation

On May 3, 2011, the Omnibus Incentive Compensation Plan (the “2011 Plan”) was approved by our shareholders. All remaining shares available for issuance under the 2007 Omnibus Incentive Compensation Plan were extinguished upon adoption of the 2011 Plan. Awards granted under previous plans remain outstanding until expiration or settlement. The 2011 Plan provides for the granting of stock options, stock appreciation rights, restricted stock awards and performance awards to employees and non-employee directors. The terms and conditions of awards to be granted are determined by our Board’s nominating and compensation committees. Vesting requirements vary by award. At December 31, 2011, there were 4,718,287 shares remaining in the 2011 Plan for future grants.

Stock options and stock appreciation rights reduce the number of shares available for grant by one share for each award granted. All other awards that will be distributed in stock under the 2011 Plan will reduce the total number of shares available for grant by an amount equal to 2.35 times the number of shares awarded. If awards made under previous plans would entitle a plan participant to an amount of West stock in excess of the target amount, the additional shares (up to a maximum threshold amount) will be distributed under the 2011 Plan.

The following table summarizes our stock-based compensation expense for the years ended December 31:

($ in millions)	2011		2010		2009
Stock option and appreciation rights	$	4.4	$	3.7	$	3.7
Performance-vesting shares		3.0		2.2		1.8
Performance-vesting units		0.2		0.1		-
Performance-vesting shares/units dividend equivalents		0.1		0.2		0.2
Employee stock purchase plan		0.3		0.3		0.3
Deferred compensation plans		0.4		1.3		1.5
Total stock-based compensation expense	$	8.4	$	7.8	$	7.5

In 2011, $0.8 million of stock option expense and $0.7 million of performance-vesting shares expense, which relate to the retirement of our former President and Chief Operating Officer, were recorded within restructuring and other items. The remainder of the 2011 stock-based compensation expense balance was recorded within selling, general and administrative expenses.

The amount of unrecognized compensation expense for all nonvested awards as of December 31, 2011, was approximately $10.8 million, which is expected to be recognized over a weighted average period of 1.6 years.

Stock Options

Stock options granted to employees vest in equal annual increments over 4 years of continuous service. All awards expire 10 years from the date of grant. Upon the exercise of stock options, shares are issued in exchange for the exercise price of the options.

The following table summarizes changes in outstanding options:

(in millions, except per share data)	2011			2010			2009
Options outstanding, January 1		2.9			2.7			2.6
Granted		0.5			0.6			0.4
Exercised		(0.4	)		(0.3	)		(0.3	)
Forfeited		(0.1	)		(0.1	)		-
Options outstanding, December 31		2.9			2.9			2.7
Options exercisable, December 31		1.8			1.8			1.7
Weighted Average Exercise Price		2011			2010			2009
Options outstanding, January 1	$	32.32		$	29.09		$	26.91
Granted		40.85			42.47			32.12
Exercised		17.69			14.88			13.70
Forfeited		41.40			41.47			37.43
Options outstanding, December 31	$	35.79		$	32.32		$	29.09
Options exercisable, December 31	$	32.91		$	27.77		$	24.52

As of December 31, 2011, the weighted average remaining contractual life of options outstanding and of options exercisable was 6.1 years and 4.7 years, respectively.

As of December 31, 2011, the aggregate intrinsic value of total options outstanding was $13.6 million, of which $12.6 million represented vested options.

The fair value of the options was estimated on the date of grant using a Black-Scholes option valuation model that used the following weighted average assumptions in 2011, 2010 and 2009: a risk-free interest rate of 2.2%, 2.4% and 1.9%, respectively; stock volatility of 24.3%, 26.9% and 27.0%, respectively; and dividend yields of 1.7%, 1.5% and 1.9%, respectively. Stock volatility is estimated based on historical data and the impact from expected future trends.  Expected lives, which are based on prior experience, averaged 5 years for 2011, 2010 and 2009. The weighted average grant date fair value of options granted in 2011, 2010 and 2009 was $8.76, $10.38 and $6.98, respectively.

For the years ended December 31, 2011, 2010 and 2009, the intrinsic value of options exercised was $10.7 million, $5.9 million and $7.1 million, respectively. The grant date fair value of options vested during those same periods was $4.0 million, $3.5 million and $3.7 million, respectively.

Stock Appreciation Rights

Stock appreciation rights (“SARs”) granted to eligible international employees vest in equal annual increments over 4 years of continuous service. All awards expire ten years from the date of grant. The fair value of each SAR is adjusted at the end of each reporting period with the resulting change reflected in expense. Upon exercise of a SAR, the employee receives cash for the difference between the grant date price and the fair market value of the Company’s stock on the date of exercise. As a result of the cash settlement feature, SAR awards are recorded within other long-term liabilities.

The following table summarizes changes in outstanding SARs:

	2011			2010			2009
SARs outstanding, January 1		111,048			78,512			56,012
Granted		63,024			36,255			22,500
Exercised		(7,685	)		(3,719	)		-
Forfeited		(4,281	)		-			-
SARs outstanding, December 31		162,106			111,048			78,512
SARs exercisable, December 31		58,900			41,439			24,861

Weighted Average Exercise Price	2011		2010		2009
SARs outstanding, January 1	$	39.74	$	38.04	$	40.43
Granted		41.13		42.68		32.09
Exercised		39.15		32.50		-
Forfeited		40.85		-		-
SARs outstanding, December 31		40.28		39.74		38.04
SARs exercisable, December 31	$	39.72	$	39.16	$	39.22

Performance Awards

In addition to stock options and SAR awards, we grant performance vesting share (“PVS”) awards and performance vesting unit (“PVU”) awards to eligible employees. These awards are earned based on the Company’s performance against pre-established targets, including annual growth rate of revenue and return on invested capital, over a specified performance period. Depending on the achievement of the targets, recipients of PVS awards are entitled to receive a certain number of shares of common stock, whereas, recipients of PVU awards are entitled to receive a payment in cash per unit based on the fair market value of a share of our common stock at the end of the performance period.

The following table summarizes changes in our outstanding PVS awards:

	2011			2010			2009
Non-vested PVS awards, January 1		347,550			327,498			330,458
Granted at target level		101,099			123,068			125,600
Adjustments above/(below) target		(58,175	)		(48,364	)		(5,112	)
Vested and converted		(51,756	)		(50,337	)		(80,083	)
Forfeited		(10,199	)		(4,315	)		(43,365	)
Non-vested PVS awards, December 31		328,519			347,550			327,498
Weighted Average Grant Date Fair Value		2011			2010			2009
Non-vested PVS awards, January 1	$	39.21		$	39.63		$	40.62
Granted at target level		40.85			42.34			32.12
Adjustments above/(below) target		41.95			44.99			32.69
Vested and converted		40.85			38.22			32.69
Forfeited		38.46			37.61			39.10
Non-vested PVS awards, December 31	$	38.77		$	39.21		$	39.63

The actual payout of PVS and PVU awards may vary from 0% to 200% of an employee’s targeted amount. The fair value of PVS awards is based on the market price of our stock at the grant date and is recognized as expense over the performance period. The weighted average grant date fair value of PVS awards granted during the years 2011, 2010 and 2009 was $40.85, $42.34 and $32.12, respectively. We expect that the PVS awards will vest at 60% of their target award amounts, converting to 209,848 shares to be issued over an average remaining term of 1.4 years.

The fair value of PVU awards is also based on the market price of our stock at the grant date. These awards are revalued at the end of each quarter based on changes in our stock price. As a result of the cash settlement feature, PVU awards are recorded within other long-term liabilities.

The following table summarizes changes in our outstanding PVU awards:

	2011			2010			2009
Non-vested PVU awards, January 1		23,420			20,792			19,346
Granted at target level		13,442			7,697			7,200
Adjustments above/(below) target		(4,165	)		(2,484	)		(345	)
Vested and converted		(3,963	)		(2,585	)		(5,409	)
Forfeited		(1,718	)		-			-
Non-vested PVU awards, December 31		27,286			23,420			20,792
Weighted Average Grant Date Fair Value		2011			2010			2009
Non-vested PVU awards, January 1	$	38.94		$	39.17		$	39.85
Granted at target level		41.11			42.30			32.09
Adjustments above/(below) target		41.05			38.22			32.59
Vested and converted		40.85			38.22			32.59
Forfeited		37.55			-			-
Non-vested PVU awards, December 31	$	39.30		$	38.94		$	39.17

Employee Stock Purchase Plan

We also offer an Employee Stock Purchase Plan (“ESPP”) which provides for the sale of our common stock to eligible employees at 85% of the current market price on the last trading day of each quarterly offering period. Payroll deductions are limited to 25% of the employee's base salary, not to exceed $25 thousand in any one calendar year. In addition, employees may not buy more than 1,000 shares during any offering period (4,000 shares per year). Purchases under the ESPP were 55,388 shares, 56,608 shares and 58,606 shares for the years 2011, 2010 and 2009, respectively.  At December 31, 2011, there were approximately 2.2 million shares available for issuance under the ESPP.

Deferred Compensation Plans

Our deferred compensation programs include a Non-Qualified Deferred Compensation Plan for Non-Employee Directors, under which non-employee directors may defer all or part of their annual cash retainers and meeting fees. The deferred fees may be credited to a stock-equivalent account. Amounts credited to this account are converted into deferred stock units based on the fair market value of one share of our common stock on the last day of the quarter. Deferred stock units are ultimately paid in cash at an amount determined by multiplying the number of units by the fair market value of our common stock at the date of termination. Similarly, a non-qualified deferred compensation plan for designated executive officers provides for the conversion of compensation into deferred stock units. As of December 31, 2011, the two deferred compensation plans held a total of 180,373 deferred stock units, which, due to their cash settlement feature, are recorded within other long-term liabilities. The liabilities are valued at the closing market price of our stock at the end of each period with the resulting change in value recorded in our income statement for the respective period. The Non-Qualified Deferred Compensation Plan for Non-Employee Directors also holds 85,782 deferred stock awards.

Management Incentive Plan

Under our management incentive plan, participants are paid bonuses on the attainment of certain financial goals, which they can elect to receive in either cash or shares of our common stock. If the employee elects payment in shares, they are also given a restricted incentive stock award equal to one share for each four bonus shares issued. The incentive stock awards vest at the end of four years provided that the participant has not made a disqualifying disposition of their bonus shares. Incentive stock award grants were 1,900 shares, 1,400 shares and 3,700 shares in 2011, 2010 and 2009, respectively. Incentive stock forfeitures of 1,400 shares, 50 shares and 400 shares occurred in 2011, 2010 and 2009, respectively. Compensation expense is recognized over the vesting period based on the fair market value of common stock on the award date: $40.85 per share granted in 2011, $38.22 per share granted in 2010 and $32.09 per share granted in 2009.

XML

Debt

12 Months Ended

Dec. 31, 2011

Debt Disclosure [Abstract]

Debt

Note 11: Debt

The following table summarizes our long-term debt obligations, net of current maturities, at December 31. The interest rates shown in parentheses are as of December 31, 2011:

($ in millions)	2011			2010
Revolving credit facility, due 2014 (2.1%)	$	6.4		$	12.2
Series A floating rate notes, due 2012 (1.2%)		50.0			50.0
Series B floating rate notes, due 2015 (1.3%)		25.0			25.0
Euro note A, due 2013 (4.2%)		26.3			27.0
Euro note B, due 2016 (4.4%)		79.0			81.0
Convertible debt, due 2047 (4.0%)		161.5			161.5
Term loan, due 2014 (8.4%)		0.2			-
Capital leases, due through 2016 (5.3 - 6.0%)		1.0			1.7
		349.4			358.4
Less current maturities of long-term debt		(50.1	)		(0.3	)
	$	299.3		$	358.1

Revolving Credit Facility

In June 2010, we entered into a multi-currency revolving credit facility agreement that replaced our prior revolving credit facility, which was scheduled to expire in February 2011. The new credit agreement, which expires in 2014, contains a $225.0 million committed credit facility and an accordion feature allowing the maximum to be increased to $275.0 million upon approval by the banks. Up to $20.0 million of the credit facility is available for swing-line loans and up to $20.0 million is available for the issuance of standby letters of credit. Borrowings under the revolving credit facility bear interest at a rate equal to LIBOR plus a margin ranging from 1.75 to 2.75 percentage points, which is determined by our leverage ratio. Under the leverage ratio, our total indebtedness cannot exceed three-and one-half (3.5) times our earnings before income tax, depreciation and amortization for any period of four consecutive quarters. The credit facility also contains usual and customary default provisions, limitations on liens securing indebtedness, asset sales, and distributions and acquisitions.

We used borrowings of $26.6 million under this facility, in June 2010, to repay all amounts outstanding under the prior credit agreement, which was then terminated. In addition, we incurred debt issuance costs of $1.7 million, consisting of legal and other professional fees, which were recorded in other noncurrent assets and are being amortized as additional interest expense over the term of the revolving credit facility. As of December 31, 2011, amounts borrowed under this credit facility totaled $6.4 million, all of which are denominated in Japanese Yen. The Yen-denominated note is accounted for as a hedge of our net investment in our Japanese affiliate. We pay a quarterly commitment fee ranging from 0.325% to 0.55% as determined by the leverage ratio on any unused commitments. The borrowings under the revolving credit agreement together with outstanding letters of credit of $3.3 million result in an unused commitment level of $215.3 million under the facility at December 31, 2011.

In June 2011, we entered into a credit agreement and related document governing the terms of a $50.0 million revolving credit facility. The proceeds of the loans will be used to finance the construction and acquisition of our new corporate office and research building. Construction is expected to be completed in late 2012 or early 2013, with final settlement occurring by early 2013. On the date of acquisition, the revolving loan balance will be converted to a five-year term loan. Borrowings under the loans will bear interest at a variable rate equal to one-month LIBOR plus a margin of 1.50 percentage points. The credit agreement requires us to maintain a total leverage ratio no greater than 3.50 to 1.00 and an interest coverage ratio greater than or equal to 2.50 to 1.00. In connection with this credit facility, we incurred debt issuance costs of $0.3 million which are recorded in other noncurrent assets and are being amortized as additional interest expense over the term of the facility. As of December 31, 2011, there were no borrowings under this credit facility.

Series A and B Notes

In 2005, we concluded a private placement of $75.0 million in senior floating rate notes. The total amount of the private placement was divided into two tranches with $50.0 million maturing on July 28, 2012 (“Series A Notes”) and $25.0 million maturing on July 28, 2015 (“Series B Notes”).  The two tranches have interest payable based on LIBOR rates, with the Series A Notes at LIBOR plus 0.8 percentage points and the Series B Notes at LIBOR plus 0.9 percentage points. We entered into two interest-rate swap agreements to protect against volatility in the interest rates payable on the Series A and B floating rate notes (discussed in Note 12, Derivative Financial Instruments).

Euro-denominated Notes

In 2006, we issued Euro-denominated notes totaling €81.5 million. Euro note A of €20.4 million (or $26.3 million at December 31, 2011) has a term of 7 years due February 27, 2013 with a fixed annual interest rate of 4.215% while Euro note B of €61.1 million ($79.0 million at December 31, 2011) has a term of 10 years due February 27, 2016 at a fixed annual interest rate of 4.38%.  These Euro-denominated notes are accounted for as a hedge of our net investment in our European subsidiaries.

Convertible Debt

In March and April 2007, the Company issued $161.5 million of Convertible Junior Subordinated Debentures (“debentures”) due March 15, 2047. The debentures bear interest at a rate of 4.0% annually and are convertible into shares of our common stock at a conversion rate, subject to adjustment, of 18.0386 shares per $1,000 of principal amount, which equals a conversion price of approximately $55.44 per share. The holders may convert their debentures at any time prior to maturity. On or after March 20, 2012, if our common stock closing price exceeds 150% of the then prevailing conversion price for at least 20 trading days during any 30 consecutive trading day period, we have the option to cause the debentures to be automatically converted into West shares at the prevailing conversion rate. As of December 31, 2011, no debentures have been converted.

Total net proceeds from this offering were $156.3 million. We have and may use the proceeds for general corporate purposes, which include capital expenditures, working capital, possible acquisitions of other businesses, technologies or products, repaying debt, and repurchasing our capital stock. In connection with the offering, we incurred debt issuance costs in the amount of $5.2 million, consisting of underwriting discounts and commissions, legal and other professional fees. These costs were recorded as a noncurrent asset and are being amortized as additional interest expense over the term of the debentures.

Covenants

Pursuant to the financial covenants in our debt agreements, we are required to maintain established interest coverage ratios and to not exceed established leverage ratios. In addition, the agreements contain other customary covenants, none of which we consider restrictive to our operations. As of December 31, 2011, we were in compliance with all of our debt covenants.

Interest costs incurred during 2011, 2010 and 2009 were $19.3 million, $17.7 million and $17.6 million, respectively. The aggregate annual maturities of long-term debt were as follows: 2013 - $26.7 million, 2014 - $6.6 million, 2015 - $25.0 million, 2016 - $79.5 million and thereafter - $161.5 million.

XML

Comprehensive Income

12 Months Ended

Dec. 31, 2011

Comprehensive Income [Abstract]

Comprehensive Income

Note 7: Comprehensive Income

Comprehensive income consists of reported net income and other comprehensive income, which reflects revenues, expenses and gains and losses that generally accepted accounting principles exclude from net income. For us, the items excluded from current net income were cumulative foreign currency translation adjustments, unrealized gains or losses on available-for-sale securities of affiliates, fair value adjustments on derivative financial instruments and pension and other postretirement liability adjustments.

The components of accumulated other comprehensive loss, net of tax, at December 31 were as follows:

($ in millions)	2011			2010
Foreign currency translation	$	10.2		$	22.0
Unrealized gains on securities of affiliates		0.4			0.1
Unrealized losses on derivatives		(5.4	)		(3.7	)
Defined benefit pension and other postretirement plans		(76.7	)		(49.7	)
	$	(71.5	)	$	(31.3	)

XML

Segment Information

12 Months Ended

Dec. 31, 2011

Segment Information [Abstract]

Segment Information

Note 5: Segment Information

Our business operations are organized into two reportable segments, which are aligned with the underlying markets and customers they serve. Our reportable segments are Packaging Systems and Delivery Systems. Packaging Systems develops, manufactures and sells primary packaging components and systems for injectable drug delivery, including stoppers and seals for vials, closures and other components used in syringe, intravenous and blood collection systems, and prefillable syringe components. Delivery Systems develops, manufactures and sells safety and administration systems, multi-component systems for drug administration, and a variety of custom contract-manufacturing solutions targeted to the healthcare and consumer-products industries. In addition, Delivery Systems is responsible for the continued development and commercialization of our line of proprietary, multi-component systems for injectable drug administration and other healthcare applications.

Packaging Systems has three operating segments: the Americas, Europe and Asia Pacific. These operating segments are aggregated for reporting purposes as they have common economic characteristics, produce and sell a similar range of products, use a similar distribution process and have a similar customer base.

During the second quarter of 2011, we revised our method of internal financial reporting for the Delivery Systems segment to better align it with how the segment’s performance is assessed by the chief executive officer, who is also the chief operating decision maker. As a result, the former Americas and International operating segments were combined into a total Delivery Systems segment and separate financial information for them is no longer available. This change had no impact on our reportable segments.

Our executive management evaluates the performance of these operating segments based on sales, operating profit and cash flow generation.  Segment operating profit excludes general corporate costs, including stock-based compensation, adjustments to annual incentive plan expense for over- or under-attainment and certain pension and other retirement benefit costs. Also excluded are items that management considers not representative of ongoing operations, such as restructuring and related charges, certain asset impairments and other specifically identified gains and losses. Corporate assets include pension assets and investments in affiliated companies.  The accounting policies of the segments are the same as those described in the summary of significant accounting policies.

The following table provides information on sales by significant product group:

($ in millions)	2011			2010			2009
Pharmaceutical packaging	$	731.1		$	661.2		$	637.3
Disposable medical components		106.9			100.0			104.6
Laboratory and other services		19.4			23.8			34.1
Packaging Systems		857.4			785.0			776.0
Healthcare devices		177.4			178.8			165.9
Consumer products		69.4			64.7			57.4
Injection and administration systems		59.0			55.3			42.9
Tooling and other services		30.9			25.3			18.8
Delivery Systems		336.7			324.1			285.0
Intersegment sales elimination		(1.8	)		(4.4	)		(5.3	)
Net sales	$	1,192.3		$	1,104.7		$	1,055.7

We do not have any customers accounting for greater than 10% of consolidated net sales.

The following table presents sales and net property, plant and equipment, by the country in which the legal subsidiary is domiciled and assets are located:

	Sales						Property, Plant and Equipment, Net
($ in millions)	2011		2010		2009		2011		2010		2009
United States	$	543.6	$	528.2	$	502.8	$	272.6	$	232.8	$	242.5
Germany		184.1		151.5		148.3		118.1		117.8		129.9
France		94.2		89.0		105.3		41.3		42.4		45.9
Other European countries		242.7		225.6		209.3		69.9		77.2		83.2
Other		127.7		110.4		90.0		91.7		84.6		75.6
	$	1,192.3	$	1,104.7	$	1,055.7	$	593.6	$	554.8	$	577.1

The following tables provide summarized financial information for our segments:

($ in millions)	Packaging Systems		Delivery Systems		Corporate and Eliminations			Consolidated
2011
Net sales	$	857.4	$	336.7	$	(1.8	)	$	1,192.3
Operating profit	$	152.6	$	9.8	$	(52.8	)	$	109.6
Interest expense, net		-		-		(16.9	)		(16.9	)
Income before income taxes	$	152.6	$	9.8	$	(69.7	)	$	92.7
Segment assets	$	843.5	$	365.6	$	190.0		$	1,399.1
Capital expenditures		66.2		26.1		3.1			95.4
Depreciation and amortization expense		53.6		18.5		3.6			75.7
2010
Net sales	$	785.0	$	324.1	$	(4.4	)	$	1,104.7
Operating profit	$	139.3	$	9.7	$	(58.3	)	$	90.7
Interest expense, net		-		-		(16.2	)		(16.2	)
Income before income taxes	$	139.3	$	9.7	$	(74.5	)	$	74.5
Segment assets	$	814.4	$	350.6	$	129.3		$	1,294.3
Capital expenditures		48.9		16.3		5.9			71.1
Depreciation and amortization expense		50.7		19.0		3.5			73.2
2009
Net sales	$	776.0	$	285.0	$	(5.3	)	$	1,055.7
Operating profit	$	138.3	$	9.9	$	(50.7	)	$	97.5
Interest expense, net		-		-		(14.4	)		(14.4	)
Income before income taxes	$	138.3	$	9.9	$	(65.1	)	$	83.1
Segment assets	$	824.7	$	335.1	$	111.2		$	1,271.0
Capital expenditures		84.8		18.6		1.5			104.9
Depreciation and amortization expense		46.7		18.5		2.9			68.1

XML

Net Income Per Share

12 Months Ended

Dec. 31, 2011

Net income per share

Net Income Per Share

Note 6: Net Income Per Share

The following table reconciles net income and shares used in the calculation of basic net income per share to those used for diluted net income per share:

($ and shares in millions)	2011		2010		2009
Net income, as reported, for basic net income per share	$	75.5	$	65.3	$	72.6
Plus: interest expense on convertible debt, net of tax		4.3		4.3		4.3
Net income for diluted net income per share	$	79.8	$	69.6	$	76.9
Weighted average common shares outstanding		33.7		33.3		32.8
Assumed stock options exercised and awards vested, based on the treasury stock method		0.4		0.5		0.6
Assumed conversion of convertible debt, based on the if-converted method		2.9		2.9		2.9
Weighted average shares assuming dilution		37.0		36.7		36.3

Options outstanding but not included in the computation of diluted net income per share because their impact was antidilutive were 1.6 million, 1.1 million and 1.1 million for fiscal years 2011, 2010 and 2009, respectively.

XML

Goodwill and Intangibles

12 Months Ended

Dec. 31, 2011

Goodwill and Intangibles [Abstract]

Goodwill and Intangibles

Note 8: Goodwill and Intangible Assets

The changes in the carrying amount of goodwill by reportable segment were as follows:

($ in millions)	Packaging Systems			Delivery Systems			Total
Balance, December 31, 2009	$	39.3		$	74.9		$	114.2
Additions		-			1.8			1.8
Foreign currency translation		(2.7	)		(0.8	)		(3.5	)
Balance, December 31, 2010		36.6			75.9			112.5
Foreign currency translation		(0.7	)		(0.3	)		(1.0	)
Balance, December 31, 2011	$	35.9		$	75.6		$	111.5

As of December 31, 2011, we had no accumulated goodwill impairment losses.

In July 2010, we acquired 100% of the outstanding shares of La Model Ltd., the developer of the SmartDose electronic patch injector system, resulting in $1.2 million of goodwill. As part of this acquisition, Delivery Systems acquired $3.3 million of in-process R&D, which was considered to have an indefinite life until the completion of the associated research and development efforts, at which point the technology will start to be amortized over 17 years.

In January 2010, we purchased a tool design and testing company based in Roskilde, Denmark in which we acquired $0.7 million of intangible assets consisting of $0.4 million in customer relationships, $0.1 million in technical know-how and $0.2 million in software and licenses. Both the customer relationships and technical know-how have a useful life of 10 years, with the software and licenses having an estimated useful life of 5 years. This acquisition resulted in goodwill of $0.6 million.

Intangible assets and accumulated amortization as of December 31 were as follows:

	2011							2010
($ in millions)	Cost		Accumulated Amortization			Net		Cost		Accumulated Amortization			Net
Patents and licensing	$	17.0	$	(6.7	)	$	10.3	$	15.7	$	(5.5	)	$	10.2
In-process R&D/technology		3.5		-			3.5		3.4		-			3.4
Trademarks		12.0		(0.8	)		11.2		12.1		(0.6	)		11.5
Customer relationships		29.7		(11.2	)		18.5		29.7		(9.5	)		20.2
Customer contracts		11.4		(3.1	)		8.3		11.5		(2.5	)		9.0
Non-compete agreements		3.9		(3.7	)		0.2		3.9		(3.1	)		0.8
	$	77.5	$	(25.5	)	$	52.0	$	76.3	$	(21.2	)	$	55.1

The cost basis of intangible assets includes foreign currency translation losses of $0.2 million and $0.9 million for the twelve months ended December 31, 2011 and 2010, respectively. Amortization expense for the years ended December 31, 2011, 2010 and 2009 was $4.3 million, $4.1 million and $3.8 million, respectively. Estimated annual amortization expense for the next five years is as follows: 2012 - $3.9 million, 2013 and 2014 - $3.7 million, 2015 - $3.4 million and 2016 - $2.8 million. Trademarks with a carrying amount of $10.0 million were determined to have indefinite lives and therefore do not require amortization.

As part of our annual long-range planning process, our sales and marketing teams updated sales projections during the third quarter of 2011, which indicated delays and lower-than-expected demand for our eris, Confidose and NovaGuard product lines. The revised projections triggered an impairment review of the assets associated with these product lines. Our review concluded that the future cash flows associated with these product lines were still expected to exceed the carrying value of the related assets and, therefore, no impairment charge was required. We continued to monitor these product lines during our annual review of goodwill and indefinite-lived intangible assets, and determined that no impairment charge was required for these product lines. At December 31, 2011, our investment in equipment and intangible assets, excluding goodwill, for eris, Confidose and NovaGuard was $13.3 million, $5.9 million and $3.4 million, respectively.

XML

Property plant and equipment (Tables)

12 Months Ended

Dec. 31, 2011

Property plant and equipment [Abstract]

Summary of gross property, plant and equipment

A summary of gross property, plant and equipment at December 31 is presented in the following table:

($ in millions)	Expected useful lives (years)		2011		2010
Land			$	8.9	$	9.0
Buildings and improvements		5-50		284.1		276.4
Machinery and equipment		10-15		565.7		568.7
Molds and dies		4-7		85.8		84.8
Computer hardware and software		3-10		76.2		68.2
Construction in progress				116.1		70.1
			$	1,136.8	$	1,077.2

XML

Stock-Based Compensation (Details) (USD $)	12 Months Ended
	Dec. 31, 2011	Dec. 31, 2010	Dec. 31, 2009
Stock-Based Compensation, by Type of Award [Line Items]
Shares remaining under the 2011 Omnibus Incentive Compensation Plan (in shares)	4,718,287
Reduction in the number of shares available for grant	Stock options and stock appreciation rights reduce the number of shares available for grant by one share for each award granted. All other awards that will be distributed in stock under the 2011 Plan will reduce the total number of shares available for grant by an amount equal to 2.35 times the number of shares awarded.
Stock-based compensation expense	$ 8,400,000	$ 7,800,000	$ 7,500,000
Unrecognized compensation expense for all nonvested awards	10,800,000
Weighted-average period to recognize unrecognized compensation expenses (in years)	1.6
Weighted Average Grant Date Fair Value [Abstract]
PVS payout, Minimum (in hundredths)	0.00%
PVS payout, Maximum (in hundredths)	200.00%
ESPP Shares available for issuance (in shares)	4,718,287
Deferred Compensation Plan [Member]
Stock-Based Compensation, by Type of Award [Line Items]
Deferred stock units (in shares)	180,373
Deferred stock awards (in shares)	85,782
Stock-based compensation expense	400,000	1,300,000	1,500,000
Stock options [Roll Forward]
Outstanding, ending balance (in shares)	180,373
Outstanding Awards [Roll Forward]
Outstanding, ending balance (in shares)	85,782
PVS awards [Roll forward]
Outstanding, ending balance (in shares)	85,782
Employee Stock Purchase Plan [Member]
Stock-Based Compensation, by Type of Award [Line Items]
Shares remaining under the 2011 Omnibus Incentive Compensation Plan (in shares)	2,200,000
Stock-based compensation expense	300,000	300,000	300,000
Weighted Average Grant Date Fair Value [Abstract]
Common stock sales price percentage offered to eligible employees (in hundredths)	85.00%
ESPP base salary, maximum (in hundredths)	25.00%
ESPP salary deduction, annual maximum	25,000
Shares employee may buy, offering period maximum (in shares)	1,000
Shares employee may buy, annual maximum (in shares)	4,000
ESPP shares purchased (in shares)	55,388	56,608	58,606
ESPP Shares available for issuance (in shares)	2,200,000
Management Incentive Plan [Member]
Stock-Based Compensation, by Type of Award [Line Items]
Ratio of restricted incentive stock award, description	given a restricted incentive stock award equal to one share for each four bonus shares issued
Incentive stock award grants (in shares)	1,900	1,400	3,700
Granted, PVS awards (in shares)	1,900	1,400	3,700
Incentive stock award forfeited (in shares)	1,400	50	400
Weighted average grant-date fair value, PVS awards (per share)	$ 40.85	$ 38.22	$ 32.09
Outstanding Awards [Roll Forward]
Granted (in shares)	1,900	1,400	3,700
Forfeited (in shares)	(1,400)	(50)	(400)
PVS awards [Roll forward]
Granted (in shares)	1,900	1,400	3,700
Forfeited (in shares)	(1,400)	(50)	(400)
Weighted Average Grant Date Fair Value [Abstract]
Granted at target level (in dollars per share)	$ 40.85	$ 38.22	$ 32.09
Stock Options [Member]
Stock-Based Compensation, by Type of Award [Line Items]
Deferred stock units (in shares)	2,900,000	2,900,000	2,700,000
Vesting period (in years)	4
Weighted average grant date fair value, options (per share)	$ 8.76	$ 10.38	$ 6.98
Intrinsic value of options exercised	10,700,000	5,900,000	7,100,000
Grant date fair value of options vested	4,000,000	3,500,000	3,700,000
Expiration period (in years)	10
Stock options [Roll Forward]
Outstanding, beginning balance (in shares)	2,900,000	2,700,000	2,600,000
Granted (in shares)	500,000	600,000	400,000
Exercised (in shares)	400,000	300,000	300,000
Forfeited (in shares)	100,000	100,000
Outstanding, ending balance (in shares)	2,900,000	2,900,000	2,700,000
Options exercisable, period end (in shares)	1,800,000	1,800,000	1,700,000
Weighted Average Exercise Price [Abstract]
Outstanding, beginning balance (in dollars per share)	$ 32.32	$ 29.09	$ 26.91
Granted (in dollars per share)	$ 40.85	$ 42.47	$ 32.12
Exercised (in dollars per share)	$ 17.69	$ 14.88	$ 13.70
Forfeited (in dollars per share)	$ 41.40	$ 41.47	$ 37.43
Outstanding, ending balance (in dollars per share)	$ 35.79	$ 32.32	$ 29.09
Exercisable, period end (in dollars per share)	$ 32.91	$ 27.77	$ 24.52
Weighted average remaining contractual life {Abstract]
Options outstanding (in years)	6.1
Options exercisable (in years)	4.7
Aggregate intrinsic value [Abstract]
Options outstanding	13,600,000
Vested options	12,600,000
Assumptions used in Black-Scholes model [Abstract]
Risk-free interest rate (in hundredths)	2.20%	2.40%	1.90%
Expected life (in years)	5	5	5
Stock volatility	24.30%	26.90%	27.00%
Dividend yield	1.70%	1.50%	1.90%
Vesting period (in years)	4
Performance-Vesting Share (PVS) Awards [Member]
Stock-Based Compensation, by Type of Award [Line Items]
Deferred stock awards (in shares)	328,519	347,550	327,498
Incentive stock award grants (in shares)	101,099	123,068	125,600
Stock-based compensation expense	3,000,000	2,200,000	1,800,000
PVS expense recorded within restructuring and other	700,000
Granted, PVS awards (in shares)	101,099	123,068	125,600
Incentive stock award forfeited (in shares)	(10,199)	(4,315)	(43,365)
Weighted average grant-date fair value, PVS awards (per share)	$ 40.85	$ 42.34	$ 32.12
Outstanding Awards [Roll Forward]
Outstanding, beginning balance (in shares)	347,550	327,498	330,458
Granted (in shares)	101,099	123,068	125,600
Forfeited (in shares)	10,199	4,315	43,365
Outstanding, ending balance (in shares)	328,519	347,550	327,498
PVS awards [Roll forward]
Outstanding, beginning balance (in shares)	347,550	327,498	330,458
Granted (in shares)	101,099	123,068	125,600
Adjustments above/(below) target (in shares)	(58,175)	(48,364)	(5,112)
Vested and converted (in shares)	51,756	50,337	80,083
Forfeited (in shares)	10,199	4,315	43,365
Outstanding, ending balance (in shares)	328,519	347,550	327,498
Weighted Average Grant Date Fair Value [Abstract]
Non-vested awards, beginning balance (in dollars per share)	$ 39.21	$ 39.63	$ 40.62
Granted at target level (in dollars per share)	$ 40.85	$ 42.34	$ 32.12
Adjustments above/(below) target (in dollars per share)	$ 41.95	$ 44.99	$ 32.69
Vested and converted (in dollars per share)	$ 40.85	$ 38.22	$ 32.69
Forfeited (in dollars per share)	$ 38.46	$ 37.61	$ 39.10
Non-vested awards, ending period (in dollars per share)	$ 38.77	$ 39.21	$ 39.63
Expected conversion of PVS awards (in shares)	209,848
Expected percentage of awards that will vest at their target amounts (in hundredths)	60.00%
Average remaining term of converted PVS awards (in years)	1.4
Stock Appreciation Rights (SARs) [Member]
Stock-Based Compensation, by Type of Award [Line Items]
Deferred stock awards (in shares)	162,106	111,048	78,512
Incentive stock award grants (in shares)	63,024	36,255	22,500
Vesting period (in years)	4
Granted, PVS awards (in shares)	63,024	36,255	22,500
Incentive stock award forfeited (in shares)	(4,281)
Expiration period (in years)	ten years
Assumptions used in Black-Scholes model [Abstract]
Vesting period (in years)	4
Outstanding Awards [Roll Forward]
Outstanding, beginning balance (in shares)	111,048	78,512	56,012
Granted (in shares)	63,024	36,255	22,500
Exercised (in shares)	7,685	3,719
Forfeited (in shares)	4,281
Outstanding, ending balance (in shares)	162,106	111,048	78,512
Exercisable, period end (in shares)	58,900	41,439	24,861
Weighted Average Exercise Price, Awards Other than Options [Abstract]
Outstanding, beginning balance (in dollars per share)	$ 39.74	$ 38.04	$ 40.43
Granted (in dollars per share)	$ 41.13	$ 42.68	$ 32.09
Exercised (in dollars per share)	$ 39.15	$ 32.50
Forfeited (in dollars per share)	$ 40.85
Outstanding, ending balance (in dollars per share)	$ 40.28	$ 39.74	$ 38.04
Exercisable, period end (in dollars per share)	$ 39.72	$ 39.16	$ 39.22
PVS awards [Roll forward]
Outstanding, beginning balance (in shares)	111,048	78,512	56,012
Granted (in shares)	63,024	36,255	22,500
Forfeited (in shares)	4,281
Outstanding, ending balance (in shares)	162,106	111,048	78,512
Performance Vesting Units Awards (PVU) [Member]
Stock-Based Compensation, by Type of Award [Line Items]
Deferred stock awards (in shares)	27,286	23,420	20,792
Incentive stock award grants (in shares)	13,442	7,697	7,200
Stock-based compensation expense	200,000	100,000
Granted, PVS awards (in shares)	13,442	7,697	7,200
Incentive stock award forfeited (in shares)	(1,718)
Weighted average grant-date fair value, PVS awards (per share)	$ 41.11	$ 42.30	$ 32.09
Outstanding Awards [Roll Forward]
Outstanding, beginning balance (in shares)	23,420	20,792	19,346
Granted (in shares)	13,442	7,697	7,200
Forfeited (in shares)	1,718
Outstanding, ending balance (in shares)	27,286	23,420	20,792
PVS awards [Roll forward]
Outstanding, beginning balance (in shares)	23,420	20,792	19,346
Granted (in shares)	13,442	7,697	7,200
Adjustments above/(below) target (in shares)	(4,165)	(2,484)	(345)
Vested and converted (in shares)	3,963	2,585	5,409
Forfeited (in shares)	1,718
Outstanding, ending balance (in shares)	27,286	23,420	20,792
Weighted Average Grant Date Fair Value [Abstract]
Non-vested awards, beginning balance (in dollars per share)	$ 38.94	$ 39.17	$ 39.85
Granted at target level (in dollars per share)	$ 41.11	$ 42.30	$ 32.09
Adjustments above/(below) target (in dollars per share)	$ 41.05	$ 38.22	$ 32.59
Vested and converted (in dollars per share)	$ 40.85	$ 38.22	$ 32.59
Forfeited (in dollars per share)	$ 37.55
Non-vested awards, ending period (in dollars per share)	$ 39.30	$ 38.94	$ 39.17
Performance Vesting Shares/ Unit Dividend Equivalent [Member]
Stock-Based Compensation, by Type of Award [Line Items]
Stock-based compensation expense	100,000	200,000	200,000
Stock Options and Appreciation Rights [Member]
Stock-Based Compensation, by Type of Award [Line Items]
Stock-based compensation expense	4,400,000	3,700,000	3,700,000
Stock option expense recorded within restructuring and other	$ 800,000

XML

Fair Value of Financial Instruments

12 Months Ended

Dec. 31, 2011

Fair Value Disclosures [Abstract]

Fair Value Measurements

Note 13: Fair Value Measurements

We define fair value as the price that would be received to sell an asset or paid to transfer a liability (an exit price) in the principal or most advantageous market for the asset or liability in an orderly transaction between market participants on the measurement date.

The following fair value hierarchy classifies the inputs to valuation techniques used to measure fair value into one of three levels:

·   Level 1: Unadjusted quoted prices in active markets for identical assets or liabilities.

·   Level 2: Inputs other than quoted prices that are observable for the asset or liability, either directly or indirectly. These include quoted prices for similar assets or liabilities in active markets and quoted prices for identical or similar assets or liabilities in markets that are not active.

·   Level 3: Unobservable inputs that reflect the reporting entity’s own assumptions.

The following tables present the assets and liabilities that are measured at fair value on a recurring basis in our balance sheets:

	Balance at		Basis of Fair Value Measurements
	December 31,
($ in millions)	2011		Level 1		Level 2		Level 3
Assets:
Short-term investments	$	26.5	$	26.5	$	-	$	-
Deferred compensation assets		3.3		3.3		-		-
	$	29.8	$	29.8	$	-	$	-
Liabilities:
Contingent consideration	$	2.1	$	-	$	-	$	2.1
Deferred compensation liabilities		4.6		4.6		-		-
Interest rate swap contracts		8.8		-		8.8		-
	$	15.5	$	4.6	$	8.8	$	2.1

	Balance at		Basis of Fair Value Measurements
	December 31,
($ in millions)	2010		Level 1		Level 2		Level 3
Assets:
Short-term investments	$	0.6	$	0.6	$	-	$	-
Deferred compensation assets		3.6		3.6		-		-
	$	4.2	$	4.2	$	-	$	-
Liabilities:
Contingent consideration	$	2.3	$	-	$	-	$	2.3
Deferred compensation liabilities		5.4		5.4		-		-
Interest rate swap contracts		6.1		-		6.1		-
	$	13.8	$	5.4	$	6.1	$	2.3

Short-term investments, which are comprised of certificates of deposit and mutual funds, are included within other current assets and are valued using a market approach based on quoted market prices in an active market. Deferred compensation assets are included within other current assets and are also valued using a market approach based on quoted market prices in an active market. The fair value of deferred compensation liabilities is based on quoted prices of the underlying employees’ investment selections and is included within other long-term liabilities.

Interest rate swaps are valued using a discounted cash flow analysis based on the terms of the contract and observable market inputs (i.e. LIBOR, Eurodollar forward rates, and swap spreads). Refer to Note 12, Derivative Financial Instruments, for further discussion of our derivatives.

The fair value of the contingent consideration was determined using a probability-weighted income approach at the acquisition date and is revalued at each reporting date or more frequently if circumstances dictate. Changes in the fair value of these obligations are recorded as income or expense within restructuring and other items in our consolidated statements of income. The fair value measurement is based on significant inputs not observable in the market, which are referred to as Level 3 inputs.

The following table provides a summary of changes in our Level 3 fair value measurements during 2011:

	($ in millions)
Balance, December 31, 2010	$	2.3
Increase in fair value recorded in earnings		0.5
Reduction in fair value recorded in earnings		(0.8	)
Changes in foreign currency exchange rates		0.1
Balance, December 31, 2011	$	2.1

The following table provides a summary of changes in our Level 3 fair value measurements during 2010:

	($ in millions)
Balance, December 31, 2009	$	2.8
Additional contingent consideration acquired		1.8
Increase in fair value recorded in earnings		0.2
Reduction in fair value recorded in earnings		(2.1	)
Changes in foreign currency exchange rates		(0.4	)
Balance, December 31, 2010	$	2.3

Refer to Note 3, Restructuring and Other Items, for further discussion of acquisition-related contingencies.

Other Financial Instruments

Cash and cash equivalents, accounts receivable and short-term debt are held at carrying amounts that approximate fair value due to their near term maturities. Quoted market prices are used to estimate the fair value of publicly traded long-term debt. Debt that is not quoted on an exchange is valued using a discounted cash flow method based on interest rates that are currently available to us for debt issuances with similar terms and maturities. At December 31, 2011, the estimated fair value of long-term debt was $279.2 million compared to a carrying amount of $299.3 million. At December 31, 2010, the estimated fair value of long-term debt was $344.2 million and the carrying amount was $358.1 million.

XML

Summary of Significant Accounting Policies (Policies)

12 Months Ended

Dec. 31, 2011

Summary of Significant Accounting Policies [Abstract]

Principles of Consolidation

Principles of Consolidation:The consolidated financial statements include the accounts of West Pharmaceutical Services, Inc. and its majority-owned subsidiaries (which may be referred to as “West”, the “Company”, “we”, “us” or “our”) after the elimination of intercompany transactions. We have no participation or other rights in variable interest entities.

Reclassifications

Reclassifications:  Certain reclassifications were made to prior period financial statements to conform to the current year presentation.

Use of Estimates

Use of Estimates: The financial statements are prepared in conformity with generally accepted accounting principles in the United States (“U.S. GAAP”). These principles require management to make estimates and assumptions that affect the reported amounts of assets, liabilities, revenues and expenses and the disclosure of contingencies in the financial statements. Actual amounts realized may differ from these estimates.

Cash and Cash Equivalents

Cash and Cash Equivalents:  Cash equivalents include time deposits, certificates of deposit and all highly liquid debt instruments with maturities of three months or less at the time of purchase.

Accounts Receivable

Accounts Receivable: Our accounts receivable balance was net of an allowance for doubtful accounts of $0.3 million and $0.5 million at December 31, 2011 and 2010, respectively. We record the allowance based on a specific identification methodology.

Inventories

Inventories: Inventories are valued at the lower of standard cost (which approximates actual cost on a first-in-first-out basis) or market.

Property, Plant and Equipment

Property, Plant and Equipment: Property, plant and equipment assets are carried at cost. Maintenance and minor repairs and renewals are charged to expense as incurred. Costs incurred for computer software developed or obtained for internal use are capitalized for application development activities and immediately expensed for preliminary project activities or post-implementation activities. Upon sale or retirement of depreciable assets, costs and related accumulated depreciation are eliminated, and gains or losses are recognized in restructuring and other items. Depreciation and amortization are computed principally using the straight-line method over the estimated useful lives of the assets, or the remaining term of the lease, if shorter.

Impairment of Goodwill and Other Intangible Assets

Impairment of Goodwill and Other Intangible Assets: Goodwill and indefinite-lived intangibles are tested for impairment at least annually, following the completion of our annual budget and long-range planning process, or whenever circumstances indicate that the carrying value of these assets may not be recoverable. Goodwill is tested for impairment as part of the reporting unit to which it belongs. Our reporting units are the same as, or one level below, our operating segments. The goodwill impairment test first requires a comparison of the fair value of each reporting unit to its carrying amount, including goodwill. If the carrying amount exceeds fair value, a second step must be performed. The second step requires the comparison of the carrying amount of the goodwill to its implied fair value, which is calculated as if the reporting unit had just been acquired as of the testing date. Any excess of the carrying amount of goodwill over the implied fair value would represent an impairment loss.

Certain trademarks and in-process R&D have been determined to have indefinite lives and, therefore, are not subject to amortization. Impairment testing for indefinite-lived intangible assets requires a comparison between the fair value and carrying value of the asset, and any excess carrying value would represent an impairment. Fair values are primarily determined using discounted cash flow analyses.

Intangible assets with finite lives are amortized using the straight-line method over their estimated useful lives of 5 to 25 years, and reviewed for recovery whenever circumstances indicate that the carrying value of these assets may not be recoverable.

Impairment of Long-Lived Assets

Impairment of Long-Lived Assets: Long-lived assets, including property, plant and equipment, are tested for impairment whenever circumstances indicate that the carrying value of these assets may not be recoverable. An asset is considered impaired if the carrying value of the asset exceeds the sum of the future expected undiscounted cash flows to be derived from the asset. Once an asset is considered impaired, an impairment loss is recorded within restructuring and other items for the difference between the asset's carrying value and its fair value. For assets held and used in the business, management determines fair value using estimated future cash flows to be derived from the asset, discounted to a net present value using an appropriate discount rate. For assets held for sale or for investment purposes, management determines fair value by estimating the proceeds to be received upon sale of the asset, less disposition costs.

Employee Benefits

Employee Benefits: The measurement of the obligations under our defined benefit pension and postretirement medical plans are subject to a number of assumptions. These include the rate of return on plan assets (for funded plans) and the rate at which the future obligations are discounted to present value. U.S. GAAP requires the recognition of an asset or liability for the funded status of a defined benefit postretirement plan, as measured by the difference between the fair value of plan assets, if any, and the benefit obligation. For a pension plan, the benefit obligation is the projected benefit obligation; for any other postretirement plan, such as a retiree health plan, the benefit obligation is the accumulated postretirement benefit obligation. See Note 14, Benefit Plans, for a more detailed discussion of our pension and other retirement plans.

Financial Instruments

Financial Instruments: All derivatives are recognized as either assets or liabilities in the balance sheet and recorded at their fair value. For a derivative designated as hedging the exposure to variable cash flows of a forecasted transaction (referred to as a cash flow hedge), the effective portion of the derivative's gain or loss is initially reported as a component of other comprehensive income, net of tax, and subsequently reclassified into earnings when the forecasted transaction affects earnings. For a derivative designated as hedging the exposure to changes in the fair value of a recognized asset or liability or a firm commitment (referred to as a fair value hedge), the derivative’s gain or loss is recognized in earnings in the period of change together with the offsetting loss or gain on the hedged item. For a derivative designated as hedging the foreign currency exposure of a net investment in a foreign operation, the gain or loss is reported in other comprehensive income, net of tax, as part of the cumulative translation adjustment. The ineffective portion of any derivative used in a hedging transaction is recognized immediately into earnings. Derivative financial instruments that are not designated as hedges are also recorded at fair value, with the change in fair value recognized immediately into earnings. We do not purchase or hold any derivative financial instrument for investment or trading purposes.

Foreign Currency Translation

Foreign Currency Translation: Foreign currency transaction gains and losses are recognized in the determination of net income. Foreign currency translation adjustments of subsidiaries and affiliates operating outside of the United States are accumulated in other comprehensive income, a separate component of equity.

Revenue Recognition

Revenue Recognition: Revenue is recognized when persuasive evidence of a sales arrangement exists, title and risk of loss have transferred, the selling price is fixed or determinable, and collectability is reasonably assured. Generally, sales are recognized upon shipment or upon delivery to our customers’ site, based upon shipping terms or legal requirements. Some customers receive pricing rebates upon attaining established sales volumes. We record rebate costs when sales occur based on our assessment of the likelihood that these volumes will be attained. We also establish product return liabilities for customer quality claims when such amounts are deemed probable and can be reasonably estimated.

Shipping and Handling Costs

Shipping and Handling Costs: Shipping and handling costs are included in cost of goods and services sold. Shipping and handling costs billed to customers in connection with the sale are included in net sales.

Research and Development

Research and Development: Research and development expenditures are for the creation, engineering and application of new or improved products and processes. Expenditures include primarily salaries and outside services for those directly involved in research and development activities and are expensed as incurred.

Environmental Remediation and Compliance Costs

Environmental Remediation and Compliance Costs: Environmental remediation costs are accrued when such costs are probable and reasonable estimates are determinable. Cost estimates include investigation, cleanup and monitoring activities; such estimates are adjusted, if necessary, based on additional findings. Environmental compliance costs are expensed as incurred as part of normal operations.

Litigation

Litigation: From time to time, we are involved in product liability matters and other legal proceedings and claims generally incidental to our normal business activities. In accordance with U.S. GAAP, we accrue for loss contingencies when it is probable that a liability has been incurred and the amount of the loss can be reasonably estimated. These estimates are based on an analysis made by internal and external legal counsel considering information known at the time. Legal costs in connection with loss contingencies are expensed as incurred.

Income Taxes

Income Taxes: Deferred income taxes are recognized by applying enacted statutory tax rates, applicable to future years, to temporary differences between the tax basis and financial statement carrying values of our assets and liabilities. Valuation allowances are established when it is more likely than not that all or a portion of a deferred tax asset will not be realized. No provision is made for the U.S. income taxes on the undistributed earnings of wholly-owned foreign subsidiaries as such earnings are intended to be permanently reinvested. We recognize interest costs related to income taxes in interest expense and penalties within restructuring and other items. The tax law ordering approach is used for purposes of determining whether an excess tax benefit has been realized during the year.

Stock-Based Compensation

Stock-Based Compensation: Under the fair value provisions of U.S. GAAP, stock-based compensation cost is measured at the grant date based on the value of the award and is recognized as expense over the vesting period. In order to determine the fair value of stock options on the grant date, the company uses the Black-Scholes valuation model.

Net Income Per Share

Net Income Per Share: Basic net income per share is computed by dividing net income attributable to common shareholders by the weighted average number of shares of common stock outstanding during each period. Net income per share assuming dilution considers the dilutive effect of outstanding stock options and other stock awards based on the treasury stock method, as well as convertible debt based on the if-converted method. The treasury stock method assumes the use of exercise proceeds to repurchase common stock at the average fair market value in the period. The if-converted method assumes conversion of the debt at the beginning of the reporting period (or at time of issuance, if later). In addition, interest charges applicable to the convertible debt, net of tax, are added back to net income for the purpose of this calculation.

XML

Goodwill and Intangibles (Details) (USD $) In Millions, unless otherwise specified	12 Months Ended			1 Months Ended			1 Months Ended																12 Months Ended
	Dec. 31, 2011	Dec. 31, 2010	Dec. 31, 2009	Jul. 31, 2010 La Model Ltd Member	Jul. 01, 2010 La Model Ltd Member	Jan. 31, 2010 Tool Design and Testing Company [Member]	Jan. 31, 2010 Tool Design and Testing Company [Member] Customer Relationships [Member]	Jan. 31, 2010 Tool Design and Testing Company [Member] Software and Licenses [Member]	Jan. 31, 2010 Tool Design and Testing Company [Member] Technical know-how [Member]	Jul. 06, 2009 Plastef Investissements SA [Member]	Dec. 31, 2011 Trademarks [Member]	Dec. 31, 2010 Trademarks [Member]	Dec. 31, 2011 Customer Contracts [Member]	Dec. 31, 2010 Customer Contracts [Member]	Dec. 31, 2011 Patents and Licensing [Member]	Dec. 31, 2010 Patents and Licensing [Member]	Dec. 31, 2011 In-process R&D/technology [Member]	Dec. 31, 2010 In-process R&D/technology [Member]	Dec. 31, 2011 Customer Relationships [Member]	Dec. 31, 2010 Customer Relationships [Member]	Dec. 31, 2011 Noncompete Agreements [Member]	Dec. 31, 2010 Noncompete Agreements [Member]	Dec. 31, 2011 Packaging Systems [Member]	Dec. 31, 2010 Packaging Systems [Member]	Dec. 31, 2011 Delivery Systems [Member]	Dec. 31, 2010 Delivery Systems [Member]
Goodwill [Roll Forward]
Goodwill, beginning balance	$ 112.5	$ 114.2																					$ 36.6	$ 39.3	$ 75.9	$ 74.9
Additions		1.8																								1.8
Foreign currency translation	(1.0)	(3.5)																					(0.7)	(2.7)	(0.3)	(0.8)
Goodwill, ending balance	111.5	112.5	114.2																				35.9	36.6	75.6	75.9
Schedule of Intangible Assets by Major Class [Line Items]
Intangible assets, cost	77.5	76.3									12.0	12.1	11.4	11.5	17.0	15.7	3.5	3.4	29.7	29.7	3.9	3.9
Accumulated Amortization	(25.5)	(21.2)									(0.8)	(0.6)	(3.1)	(2.5)	(6.7)	(5.5)			(11.2)	(9.5)	(3.7)	(3.1)
Intangible assets, net	52.0	55.1									11.2	11.5	8.3	9.0	10.3	10.2	3.5	3.4	18.5	20.2	0.2	0.8
Acquired Intangible Assets [Line Items]
Outstanding shares acquired (in hundredths)					100.00%
Goodwill acquired					1.2	0.6				7.8
Intangible assets acquired					3.3	0.7	0.4	0.2	0.1
Useful life (in years)				17			10	5	10
Foreign currency translation adjustments	0.2	0.9
Amortization expense	4.3	4.1	3.8
Accumulated goodwill impairment losses	0
Estimated annual amortization expense [Abstract]
Estimated annual amortization expense 2012	3.9
Estimated annual amortization expense 2013	3.7
Estimated annual amortization expense 2014	3.7
Estimated annual amortization expense 2015	3.4
Estimated annual amortization expense 2016	2.8
Investment in equipment and intangible assets - eris	13.3
Investment in equipment and intangible assets - Confidose	5.9
Investment in equipment and intangible assets - NovaGuard	3.4
Indefinite-lived intangible assets	$ 10.0

XML

Commitments and Contingent Liabilities (Tables)

12 Months Ended

Dec. 31, 2011

Commitments and Contingent Liabilities [Abstract]

Future minimum rental payments under non-cancelable operating leases

At December 31, 2011, future minimum rental payments under non-cancelable operating leases were:

Year	($ in millions)
2012	$	12.2
2013		6.3
2014		5.6
2015		4.1
2016		3.5
Thereafter		17.6
Total		49.3
Less sublease income		0.4
	$	48.9

XML

CONSOLIDATED BALANCE SHEETS (USD $) In Millions, unless otherwise specified	Dec. 31, 2011	Dec. 31, 2010
Current assets:
Cash, including cash equivalents	$ 91.8	$ 110.2
Accounts receivable, net	147.2	126.4
Inventories	151.8	147.0
Deferred income taxes	7.9	10.5
Other current assets	73.3	42.5
Total current assets	472.0	436.6
Property, plant and equipment	1,136.8	1,077.2
Less accumulated depreciation and amortization	543.2	522.4
Property, plant and equipment, net	593.6	554.8
Investments in affiliated companies	56.2	48.2
Goodwill	111.5	112.5
Deferred income taxes	85.1	64.5
Intangible assets, net	52.0	55.1
Other noncurrent assets	28.7	22.6
Total Assets	1,399.1	1,294.3
Current liabilities:
Notes payable and other current debt	50.1	0.3
Accounts payable	89.8	63.2
Pension and other postretirement benefits	2.3	2.1
Accrued salaries, wages and benefits	45.0	48.3
Income taxes payable	7.8	5.0
Taxes other than income	9.2	10.0
Other current liabilities	39.0	40.8
Total current liabilities	243.2	169.7
Long-term debt	299.3	358.1
Deferred income taxes	21.6	20.0
Pension and other postretirement benefits	126.0	87.2
Other long-term liabilities	54.1	33.6
Total Liabilities	744.2	668.6
Commitments and contingencies (Note 16)	0	0
Equity:
Preferred stock	0	0
Common stock, par value $.25 per share; 50.0 million shares authorized; shares issued: 34.3 million in 2011 and 2010; shares outstanding: 33.7 million in 2011 and 33.3 million in 2010	8.6	8.6
Capital in excess of par value	76.3	77.3
Retained earnings	664.5	612.6
Accumulated other comprehensive loss	(71.5)	(31.3)
Treasury stock, at cost (0.6 million shares in 2011; 1.0 million shares in 2010)	(23.0)	(41.5)
Total equity	654.9	625.7
Total Liabilities and Equity	$ 1,399.1	$ 1,294.3

XML

Acquisitions

12 Months Ended

Dec. 31, 2011

Acquisitions [Abstract]

Acquisitions

Note 2: Acquisitions

On July 1, 2010, we acquired 100% of the outstanding shares of La Model Ltd., the developer of the SmartDose electronic patch injector system. The purchase price included cash paid at closing of $2.5 million and contingent consideration with an estimated fair value of $1.5 million. The purchase price allocation consisted of $3.3 million of in-process research and development intangible assets, $1.2 million of goodwill and $0.6 million of deferred tax liabilities. We will continue to evaluate the fair value of the contingent consideration obligation at each reporting date, with any increases or decreases recorded within restructuring and other items in our consolidated statements of income. The contingent consideration is payable to the selling shareholders based upon a percentage of product sales over the life of the underlying product patent with no cap on total payments. Given the length of the earnout period and the uncertainty in forecasted product sales, we do not believe it is meaningful to estimate the upper end of the range over the entire period. However, our estimated probable range which could become payable over the next five years is between zero and $5.0 million.

On July 6, 2009, we acquired certain business assets of Plastef Investissements SA, a developer and manufacturer of drug delivery devices including the éris safety syringe system. The purchase price included cash paid at closing of $16.9 million and contingent consideration with an initial fair value of $2.6 million dependent upon the achievement of operating goals and other milestones over the period ending December 31, 2014. The purchase price allocation consisted primarily of $4.9 million of property, plant and equipment, $7.8 million of goodwill and $8.8 million of other intangible assets, offset by $2.4 million of real property and equipment lease obligations.

Operating results for these acquired businesses were included within the Delivery Systems segment from the date of acquisition. Pro forma results were not presented as these acquisitions were not considered material to our consolidated balance sheets or results of operations.  See Note 3, Restructuring and Other Items, for further discussion of contingent consideration obligations.

XML

Schedule II Valuation and Qualifying Accounts (Details) (USD $) In Millions, unless otherwise specified	12 Months Ended
	Dec. 31, 2011	Dec. 31, 2010	Dec. 31, 2009
Valuation and qualifying accounts [Roll Forward]
Balance at beginning of period	$ 25.4	$ 25.0	$ 24.1
Charged to costs and expenses	(0.3)	0.6	0.2
Deductions	(5.5)	(0.2)	0.7
Balance at end of period	19.6	25.4	25.0
Deferred Tax Asset Valuation Allowance [Member]
Valuation and qualifying accounts [Roll Forward]
Balance at beginning of period	24.9	24.3	23.4
Charged to costs and expenses	(0.2)	0.8	0.4
Deductions	(5.4)	(0.2)	0.5
Balance at end of period	19.3	24.9	24.3
Allowance for Doubtful Accounts Receivable [Member]
Valuation and qualifying accounts [Roll Forward]
Balance at beginning of period	0.5	0.7	0.7
Charged to costs and expenses	(0.1)	(0.2)	(0.2)
Deductions	(0.1)		0.2
Balance at end of period	$ 0.3	$ 0.5	$ 0.7

XML

Summary of Significant Accounting Policies (Tables)

12 Months Ended

Dec. 31, 2011

Summary of Significant Accounting Policies [Abstract]

Inventories

Inventories: Inventories are valued at the lower of standard cost (which approximates actual cost on a first-in-first-out basis) or market. The following is a summary of inventories at December 31:

($ in millions)	2011		2010
Finished goods	$	67.1	$	65.1
Work in process		19.6		21.4
Raw materials		65.1		60.5
	$	151.8	$	147.0

XML

Fair Value of Financial Instruments (Tables)

12 Months Ended

Dec. 31, 2011

Fair Value Disclosures [Abstract]

Schedule assets and liabilities measured at fair value on a recurring basis

The following tables present the assets and liabilities that are measured at fair value on a recurring basis in our balance sheets:

	Balance at		Basis of Fair Value Measurements
	December 31,
($ in millions)	2011		Level 1		Level 2		Level 3
Assets:
Short-term investments	$	26.5	$	26.5	$	-	$	-
Deferred compensation assets		3.3		3.3		-		-
	$	29.8	$	29.8	$	-	$	-
Liabilities:
Contingent consideration	$	2.1	$	-	$	-	$	2.1
Deferred compensation liabilities		4.6		4.6		-		-
Interest rate swap contracts		8.8		-		8.8		-
	$	15.5	$	4.6	$	8.8	$	2.1

	Balance at		Basis of Fair Value Measurements
	December 31,
($ in millions)	2010		Level 1		Level 2		Level 3
Assets:
Short-term investments	$	0.6	$	0.6	$	-	$	-
Deferred compensation assets		3.6		3.6		-		-
	$	4.2	$	4.2	$	-	$	-
Liabilities:
Contingent consideration	$	2.3	$	-	$	-	$	2.3
Deferred compensation liabilities		5.4		5.4		-		-
Interest rate swap contracts		6.1		-		6.1		-
	$	13.8	$	5.4	$	6.1	$	2.3

Summary of changes in Level 3 Fair Value Measurements

The following table provides a summary of changes in our Level 3 fair value measurements during 2011:

	($ in millions)
Balance, December 31, 2010	$	2.3
Increase in fair value recorded in earnings		0.5
Reduction in fair value recorded in earnings		(0.8	)
Changes in foreign currency exchange rates		0.1
Balance, December 31, 2011	$	2.1

The following table provides a summary of changes in our Level 3 fair value measurements during 2010:

	($ in millions)
Balance, December 31, 2009	$	2.8
Additional contingent consideration acquired		1.8
Increase in fair value recorded in earnings		0.2
Reduction in fair value recorded in earnings		(2.1	)
Changes in foreign currency exchange rates		(0.4	)
Balance, December 31, 2010	$	2.3

XML

Derivative Financial Instruments

12 Months Ended

Dec. 31, 2011

Derivative Financial Instruments [Abstract]

Derivative Financial Instruments

Note 12: Derivative Financial Instruments

Our ongoing business operations expose us to various risks such as fluctuating interest rates, foreign exchange rates and increasing commodity prices. To manage these market risks, we periodically enter into derivative financial instruments such as interest rate swaps, options and foreign exchange contracts for periods consistent with and for notional amounts equal to or less than the related underlying exposures. We do not purchase or hold any derivative financial instruments for speculation or trading purposes. All derivatives are recorded on the balance sheet at fair value.

Interest Rate Risk

On February 25, 2011, we exercised an option to purchase our new corporate office and research building.  In conjunction with this, we anticipate that, during the first quarter of 2013, we will borrow $43.0 million pursuant to a five-year term loan with a variable interest rate. In anticipation of this debt, we entered into a forward-start interest rate swap with the same notional amount in order to hedge the variability in cash flows due to changes in the applicable interest rate over the five-year period beginning January 2013. Under this swap, we will receive variable interest rate payments based on one-month LIBOR plus a margin in return for making monthly fixed interest payments at 5.41%. We designated the forward-start interest rate swap as a cash flow hedge.

As a result of our normal borrowing activities, we have entered into debt obligations with both fixed and variable interest rates. As of December 31, 2011, we have two interest rate swap agreements outstanding. Both swap agreements are designated as cash flow hedges to protect against volatility in the interest rates payable on our Series A and B notes. Under both of these swaps, we will receive variable interest rate payments based on three-month LIBOR in return for making quarterly fixed rate payments. Including the applicable margin, the interest rate swap agreements effectively fix the interest rates payable on the Series A and B notes at 5.32% and 5.51%, respectively.

Foreign Exchange Rate Risk

As described in more detail below, during 2011, we entered into several foreign currency hedge contracts that were designated as cash flow hedges of forecasted transactions denominated in foreign currencies.

We entered into a series of foreign currency contracts intended to hedge the currency risk associated with a portion of our forecasted Japanese Yen (“JPY”) denominated purchases of inventory from Daikyo Seiko Ltd. made by certain European subsidiaries. We had also entered into a series of foreign currency contracts to hedge the currency risk associated with a portion of our forecasted U.S. dollar (“USD”) denominated inventory purchases by certain European subsidiaries. In addition, we entered into a series of foreign currency contracts to hedge the currency risk associated with a portion of our forecasted Euro-denominated sales of finished goods by one of our USD functional-currency subsidiaries. As of December 31, 2011, there were no contracts outstanding.

In 2010, we entered into a series of foreign currency hedge contracts, designated as cash flow hedges, to eliminate the currency risk associated with a portion of our forecasted JPY denominated purchases of finished goods from Daikyo Seiko, Ltd. and other JPY purchases made by West in the United States. The last contract matured on December 28, 2010.

We have also designated our €81.5 million Euro-denominated notes as a hedge of our net investment in certain European subsidiaries. A cumulative foreign currency translation loss of $5.2 million pre-tax ($3.2 million after tax) on this debt was recorded within accumulated other comprehensive income as of December 31, 2011.  We have also designated our 500.0 million Yen-denominated note payable as a hedge of our net investment in a Japanese affiliate. At December 31, 2011, there was a cumulative foreign currency translation loss on this Yen-denominated debt of $1.0 million pre-tax ($0.6 million after tax) which was also included within accumulated other comprehensive income.

Commodity Price Risk

Many of our Packaging Systems products are made from synthetic elastomers, which are derived from the petroleum refining process. We purchase the majority of our elastomers via long-term supply contracts, some of which contain clauses that provide for surcharges related to fluctuations in crude oil prices. We entered into the following economic hedges that did not qualify for hedge accounting treatment since they did not meet the highly effective requirement at inception.

In January 2011, we purchased a series of call options for a total of 77,900 barrels of crude oil, intended to mitigate our exposure to such oil-based surcharges and protect operating cash flows with regard to a portion of our forecasted elastomer purchases during the months of May through November 2011. With these option contracts, we may benefit from a decline in crude oil prices, as there is no downward exposure other than the $0.5 million premium that we paid to purchase the contracts.

During the year ended December 31, 2011 and 2010, a gain of $0.6 million and $0.3 million, respectively, was recognized in cost of goods and services sold related to these call options. As of December 31, 2011, there were no call options outstanding.

Effects of Derivative Instruments on Financial Position and Results of Operations

Refer to Note 13, Fair Value Measurements, for the balance sheet location and fair values of our derivative instruments as of December 31, 2011 and 2010.

The following table summarizes the effects of derivative instruments designated as hedges on other comprehensive income (“OCI”) and earnings for the year ended December 31:

	Amount of Gain (Loss) Recognized in OCI						Amount of (Gain) Loss Reclassified from Accumulated OCI into Income					Location of Gain (Loss) Reclassified from Accumulated OCI into Income
($ in millions)	2011			2010			2011		2010
Cash Flow Hedges:
Foreign currency hedge contracts	$	(0.3	)	$	-		$	0.3	$	-		Net sales
Foreign currency hedge contracts		-			0.5			-		(0.5	)	Cost of goods and services sold
Interest rate swap contracts		(4.9	)		(3.5	)		3.2		3.2		Interest expense
Total	$	(5.2	)	$	(3.0	)	$	3.5	$	2.7
Net Investment Hedges:
Foreign currency-denominated debt	$	1.3		$	3.9		$	-	$	-		Foreign exchange losses and other
Total	$	1.3		$	3.9		$	-	$	-

During 2011 and 2010, there was no ineffectiveness related to our cash flow and net investment hedges.